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ABSTRACT 
 
Natural products are a rich source of compounds with interesting structures and 
biological activities. Three bioactive natural products, iriomoteolide-1a, alotaketal A, 
and an unnamed quinone methide diterpenoid, attracted our attention during our course 
of exploring natural products as potential leads for biomedical discovery.  
The structure of iriomoteolide-1a had been misassigned, but the potent 
cytotoxicity reported for this natural product warranted further studies to elucidate its 
true structure. As part of our effort toward this goal, we finished the total synthesis of a 
diastereomer of iriomoteolide-1a. Our total synthesis featured a lithium acetylide-
chloroformate coupling to assemble the alkyne and chloroformate fragments, the ring 
closing metathesis to exclusively generate the 15E-macrocyclic diolide, and a SmI2-
mediated intramolecular reductive allylation to form the cyclic hemiketal. The 
bioactivities of this diastereomer were evaluated, but only weak inhibition of cell 
proliferation was observed at 10 µM toward HeLa and PC3 cell lines. 
Alotaketal A was reported to potently (EC50 = 18 nM) activate the cAMP (cyclic 
adenosine monophosphate) signaling pathway in HEK293 cells transformed with the 
pHTS-CRE plasmid. Our synthetic efforts toward this natural product culminated in the 
first enantioselective total synthesis of (-)-alotaketal A. Our total synthesis employed 
both intra- and inter-molecular reductive allylation of esters for assembling the bicyclic 
lactone and coupling the fragments. A Hg(OAc)2-mediated allylic mercuration was used 
to introduce the C22-hydroxyl group. The subtle influence of substituents over the 
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course of the spiroketalization process was revealed. The synthesis confirmed the 
relative and absolute stereochemistry of (-)-alotaketal A and allowed verification of 
alotaketal A’s effect over cAMP signaling using reporter-based FRET imaging assays 
with HEK293 cells. Our studies also revealed alotaketal A’s unique activity in 
selectively targeting nuclear PKA signaling in living cells. 
Our synthetic efforts toward the unnamed quinone methide diterpenoid 1.67 led 
to the first total synthesis of this potent antifungal product (MIC = 0.19 µM). Our total 
synthesis was highlighted by a Stille coupling to introduce the allyl group, a 
lithium/naphthalene-mediated coupling reaction for fragment assembling, and a BBr3-
mediated one-pot bis-demethylation and intramolecular Friedel-Crafts alkylation to build 
the tricyclic molecular framework. Our preliminary structure-activity relationship study 
showed that the 2'-hydroxyethyl side chain of the natural product was nonessential to its 
antifungal activity.  
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NOMENCLATURE 
 
2,6-lutidine                  2,6-dimethylpyridine 
BBN                            borabicyclo[3.3.1]nonane 
BMS                            borane dimethyl sulfide 
Bn                                benzyl 
Bu                                butyl 
cAMP                          cyclic adenosine monophosphate 
c-Hex                           cyclohexyl 
dba                               dibenzylideneacetone 
DBU                            1,8-diazabicyclo[5.4.0]undec-7-ene 
DDQ                            2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DEAD                         diethyl azodicarboxylate 
DIBAL-H                    diisobutylaluminium hydride 
DMAP                         4-dimethylaminopyridine 
DMDO                         dimethyldioxirane 
DME                            dimethoxyethane 
DMF                            dimethylformamide 
DMSO                         dimethyl sulfoxide 
dppf                              1,1'-bis(diphenylphosphino)ferrocene 
EC50                              half maximal effective concentration 
Et                                  ethyl 
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HEK                             human embryonic kidney 
HMPA                          hexamethylphosphoramide 
IBX                               2-iodoxybenzoic acid 
IC50                               half maximal inhibitory concentration 
InI                                 indium iodide 
KHMDS                       potassium bis(trimethylsilyl)amide 
LiDBB                          lithium di-tert-butylbiphenyl 
Me                                methyl 
mCPBA                        meta-chloroperbenzoic acid 
Mes                               mesityl 
MFC                             minimum fungicidal concentration 
MIC                              minimum inhibitory concentration 
MOM                           methoxymethyl 
Ms                                mesylate 
NBS                             N-bromosuccinimide 
NCS                             N-chlorosuccinimide 
NIS                               N-iodosuccinimide 
NMP                             N-methyl-2-pyrrolidone 
NMR                            nuclear magnetic resonance 
PhH                              benzene 
PMB                             p-methoxybenzyl 
PMBTCA                     p-methoxybenzyl trichloroacetimidate 
 ix 
 
PPTS                            pyridinium p-toluenesulfonate 
pTSA                            p-toluenesulfonic acid 
Py                                 pyridine 
RCM                             ring closing metathesis 
ROESY                        rotating-frame nuclear overhauser effect correlation    
                                     spectroscopy 
sp.                                 species 
TBAF                           tetra-n-butylammonium bromide 
TBS                              tert-butyldimethylsilyl 
TBSOTf                        trimethylsilyl trifluoromethanesulfonate 
TCBC                           2,4,6-trichlorobenzoyl chloride 
TES                               triethylsilyl 
THF                              tetrahydrofuran 
TIPS                              triisopropylsilyl 
TMS                              trimethylsilyl 
TMSOTf                       trimethylsilyl trifluoromethansulfonate 
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CHAPTER I  
BACKGROUND OF IRIOMOTEOLIDE-1A, ALOTAKETAL A AND AN 
ANTIFUNGAL O-HYDROXY-P-QUINONE METHIDE DITERPENOID 
 
1.1 Background of Iriomoteolide-1a 
1.1.1 Isolation and Bioactivities of Iriomoteolide-1a 
             Amphidinolides are a group of macrolides isolated from marine dinoflagellates 
Amphidinium sp.1 They are characterized by highly oxygenated macrocyclic lactones of 
various sizes (12 to 29-membered rings) and side chains of different lengths and 
substitutions. The potent cytotoxicity and the unique molecular structure of 
amphidinolides attracted the attention of synthetic chemists and the syntheses of several 
of these macrolides have been reported. 2  Continued research of Amphidinium sp. in the 
laboratory of Tsuda led to the isolation of three new macrolides named iriomoteolide-1a, 
-1b and -1c (Figure 1.1) from monoclonal HYA024 strain originated from sea sand 
collected off Iriomote Island, Japan in 2007.3 
            The relative and absolute stereochemistry of iriomoteolide-1a were assigned by 
the combination of conformational analyses using NMR data and modified Mosher's 
method while the structures of iriomoteolide-1b and -1c were elucidated on the basis of 
analyses of NMR and chemical correlation with iriomoteolide-1a. The absolute 
configurations at C22 and C23 of the side chain of iriomoteolide-1c have not been 
determined. Iriomoteolide-1a and -1c share the same 20-membered macrolide core 
possessing the characteristic exocyclic C11-C26 alkene, six-membered C9/C13-cyclic 
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hemiketal, C2-C3 trisubstituted Z-double bond and two E-endocyclic double bonds. 
Iriomoteolide-1b features an endocyclic C11-C12 alkene, thus a stable enone in 
iriomoteolide-1b replaces the cyclic hemiketal present in iriomoteolide-1a and -1c. 
 
 
Figure 1.1. Originally proposed structures of iriomoteolides 
 
            Preliminary studies showed iriomoteolide-1a and -1c to be potently cytotoxic 
against human B lymphocyte DG-75 cells (IC50 value of 2 ng/mL for both of the 
macrolides) and Epstein-Barr virus-infected human B lymphocyte Raji cells (IC50 values 
of 3-4 ng/mL). However, the IC50 value (900 ng/mL) of iriomoteolide-1b against DG-75 
cells is 450 times less potent than those of iriomoteolide-1a and -1c. This result 
suggested that the C9/C13-cyclic hemiketal and/or the exocyclic C11-C26 alkene are 
essential for the observed potent cytotoxicity of iriomoteolide-1a and -1c.  
 
1.1.2 Synthetic Efforts Toward Iriomoteolide-1a 
            The intriguing molecular architecture and potent biological activity of 
iriomoteolide-1a attracted considerable attention for its total synthesis. 4  In 2010, 
Horne,4m Ghosh4n and our groups4o independently arrived at the conclusion that the 
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original structural assignment of iriomoteolide-1a was incorrect. While both Horne and 
Ghosh synthesized the originally proposed iriomoteolide-1a and reported the 
inconsistency of its spectra with those of the natural product, our conclusion that the C2-
C3 trisubstituted Z-double bond of the original structure must have been misassigned 
prompted us to target the 2E diastereomer (i.e., 1.1, Figure 1.2). This isomer was found 
to be different from the natural product too. Our group also synthesized two additional 
2E-diastereomers (i.e., 1.2 and 1.3). However, they didn't match the natural product 
either. More recently, Dai and co-workers reported their syntheses of 1.1 and another 
2E-diastereomer 1.4,4q which were also found to be different from the natural product. 
These results collectively show that, if the connectivity of the natural product has been 
correctly assigned, the original structure of iriomoteolide-1a likely has been misassigned 
at more than one stereocenter.  
 
 
Figure 1.2. The original iriomoteolide-1a and some of the diastereomers 
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1.1.2.1 Horne's Total Synthesis of the Proposed Iriomoteolide-1a 
           Horne and co-workers accomplished the first total synthesis of the proposed 
structure of iriomoteolide-1a.4m They disconnected the complex molecule into three key 
building blocks: C1-C6, C7-C16 and C17-C23 fragments (Figure 1.3 and Scheme 1.1).  
The stereocenters in C1-C6 fragment 1.6 were obtained from the known compound 1.5. 
The key step in the synthesis of C7-C16 fragment 1.12 was a Sakurai reaction between 
allyltrimethylsilane 1.9 and aldehyde 1.11 mediated by SnCl4. The synthesis of C17-C23 
fragment 1.17 featured an anti-aldol reaction with chiral auxiliary 1.15 to control the 
stereocenters at C18 and C19.  
 
 
Figure 1.3. Horne's disconnection of iriomoteolide-1a 
 
 
Scheme 1.1. Horne's synthesis of key fragments 
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Scheme 1.1. (Continued) Horne's synthesis of key fragments  
 
            The coupling of these fragments and the completion of the synthesis of the 
original iriomoteolide-1a were shown in Scheme 1.2. Suzuki-Miyaura coupling between 
1.12 and 1.17 produced C7-C23 fragment 1.18. Selective removal of the TES protecting 
group afforded alcohol 1.19 for Yamaguchi esterification. Global deprotection along 
with concomitant hemiketalization occurred upon treatment of 1.21 with DDQ afforded 
intermediate 1.22. Treatment of 1.22 with Grubbs II catalyst gave the original 
iriomoteolide-1a and its 6, 7-Z-isomer in 2.5:1 ratio.  
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Scheme 1.2. Horne's total synthesis of proposed iriomoteolide-1a 
 
1.1.2.2 Ghosh's Total Synthesis of Proposed Iriomoteolide-1a 
            Ghosh and co-workers also accomplished the synthesis of the proposed structures 
of iriomoteolide-1a and -1b.4n Unlike Horne's synthesis, they employed two stages of 
Julia-Kocienski olefination to control the two E-alkenes (Figure 1.4). Ghosh's strategy 
also involved disassembling iriomoteolide-1a into three portions (Scheme 1.3), i.e. C1-
C6, C7-C15 and C16-C23 fragments. The C7-C15 fragment was derived from a Sakurai 
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reaction of aldehyde 1.26 and allyl silane 1.28. The C1-C6 and C16-C23 fragments were 
prepared from known compounds 1.23 and 1.30, respectively.  
 
 
Figure 1.4. Ghosh's disconnection of iriomoteolide-1a 
 
 
Scheme 1.3. Ghosh's synthesis of key fragments 
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            The above three fragments were coupled by two stages of Julia-Kocienski 
olefination to give the intermediate 1.34, which was converted to 1.35 in 10 steps 
including a Yamaguchi esterification to form the macrocyclic lactone (Scheme 1.4). 
Removal of the silyl ethers with HF•Py resulted in a mixture (3:1) of the proposed 
iriomoteolide-1a and -1b. The 1H and 13C NMR spectra of Ghosh's synthetic 
iriomoteolide-1a were consistent with those of Horne's, but none of them matched the 
data reported for the natural product. Both of these research groups suggested that the 
configuration of the C2-C3 double bond of the natural product is E rather than Z.         
                                                                                                                                                            
 
 Scheme 1.4. Ghosh's total synthesis of iriomoteolide-1a and -1b 
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1.1.2.3 Yang's Total Synthesis of Iriomoteolide-1a Diastereomers 
            Our group is the first to report the synthesis of the C1-C12 fragment of the 
originally proposed iriomoteolide-1a.4k However, during our studies, it became clear that 
the C2-C3 alkene of the natural product should be revised to 2E- instead of the originally 
proposed 2Z- configuration. Thus, we adjusted our synthetic plan to target the 2E- 
isomer 1.1 rather than the originally proposed iriomoteolide-1a.4o We disconnected the 
2E-isomer 1.1 into three fragments: alkyne fragment, chloroformate fragment and a 
known -hydroxy fragment (Figure 1.5 and Scheme 1.5). Our synthesis of alkyne 
fragment was highlighted by a catalytic asymmetric vinylogous Mukaiyama aldol 
reaction to introduce the C9 stereocenter. Another key reaction was the formation of 
anti-homopropargylic alcohol 1.41 from aldehyde 1.39 by addition of the 
triisopropylsilylallenylindium reagent generated in situ from mesylate 1.40.  
 
 
Figure 1.5. Yang's disconnection of iriomoteolide-1a 
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Scheme 1.5. Yang's synthesis of key fragments 
 
            Our enantioselective synthesis of 1.1, a diastereomer of iriomoteolide-1a, was 
shown in Scheme 1.6. It featured an acetylide-chloroformate coupling strategy to 
synthesize the intermediate 1.45, which could be converted to macrocyclic lactone 1.46 
in 10 steps. Among these ten steps, a Mitsunobu reaction was used to invert the 
stereocenter at C9 with -hydroxy fragment 1.44 and a ring closing metathesis was 
employed to build the macrocycle. Also highlighted in our total synthesis was a SmI2-
mediated intramolecular reductive cyclization approach to the complex cyclic hemiketal. 
Two additional 2E-diastereomers 1.2 and 1.3 (Figure 1.2) were also synthesized in order 
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to determine the correct structure of the natural product. Unfortunately, none of them 
matched the natural product.  
 
 
Scheme 1.6. Yang's total synthesis of a diastereomer of iriomoteolide-1a, 1.1 
 
1.1.2.4 Dai's Total Synthesis of Iriomoteolide-1a Diastereomers 
            In 2011, employing a strategy similar to that of Horne's, the Dai group 
accomplished the total syntheses of two 2E-isomers of the original iriomoteolide-1a with 
different stereocenters at C4 and C5 (1.1 and 1.4, Figure 1.1).4q The key reactions of 
Dai's approach were shown in Figure 1.6.  The C1-C6 fragment 1.49 and its enantiomer 
were prepared from acrolein 1.48 through anti-selective aldol reactions with chiral 
propionate 1.47 and 1.15, respectively (Scheme 1.7). Unlike Horne's disconnection of 
C7-C23 into C7-C16 and C17-C23 fragments, Dai's approach involved preparation of 
the C13-C23 fragment at first through the B-alkyl Suzuki-Miyaura coupling between 
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primary iodide 1.53 and vinyl iodide 1.55. The C7-C23 fragment was then achieved 
through the indium-mediated aldehyde allylation of C13-C23 fragment 1.56 with C7-
C12 fragment 1.51. The final product 1.1 was synthesized using a reaction sequence that 
is similar to Horne's, i.e. Yamaguchi esterification, hemiketalization and ring closing 
metathesis.  
 
 
Figure 1.6. Dai's disconnection of iriomoteolide-1a 
 
 
Scheme 1.7. Dai's synthesis of key fragments 
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Scheme 1.7. (Continued) Dai's synthesis of key fragments 
 
1.1.2.5 Other Research Groups' Synthetic Studies Toward Iriomoteolide-1a  
            Except the above total syntheses of proposed iriomoteolide-1a or its 
diastereomers, other research groups also reported their synthetic efforts toward 
iriomoteolide-1a. Loh and co-workers developed two different synthetic routes to the 
C13-C23 fragments.4f, h The C13-C23 fragment was also achieved by Zhao and co-
workers.4g Their synthetic efforts eventually led to the enantioselective total synthesis of 
the proposed structure of iriomoteolide-1b.4r Paterson group accomplished the 
construction of C1-C9 and C11-C23 segments using lactate aldol chemistry.4c Crimmins 
and co-workers finished the enantioselective syntheses of the C1-C6 and C7-C23 
fragments using various aldol reactions of metallo enolates of thiazolidinethiones to set 
up 7 of the 9 stereocenters of the proposed iriomoteolide-1a.4a The advanced 
macrocyclic core of iriomoteolide-1a was prepared by Ye team utilizing ring-closing 
metathesis (RCM) to construct the C15-C16 E-alkene.4d 
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1.2 Background of Alotaketal A 
1.2.1 Isolation and Bioactivity of Alotaketal A   
            Marine organisms continue to provide an unrivalled array of novel, biologically 
active natural products as potential lead compounds for the development of new 
therapeutic agents and tools for biomedical studies.5  In search of these compounds, 
recent screening of extracts of the marine sponge Hamigera sp., collected in Papua New 
Guinea by Andersen and co-workers, led to the isolation of new sesterterpenoids 
alotaketal A and B (Figure 1.7).6 These natural products feature an "alotane" terpenoid 
carbon skeleton that cyclizes into a unique tricyclic spiroketal ring system. In particular, 
simultaneous substitution of the spiroketal center of alotaketal A by both ally and vinyl 
groups is unprecedented in natural spiroketals. Contemporaneous to the Andersen report, 
the Rho group described the isolation of the closely related phorbaketal A-C from the 
sponge Phorbas sp.7              
            The structures of these natural products were mostly assigned based on 1D and 
2D NMR studies. Rho and co-workers assigned the absolute configuration of the 
phorbaketals as those drawn in Figure 1.7 using Mosher ester methodology. Andersen 
and co-workers originally assigned the absolute configuration of alotaketals based on the 
positive Cotton effect of the enone n to π* transition observed in the CD spectrum using 
Snatzke’s rules. However, their assignment for C1, C6, C9, C13 were opposite to those 
assigned by Rho group in phorbaketals. Andersen group subsequently revised their 
stereochemical assignment to the same as that of the Rho group.8 
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Figure 1.7. Structures of forskolin, alotaketals and phorbaketals 
 
            Along with their unique molecular structures, these natural products exhibit 
interesting biological activities.6 For example, using HEK293 cells transformed with 
pHTS-CRE luciferase reporter genes, alotaketal A and B were found to potently activate 
the cAMP signaling pathway with EC50 values of 18 nM and 240 nM in the absence of 
hormone binding. cAMP is a secondary messenger used for intracellular signal 
transduction, which is fundamental to cell signaling.9 Such signaling is typically initiated 
by the binding of hormones to cell-surface G protein-coupled receptors (GPCRs), which 
leads to the recruitment of trimeric guanine-nucleotide binding proteins (G proteins) and 
activation of adenylyl cyclases, the enzyme responsible for converting adenosine 
triphosphate (ATP) to cAMP. The cAMP thus formed binds to and activates cAMP-
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dependent protein kinase (PKA) that regulates a wide array of cellular events including 
cell growth and differentiation.10 Small molecules that selectively modulate signaling 
pathways are important tools for cell biology research and potential lead compounds for 
drug development.11 Forskolin, a natural product activator of adenylyl cyclase,12  has 
been widely used by biologists to raise intracellular cAMP levels. It also attracted some 
attention as a drug candidate.13 However, compared with alotaketal A, forskolin is a 
relatively inefficient signaling molecule for cAMP pathway activation with an EC50 of 3 
µM in the same assay using HEK-pHTS-CRE. Alotaketal A shows an EC50 that is 167-
fold more potent than that of forskolin. Thus, alotaketal A represents a potentially 
superior small molecule probe for studying cAMP signaling and a potential lead for 
therapeutic development.  
 
1.2.2 Synthetic Efforts Toward Alotaketal A 
            Attracted by its unprecedented spiroketal molecular structure and appealing 
bioactivities in potently activation the cAMP signaling pathway, we accomplished the 
first total synthesis of alotaketal A and elucidated its structure-activity relationship in 
2012. Five months later, the second total synthesis of alotaketal A was achieved by 
Dalby and co-workers.14 They developed a convergent synthetic approach to alotaketal 
A through coupling of bicyclic lactone 1.61 and allyl bromide 1.65.  The two hydroxyl 
groups in the intermediate 1.58 were introduced using a stepwise sequence from (R)-
carvone (Scheme 1.8). Yamaguchi esterification of the allyl alcohol with phosphonate 
1.59 provided keto-phosphonate 1.60, which was subjected to Horner-Wadsworth-
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Emmons reaction to finish the bicyclic lactone 1.61. Nagao-Fujita aldol reaction was 
featured in the synthesis of allyl bromide 1.65 to install the C13 hydroxyl group with 
excellent yield and high diastereoselectivity.  
 
 
Scheme 1.8. Dalby's synthesis of key fragments 
 
            With both key fragments in hand, the pivotal coupling of bicyclic lactone 1.61 
and allyl bromide 1.65 was achieved through the addition of excess lithium di-tert-
butylbiphenyl (LiDBB) to a solution of 1.61 and 1.65 in THF (Scheme 1.9). The rather 
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acid-sensitive hemiketal 1.66 thus obtained was then converted to the alotaketal A in 4 
steps through thermodynamically controlled spiroketalization upon desilylation. Dalby 
and co-workers completed the total synthesis of alotaketal A in 0.5% yield over 17 steps.  
 
 
Scheme 1.9. Dalby's total synthesis of alotaketal A 
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1.3 Background of an Antifungal o-Hydroxy-p-Quinone Methide Diterpenoid 
1.3.1 Introduction of o-Hydroxy-p-Quinone Methide Terpenoids   
            Quinone methides are typically reactive electrophilic species that are formed as 
transient intermediates in chemical transformations. 15  However, in the presence of 
stabilizing structural elements, such as extended conjugation, relatively stable quinone 
methides may form. Indeed, a number of o-hydroxy-p-quinone methide diterpenoids and 
triterpenoids, such as fuerstion, taxodione and its dimer 1.68, pristimerin, celastrol, 
tingenone, many of which show interesting biological activities, have been isolated from 
Nature (Figure 1.8).16 As part of our efforts in investigating natural products with useful 
pharmacological properties, we became interested in 1.67, an unnamed o-hydroxy-p-
quinone methide diterpenoid isolated from Bobgunnia madagascariensis. 17 
 
 
Figure 1.8. Structures of some o-hydroxy-p-quinone methide terpenoids 
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1.3.2 Isolation and Bioactivities of Unnamed o-Hydroxy-p-Quinone Methide 
Diterpenoid 1.67   
            Bobgunnia madagascariensis (Desv.) J.H.Kirkbr & Wiersema (formerly known 
as Swartzia madagascariensis) is a tree widely distributed in tropical Africa.18 Various 
parts of this plant have been used by traditional healers for medicinal purposes. For 
example, its roots have been employed as a cure for leprosy and syphilis. 19 
Phytochemical investigation of its dried fruits gave triterpenoid saponins, which were 
shown to be responsible for its high molluscicidal activity against B. glabrata. 20  B. 
madagascariensis has attracted much attention in the past decade. The screening efforts 
aimed at the discovery of new antifungal lead compounds in the laboratory of 
Hostettmann led to the isolation of a new o-hydroxy-p-quinone methide diterpenoid 1.67 
from the root bark of B. madagascariensis (Figure 1.9).17 The relative and absolute 
stereochemical structure of 1.67, which features a cassane skeleton, were assigned by 
NMR and confirmed by single-crystal X-ray analysis. Whereas unnamed, this quinone 
methide diterpenoid 1.67 shows potent antifungal activity (MIC = 0.19 µM) that even 
rivals amphotercin B and fluconazole, two antifungal drugs that are currently in clinical 
use.  
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Figure 1.9. Structures of 1.67 and cassane skeleton 
 
1.3.3 Synthetic Background of o-Hydroxy-p-Quinone Methide Diterpenoid 1.67   
            Despite its potent antifungal activity, no synthetic studies have been reported 
toward 1.67 in the past decade. However, the structurally similar taxodione has been 
synthesized for several times (Figure 1.8).  Most of these syntheses, developed prior to 
1995, were racemic and required stepwise construction of the tricyclic quinone methide 
moiety. 21  Among them, we were attracted by Stevens' approach,21f which used the 
intramolecular Friedel-Crafts alkylation as the key reaction to build the tricyclic core. 
However, the synthetic route employed rather harsh conditions using formic acid as the 
solvent at high temperature.  
 
 
Scheme 1.10. Stevens' approach to taxodione 
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            Recently, a number of asymmetric intermolecular Friedel-Crafts alkylations 
using Brønsted acid catalysts have been reported.22  We were also aware of one example 
of Brønsted acid catalyzed asymmetric intramolecular Friedel-Crafts reaction reported 
by You and co-workers.23 Most of these reactions involve electron-rich heteroarenes, but 
1- and 2-hydroxynaphthalenes have also been used.24 Based on these results, a catalytic 
asymmetric intramolecular Friedel-Crafts alkylation approach was envisioned for 
synthesis of the tricyclic molecular skeleton of this family of diterpenoids. As an 
alternative, we would also test chiral amines for iminium-catalyzed asymmetric Friedel-
Crafts alkylations. The focus would be on quinidine-derived primary amines since they 
were more likely to form the electrophilic iminium intermediate 1.72 with the relatively 
hindered carbonyl of 1.69 for asymmetric catalysis through iminium activation (Scheme 
1.11, pathway I). 25  A reaction pathway of 6π-electrocyclization of the enamine 
intermediate 1.74 is also possible (Scheme 1.11, pathway II).  
 
 
Scheme 1.11. Cyclization catalyzed by an amine 
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CHAPTER II  
SYNTHETIC STUDIES OF IRIOMOTEOLIDE-1A* 
 
2.1 Retrosynthesis of Iriomoteolide-1a 
            The structure of iriomoteolide-1a had been misassigned, but the potent 
cytotoxicity reported for iriomoteolide-1a warranted further studies to elucidate the true 
structure of the natural product and enable mode-of-action studies of this potent 
cytotoxin. As part of our effort toward this goal, we decided to synthesize macrolide 2.1 
(Scheme 2.1) based on our observation of a significant ROESY (CDCl3) correlation 
between H19 and 13-OH from the original report by Tsuda group.3 Molecular mechanics 
simulation at the MM2 level suggests that H19 and 13-OH have to be oriented to the 
same side of the macrocycle in order for such a correlation to occur. This and results 
obtained in our previous work prompted us to choose 2.1 as the target.26 The goal for 
synthesizing 2.1 was to identify if it matches the real structure of iriomoteolide-1a or (if 
it does not), in combination with the diasteromers that have been previously synthesized, 
to provide a 'training set' for computational elucidation of the stereochemical structure of 
the natural product.  
            Our retrosynthetic analysis of iriomoteolide-1a was shown in Scheme 2.1. To 
maximize synthetic convergency, our synthetic plan relied on a late stage intramolecular 
                                                 
* Reprinted with permission from “Studies Toward Elucidating the Stereochemical 
Structure of Iriomoteolide 1a” by Huang, J.; Yang, J. Synlett 2012, 23, 737-740, 
Copyright [2012] by Georg Thieme Verlag Stuttgart • New York. 
   
24 
 
reductive allylation to form the C9/C13 cyclic hemiketal from iodoester 2.2. The 
macrocycle 2.2 could be prepared by ring closing metathesis across the C15-C16 double 
bond of diene 2.3, which in turn would be assembled from building blocks 2.4-2.6.  
 
 
Scheme 2.1. Retrosynthetic analysis of 2.1 
 
2.2 The First Synthetic Approach to Alkyne Fragment 2.4 
            Our synthesis commenced with the preparation of alkyne fragment 2.4. 
Stereoselective preparation of alkyne 2.4 by direct coupling of , -unsaturated 
aldehydes and allenic tin reagents developed by Marshall and co-workers was 
problematic.27 For example, the reaction of 2.74o with 2.8 led to a mixture of the desired 
homopropargylic alcohol 2.4 and an unassigned diastereomer with high yield but little 
stereochemical control (1.4:1 ratio, Scheme 2.2). Additionally, these two diasteromers 
couldn’t be separated even after silylation of the resulting hydroxyl group.  
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Scheme 2.2. Homopropargylation of 2.7 
 
2.3 The Second Synthetic Approach to Alkyne Fragment 2.4 
            To address this difficulty, we opted to apply the Evans chiral auxiliary approach 
to synthesize alkyne 2.4 (Scheme 2.3). While being stepwise, this approach was 
expected to be reliable in delivering the desired homopropargylic alcohol in a 
diasteroselective manner. To this end, the , -unsaturated aldehyde 2.7 was reacted 
with chiral auxiliary 2.9 under the standard syn-aldol reaction conditions to give 2.10.28 
This was followed by the Weinreb amidation with MeNH(OMe)•HCl/Me3Al and 
silylation of the hydroxyl group to give 2.11 in high yield.29 DIBAL-H reduction of the 
Weinreb amide gave an aldehyde intermediate, which was converted to 2.4 as a single 
diasteromer by the Colvin rearrangement under the conditions developed by Aoyama 
and Shioiri.30 Although multiple steps were necessary, this procedure provided a reliable 
approach for preparation of adequate quantities of diastereomerically pure 2.4 to 
complete the synthesis of the macrolide 2.1 
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Scheme 2.3. Synthesis of alkyne 2.4 
 
2.4 Synthesis of Chloroformate Fragment 2.6 
            Preparation of chloroformate 2.6 started from the known aldehyde 2.134h 
(Scheme 2.4). Brown asymmetric crotylation of 2.13 and protection of the resulting 
secondary alcohol as PMB ether led to alkene 2.14,31 which was subjected to a three-step 
homologation sequence (hydroboration, IBX oxidation, and Witting olefination) to give 
homologated alkene 2.15. The PMB ether 2.15 was oxidatively hydrolyzed with DDQ, 
and the building block 2.6 was synthesized through the reaction of the resulting 
secondary alcohol with triphosgene, which was used for next step without any 
purification.  
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Scheme 2.4. Synthesis of chloroformate 2.6 
 
2.5 Synthesis of Macrocycle 2.19 
            With both of the key building blocks in hand, our attention turned to their 
coupling and conversion to the trisubstituted 2E-alkenoic ester 2.17. For this purpose, it 
requires deprotonation of the terminal alkyne of 2.4 to form an acetylide prior to addition 
of chloroformate 2.6. To our surprise, this coupling reaction couldn't be consistently 
reproduced when the syn diastereomer 2.4 was employed. After extensive 
experimentation, this coupling was eventually solved through addition of HMPA as a co-
solvent. The coupling product 2.16 was subjected to the conjugate addition with the 
Gilman reagent in the presence of TMSCl, followed by acidic work up to hydrolize the 
silyl ketene acetal intermediate to stereoselectively give the (E)-trisubstituted C2-C3 
alkenoic ester 2.17 in 99% yield.  
            With the C1-trisubtituted alkenoic ester functionality secured, the C13 ester was 
introduced by oxidative hydrolysis of the C9 PMB ether of 2.16 followed by Mitsunobu 
reaction with known -hydroxy acid 2.5.32 The strategic decision of assembling the 
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macrocyclic diolide 2.19 by ring-closing metathesis was demanding as it required 
selective activation of two of the five double bonds of the cyclization precursor 2.18. 
Moreover, stereochemical control of the resulting C15-C16 double bond was also 
necessary. Thus, we were gratified to observe that the desired E-isomer of the C15-C16 
double bond was formed exclusively with 72% yield when 2.18 was treated with the 
second-generation Grubbs catalyst.33 
 
 
Scheme 2.5. Synthesis of macrocycle 2.19 
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2.6 Completing the Total Synthesis of 2.1 
            To prepare for the intramolecular reductive cyclization to build the C9/C13 
cyclic hemiketal, functional group manipulations of 2.18 was carried out. This involved 
selective desilylation of the C26 hydroxyl group under acidic conditions (PPTS, EtOH, 
reflux), chlorination (MsCl, Et3N, CH2Cl2; LiCl, HMPA), and exchange the protection 
of the hydroxy groups from TBS to the more labile trimethylsilyl group to give 2.20 
(Scheme 2.6). This allyl chloride 2.20 was converted to the iodide by the Finkelstein 
reaction. 34  Employing the intramolecular reductive cyclization conditions recently 
reported by Keck, 35  formation of the six-membered cyclic hemiketal of 2.1 was 
successfully implemented despite the presence of a myriad of other functional groups. 
While this reaction was facile, the crude product had to be immediately desilylated under 
buffered conditions (pH = 7).36 The final product was obtained as a mixture of 2.1 and a 
minor isomer (~ 7:1 ratio) which was tentatively assigned as the ketol form of the 
C9/C13 cyclic hemiketal. These two isomers could be resolved by preparative thin-layer 
chromatography. However, mixtures of the same composition were recovered when 
these resolved component were eluted with ethyl acetate, suggesting relatively rapid 
equilibration of the two isomers. A similar equilibration was observed for 1.1, but not for 
the natural product or the other diasteromers (i.e., 1.2-1.4, Chapter I). The NMR spectra 
of 2.1 was found to be different from those reported for the natural product.  
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Scheme 2.6. Synthesis of macrolide 2.1 by the reductive allylation 
 
2.7 Bioactivities of Synthetic Diastereomers 1.1-1.3 and 2.1 
            With diastereomer 2.1 in hand, we collaborated with Prof. Jun Liu of Johns 
Hopkins University to evaluate the bioactivities of diastereomer 2.1 and previously 
synthesized  diastereomers 1.1-1.3 using cell proliferation assays with HeLa and PC3 
cell lines. As shown in the Table 2.1, only diastereomer 2.1 showed weak inhibition of 
cell proliferation on both cell lines at 10 µM.   
 
2.8 Summary 
            We accomplished the total synthesis of 2.1 using a synthetic route that featured a 
lithium acetylide-chloroformate coupling in the presence of HMPA as the co-solvent, the 
ring-closing metathesis to form the macrocyclic diolide, and a SmI2-mediated 
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intramolecular reductive allylation to form the cyclic hemiketal. The bioactivities of 1.1-
1.3 and 2.1 were evaluated using cell proliferation assays with HeLa and PC3 cell lines. 
Only 2.1 showed weak cell growth inhibition at 10 µM.  
 
Table 2.1. Bioactivities of synthetic diastereomers 
Concentration 
(µM) 
Growth inhibition(%) of HeLa Growth inhibition(%) of PC3 
 1.1 1.2 1.3 2.1 1.1 1.2 1.3 2.1 
10.00 2.78 -4.15 -6.42 19.12 11.35 -5.72 8.08 17.94 
1.00 -10.56 -10.39 -3.86 6.08 -3.48 -5.89 8.80 -0.75 
0.10 -3.53 -7.19 4.90 -1.90 -9.89 -2.97 -0.37 -1.87 
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CHAPTER III  
TOTAL SYNTHESIS OF ALOTAKETAL A* 
 
3.1 Retrosynthesis of Alotaketal A 
            Alotaketal A, isolated by Andersen and co-workers in 2009, potently activates 
the cAMP signaling pathway with an EC50 value of 18 nM. Along with its potent 
bioactivity, it also possesses an unprecedented tricyclic spiroketal molecular skeleton in 
which the spiroketal center is simultaneously substituted by both an allyl and a vinyl 
group. No synthetic studies of alotaketal A have been reported until we published the 
first enantioselective total synthesis of this potent cAMP signaling agonist in 2012.  
            Our convergent synthetic design of alotaketal A relied on a late stage 
spiroketalization to assemble its tricyclic spiroketal ring system. Two such cyclization 
processes could be envisioned as shown in Scheme 3.1. One involved spiroketalization 
through lactol 3.1 (process I) while the other involved a similar process through lactol 
3.2 (process II). The former lactol 3.1 could be assembled by intermolecular reductive 
allylation of bicyclic lactone 3.4 with allyl iodide 3.5 while the latter 3.2 could be 
accessed by intramolecular reductive allylation of ester 3.3, which in turn could be 
                                                 
* Reprinted with permission from “Total Synthesis of the Potent cAMP Signaling 
Agonist (-)-Alotaketal A” by Huang, J.; Yang. J. R.; Zhang, J.; Yang, J. J. Am. Chem. 
Chem. Soc. 2012, 134, 8806-8809, Copyright [2012] by American Chemical Society; 
Reprinted with permission from “Total Synthesis and Structure-Activity Relationship 
Study of the Potent cAMP Signaling Agonist (-)-Alotaketal A” by Huang, J.; Yang. J. 
R.; Zhang, J.; Yang, J. Org. Biomol. Chem. 2013, 11, 3212-3222, Copyright [2013] by 
The Royal Society of Chemistry.    
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synthesized by coupling of 3.4 and 3.6. These building blocks (i.e. 3.4, 3.5, 3.6) could be 
prepared from 5-hydroxyl carvone 3.7 and ethyl acetoacetate. Unknown at the outset 
was the compatibility of the Δ11,23 alkene with the acidic conditions that would be 
necessary to elaborate the unprecedented spiroketal ring system. Specifically, activation 
of the C10 methylene by both the Δ11,23 alkene and C9 oxocarbenium intermediate 
formed during spiroketalization would significantly increase the chance of exo-to-endo 
migration of the alkene through a process of deprotonation and re-protonation. With the 
expectation that the alkene isomerization could be suppressed by fine-tuning the reaction 
conditions and the substrates themselves, we initiated our synthetic studies.  
 
3.2 Efforts Toward a Ring-Closing Metathesis Approach to Bicyclic Lactone 3.4 
            Our synthesis of alotaketal A required 5-hydroxyl carvone 3.7 as a starting 
material. A natural product by itself, 5-hydroxyl carvone 3.7 was previously 
synthesized by Yoshikoshi and co-workers in 9 steps from R-carvone. 37  Our group 
designed a -oxygenation process based on vinylogous O-nitroso Mukaiyama aldol 
reactions to convert R-carvone into 5-hydroxyl carvone 3.7 in just two steps. 38  It 
involves regioselective formation of the extended silyl dienol ether 3.8 using the 
Kharasch reagent followed by treatment with nitrosobenzene in the presence of acetic 
acid. A -aminoxylation product 3.9 was initially formed, but heterolysis of its N-O bond 
by the excess nitrosobenzene led to a one-pot procedure to 5-hydroxy carvone. 
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Scheme 3.1. Synthetic design 
 
 
Scheme 3.2. Synthesis of 5-hydroxy carvone 
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            With 5-hydroxy carvone in hand, we initiated our synthetic efforts focusing on 
developing a ring-closing metathesis approach to bicyclic lactone 3.11 en route to 
hydrobenzopyranone 3.4 (Scheme 3.3). The metathesis substrates 3.10a/3.10b were 
synthesized by Mitsunobu reaction of 5-hydroxy carvone 3.7 and acrylic/trans-2-
pentenoic acid, which also served to invert the configuration of hydroxyl group to that of 
the natural product. Unfortunately, only the starting material was recovered when 
3.10a/3.10b was subjected to ring closing metathesis conditions with different Grubbs 
catalysts in various solvents (dichloromethane and toluene) and reaction temperatures 
(room temperature, 40 oC and 80 oC).39  
 
 
Scheme 3.3. Studies of a ring-closing metathesis approach 
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            We then turned to the "relay metathesis" approach, which was expected to 
facilitate the cyclization by assisted formation of the initiating ruthenium alkylidene 
species.40  To this end, ester 3.10c was prepared and subjected to reaction with the 
second-generation Grubbs catalyst (Scheme 3.3). To our surprise, 3.10a was isolated as 
the sole product. The formation of 3.10a suggested that the -carbonyl carbene species 
3.14 was indeed generated from 3.10c and was competent for intermolecular cross 
metathesis with styrene, but not for the intramolecular ring-closing metathesis to give 
3.11 (Figure 3.1). 41  Despite their electronically and sterically deactivated nature, 
acrylates and 1, 1-disubstituted alkenes have been shown to be effective for ring-closing 
metathesis to give related benzohydropyranones.42 Thus, the difficulty for the metathesis 
cyclization of 3.10 likely was due to unfavorable conformational effects, such as 
developing 1, 2-interactions during the formation of the metallocyclobutane intermediate 
3.15. Esters 3.12a/b, prepared by diastereoselective Luche reduction of 3.10b and TBS-
protection of the derived allyl alcohol, also remained intact under ring-closing 
metathesis conditions (Scheme 3.3).  
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Figure 3.1. Relay ring-closing metathesis approach 
 
3.3 An Intramolecular Reductive Allylation Approach to Bicyclic Lactone 3.4 
3.3.1 Synthetic Efforts Toward Bicyclic Lactone 3.20 
            The difficulty encountered in ring-closing metathesis of 3.10 and 3.12 prompted 
us to develop a second generation approach to bicyclic lactone 3.20 based on 
intramolecular reductive allylation of ester (Scheme 3.4).  This new route commenced 
with regioselective allylic chlorination of 3.7 with hypochloric acid, generated in situ 
from calcium hypochlorite and CO2, to give allyl chloride 3.16.
43 Formate 3.17 was 
formed when 3.16 was subjected to Mitsunobu reaction with formic acid, DEAD, and 
PPh3. The allylic chloride of 3.16 remain intact in the presence of nucleophilic PPh3. The 
, -unsaturated cyclic ketone 3.17 was exposed to Luche reduction conditions and only 
one diastereomer was obtained (based on 1H NMR analysis) in 92% yield. 44  The 
structure of 3.18 was further confirmed by X-ray crystallography. With allyl chloride 
   
38 
 
3.18 in hand, our next step was to construct the bicyclic AB rings of alotaketal A, which 
was proved to be difficult using the ring-closing metathesis approach. For this purpose, 
allyl chloride 3.18 was converted to allyl iodide by reaction with NaI under Finkelstein 
conditions to give the corresponding allyl iodide and set up the stage for intramolecular 
reductive allylation. Despite some initial concerns, the free hydroxyl group proved to be 
compatible with SmI2-mediated intramolecular reductive allylation. The cyclization went 
smoothly upon treating the allyl iodide with SmI2 to give epimers of bicyclic lactol 3.19 
at 0 oC in the presence of HMPA. However, despite our efforts, further functionalization 
of 3.19 was problematic.  
 
 
Scheme 3.4. Synthetic efforts toward 3.20 
 
3.3.2 Synthesis of Bicyclic Lactone 3.23a/b 
            Since we have been unsuccessful in further functionalization of diol 3.19, we 
decided to protect the allyl alcohol first. Thus, allyl alcohol 3.18 was protected as its 
tert-butyldimethylsilyl ether 3.21a, and converted to allyl iodide by reaction with NaI. 
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Again, SmI2-mediated reductive allylation under the conditions developed by Keck and 
co-workers gave bicyclic lactol 3.22a. The cyclic hemiacetal was obtained as an 
inconsequential 1:1 mixture of diastereomers, which were oxidized by IBX at 40 oC to 
give the desired , -unsaturated lactone 3.22a. During this process, a MOM-protected 
variant 3.22b was similarly prepared from 3.18 in three steps. However, it was not 
further pursued because of the relatively harsh conditions that would be necessary for 
removal of the MOM-protecting group.  
 
 
Scheme 3.5. Synthesis of bicyclic lactone 3.23a/b 
 
3.3.3 Synthetic Studies Toward -Oxygenation of 3.23a 
            After the bicyclic ring system was secured, our next objective was to 
functionalize the , -unsaturated lactone 3.23a to introduce the C22-hydroxyl group of 
3.4. We envisioned that the 1, 1-disubstituted Δ7,22 alkene could be selectively 
epoxidized in the presence of the sterically hindered  and electronically deactivated (by 
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the C1-oxygen, Scheme 3.6) trisubstituted Δ2,3 alkene. However, to our surprise, , -
unsaturated lactone 3.23a was recovered when it was subjected to epoxidation with 
mCPBA at rt to 40 oC while complex mixtures were obtained with low conversion when 
3.23a was treated with DMDO or CF3CO3H. Treatment of , -unsaturated lactone 3.23a 
with B2H6 also led to full recovery of the starting material while dihydroxylation with 
OsO4 gave a complex mixture. Efforts to prepare the silyl dienol ether 3.27 for 
vinylogous oxidation were also unsuccessful,38 as only , -unsaturated bicyclic lactone 
3.28 was isolated upon reaction of 3.23a with TBSOTf-Et3N or under other silylation 
conditions. 
 
 
Scheme 3.6. Synthetic studies toward -oxygenation of 3.23a 
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3.3.4 Completing the Synthesis of Bicyclic Allyl Iodide 3.31 
            Since -oxygenation of 3.23a was problematic, we turned to -halogenation for 
preparation of the corresponding allyl halide as an intermediate for introducing the 
hydroxyl group. However, attempts at allylic halogenation of 3.23a with NIS, NCS, I2, 
or Br2 led to complex reaction mixtures or recovery of 3.23a. A solution was eventually 
identified after extensive experimentation. It started from migratory mecuration of 3.23a 
with Hg(OAc)2 to give allylmercury intermediate 3.30, apparently through facile 
rearrangement of the reversibly formed Δ7, 22 mercurinium intermediate under the 
influence of the lactone. Iodinolysis of 3.30 with I2 gave allyl iodide 3.31. Attempts for 
direct oxidation of allyl mercury intermediate 3.30 to give allyl alcohol 3.32 afforded 
reductive demercuration product 3.28 only.45  
 
 
Scheme 3.7. Synthesis of allyl iodide 3.31 
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3.3.5 Completing the Synthesis of Bicyclic Lactone 3.4 
            With allyl iodide 3.31 in hand, our next step was to introduce the C22-hydroxyl 
group. Because it was still necessary to protect the hydroxyl group before the coupling 
of the two fragments, direct introduction of a PMB protected hydroxyl group would be 
more straightforward. We tested the possibility of displacing allyl iodide 3.31 with p-
methoxybenzyl alcohol (Scheme 3.8). However, common substitution reaction 
conditions, such as with NaH, KHMDS, Cs2CO3, K2CO3, or Ag2O, all failed to deliver 
3.4 directly. This problem was finally solved using a two-step sequence. Treatment of 
allyl iodide 3.31 with sodium formate, formed in situ from formic acid and sodium 
bicarbonate, provided allyl alcohol 3.32 after basic workup. The hydroxyl group was 
protected as its PMB ether to give bicyclic lactone 3.4.  
 
 
Scheme 3.8. Synthesis of bicyclic lactone 3.4 
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3.4 Synthetic Studies Toward Fragment 3.6 
            Our efforts toward synthesis of fragment 3.6 built upon the ease of access of 
known -keto ester 3.34 through -alkylation of the dienolate of ethyl acetoacetate with 
4-bromo-2-methylbut-1-ene 3.33 (Scheme 3.9).46 -keto ester 3.34 was stereoselectively 
(>20:1) converted to E-enoate 3.36 by CuCN-mediated methylation of the corresponding 
Z-enol triflate 3.35,47 which was prepared from 3.34 under biphasic reaction conditions 
with aqueous LiOH-Tf2O.
48  Whereas Fe-catalyzed methylation of enol triflate often 
proceeds with excellent yield and stereoselectivity,49 we were surprised that the reaction 
of 3.35 under such conditions caused significant isomerization of the enoate alkene of 
3.36 (E:Z ~ 3:1 to 1:1). Reaction of 3.36 with N, O-dimethylhydroxylamine by the 
Merck procedure gave Weinreb amide 3.37,50 which was converted to ketone 3.39 upon 
alkylation with allylmagnesium chloride 3.38.51 To our relief, no isomerization of the , 
-enone moiety of 3.39 was observed. Preparation of allyl alcohol 3.6 required 
enantioselective reduction of ketone 3.39. However, this -disubstituted enone was 
unreactive under Noyori transfer hydrogenation52 and LiAlH4/R-(+)-BINOL reduction 
conditions.53 While allyl alcohol 3.6 could be obtained by the CBS reduction of 3.39, 54 
no enantioselectivity was observed during this process.  
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Scheme 3.9.  Preparation of fragment 3.6 
 
3.5 Synthesis of the Allyl Iodide Fragment 3.5 
            We then turned to an aldol approach for stereoselective introduction of the C13 
hydroxyl group (Scheme 3.10). For this purpose, treatment of ester 3.36 with DIBAL-H 
followed by oxidation of the resulting allyl alcohol with Dess-Martin periodinane gave 
aldehyde 1.62. The tin (II) triflate mediated Nagao-Fujita aldol reaction of 1.62 with 
thiazolidinethione 1.63 in the presence of N-ethylpiperidine proceeded with excellent 
diastereoselectivity (>20:1, based on 1H NMR analysis) to give aldol product 1.64.55 
Protection of 1.64 as its tert-butyldimethylsilyl ether and methanolysis of the thione 
chiral auxiliary gave ester 3.41. Treatment of ester 3.41 with 3 equiv of organocerium 
reagent generated in situ by the reaction of trimethylsilylmethyllithium with anhydrous 
cerium (III) chloride resulted in double addition to give a bis(silylmethyl)carbinol.56 
Workup and exposure of the crude tertiary alcohol to silica gel facilitated Peterson 
elimination and delivered the allyl silane 3.42. Consistent with previous reports, 
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successful preparation of the allylsilane required the trimethylsilylmethylcerium reagent 
to be meticulously prepared. Under less stringent conditions, methyl ketone 3.44 was 
formed as the major product (>95% yield).57 Fortunately, methyl ketone 3.44 could be 
converted to allylsilane 3.42 in a two-step sequence that consists of transformation of 
methyl ketone 3.44 into its enol triflate followed by Pd-catalyzed Kumada coupling with 
trimethylsilylmethylmagnesium bromide (under the dash line, Scheme 3.10). Various 
protocols for iodinolyisis of allylsilane 3.42 were tested. The optimal results were 
obtained when 3.42 was treated with freshly recrystallized NBS followed by Finkelstein 
reaction with NaI to give allyl iodide 3.5. It was crucial to maintain the reaction in the 
dark to suppress radical bromination of the remote terminal 1, 1-disubstituted alkene.  
 
 
Scheme 3.10. Synthesis of fragment 3.5 
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Scheme 3.10. (Continued) Synthesis of fragment 3.5 
 
3.6 Synthesis of C22-Deoxyalotaketal A 
            To shed light on potential obstacles that might be encountered in the synthetic 
route, a pilot study of fragment coupling and subsequent transformations was carried out 
using 3.5 and 3.28 as model substrates. This study not only would illuminate nuances in 
assembling the unique spiroketal ring system of alotaketal A, but also would provide 
access to C22-deoxy and other analogues of alotaketal A for structure-activity 
relationship (SAR) studies. Process I of our synthetic design (Scheme 3.1) was 
employed because of the availability of fragment 3.5 and the perceived simplicity of its 
coupling event. Bicyclic lactone 3.28 was previously isolated as a side product (Scheme 
3.6 and Scheme 3.7). It could also be obtained in 95% yield upon treating 3.23a with 
DBU (Scheme 3.11). With 3.28 in hand, we explored its coupling with allyl iodide 3.5 
and the corresponding bromide 3.43 under a variety of conditions. Whereas all attempts 
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of coupling through the intermediacy of the allyllithium or allyl Grignard reagents 
prepared in situ were hampered by competing dimerization of the allyl halides, the two 
fragments (i.e. 3.28 and 3.5) were eventually coupled under Barbier conditions with 
SmI2 through an intermolecular reductive allylation to give lactol 3.45. No over 
reduction was observed even though excess of SmI2 was used.  Our attempts for global 
desilylation and spiroketalization of 3.45 with HF•Py or pTSA were unsuccessful due to 
the acid-sensitive nature of 3.45. Fortunately, the desired transformations could be 
effected in a stepwise manner. Thus, global desilylation of crude 3.45 with TBAF gave 
lactol 3.46, which was subjected to pTSA-mediated spiroketalization without 
purification. This led to the formation of tricyclic spiroketal 3.47 and its Δ10,11 isomer 
3.48 due to migration of Δ11, 23 alkene under the acidic conditions, with the latter isolated 
as the major product (1:3 to 1:6). Spiroketals 3.47 and 3.48 were oxidized with IBX to 
give C22-deoxyalotaketal A 3.49 and its isomer 3.50, respectively. The stereochemistry 
of the spiroketal centers was assigned by analogy to that of the natural product.        
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Scheme 3.11. Synthesis of C22-deoxyalotaketal A 
 
            The formation of 3.48 was mechanistically interesting because it could arise 
either from isomerization of oxocarbenium intermediate A by deprotonation/protonation 
to form D followed by cyclization to give 3.48 or from isomerization of the initially 
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formed product 3.47 through the intermediacy of oxocarbenium A and/ or B under the 
acidic conditions (Scheme 3.12). To illuminate the mechanistic subtleties of this process, 
the spiroketalization of 3.46 was tested with less acidic pyridinium p-toluenesulfonate 
(PPTS). Interestingly, spiroketalization of 3.46 with PPTS led to the formation of 
spiroketals 3.47 and 3.48 in equal amounts. Further experiments showed that 3.47 could 
be easily isomerized to 3.48 upon treatment with pTSA. However, no isomerization of 
3.47 was observed when it was treated with PPTS. These results suggested that part of 
the exo-to-endo isomerization of the Δ11, 23 alkene occurred through the intermediary of 
oxocarbenium A prior to spiroketalization. However, the significant isomerization of the 
alkene in the pTSA-promoted spiroketalization of 3.47 was mostly due to the unchecked 
equilibration of 3.47 to its thermodynamically more favorable Δ10,11 isomer 3.48.  
 
 
Scheme 3.12. Isomerization of the Δ11, 23 alkene 
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3.7 Completing the Total Synthesis of Alotaketal A 
            Building upon our preliminary studies, the successful synthesis of alotaketal A 
was shown in Scheme 3.13. The coupling of fragments 3.4 and 3.5 went smoothly by 
SmI2 mediated intermolecular reductive allylation under Barbier conditions to give lactol 
3.52. Desilylation of 3.52 with TBAF gave 3.53. This was followed by spiroketalization 
of crude 3.53 with PPTS. Interestingly, only the desired spiroketal 3.54 was formed 
during this process and the exo-to-endo isomerization of Δ7,22 alkene was not observed. 
Since 3.46 and 3.53 differ only by the C22 p-methoxybenzyloxy group, we speculated 
that the electron-withdrawing inductive effect of the alkoxy group and/or the cation-π 
stabilization of the oxocarbenium by the p-methoxybenzyloxy group might be 
responsible for their different reactivity profiles for spiroketalization. Oxidative removal 
of the PMB group with DDQ gave diol 3.55, an alotaketal A analogue with the enone 
moiety reduced to an allyl alcohol. Oxidation of 3.54 with IBX followed by oxidative 
cleavage of PMB group with DDQ gave synthetic alotaketal A. Its 1H and 13C NMR 
spectra were consistent with those of the natural product, as was its specific optical 
rotation. In addition, synthetic (-)-aloketal A was found to be identical to an authentic 
sample of the natural product on the basis of TLC and HPLC.  
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Scheme 3.13. Synthesis of (-)-alotaketal A 
 
3.8 Investigating the Bioactivity of Alotaketal A and Analogs 
            The goal of the next series of experiments was to collaborate with Prof. Jin 
Zhang from Johns Hopkins University to examine the effects of alotaketal A and its 
analogs 3.47-3.50 and 3.55 on cAMP/Protein Kinase A (PKA) signaling pathway. These 
effects were studied in HEK293 cells by fluorescence imaging using an optimized 
genetically encoded A kinase activity reporter (AKAR4),58 which is able to directly 
report the PKA activity by its change in fluorescence. The change in fluorescence is due 
to the phosphorylation-dependent conformational change of a tandem fusion domain, 
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composed of a substrate peptide for PKA and a phosphorylation recognition domain 
(Figure 3.2, a). The conformation change alters the distance or orientation between the 
two fluorescent proteins at the N and C termini of the reporter, generating a change in 
Förster resonance energy transfer (FRET) between them. In the context of AKAR4, the 
phosphorylation of the substrate domain by activated PKA causes a conformational 
change that brings the fluorescent proteins in close proximity to produce an increase in 
FRET which is detected as an increase in the ratio of yellow to cyan emission.  
            First, we tested each of these compounds (alotaketal A and its analogs 3.47-3.50 
and 3.55) in HEK293 cells transfected with AKAR4. Among them, 3.47-3.50 at 1 µM  
only induced slight changes in the ratio of yellow to cyan emission from the reporter, 
increasing the emission ratio by 1.07 ± 0.3% (n = 11; n = number of cells), 1.55 ± 0.8% 
(n =8), 1.28 ± 0.6% (n = 5), 1.22 ± 0.4% (n = 8), respectively (Figure 3.2, b and c). The 
relatively small responses from analogs 3.47-3.50 were due to the inactivity of the 
analogs and not from poorly functioning AKAR4 which was confirmed by the control 
experiment. The probes responded maximally upon addition of a cAMP-elevating 
cocktail consisting of the AC activator forskolin (Fsk) and the general PDE inhibitor 3-
isobutyl-1-methylxanthine (IBMX). 59  In contrast to analogs 3.47-3.50, 3.55 and 
alotaketal A produced significant responses of 6.7 ± 2.2% (n = 24) and 5.3 ± 2.5% (n = 
13) from AKAR4, respectively (Figure 3.2, b and c). Thus, these results show that 3.55 
and alotaketal A are active and involved in PKA activation.  
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Figure 3.2. Effects of alotaketal A and its analogs on cAMP/PKA signaling. (a) 
Schematic diagram of the AKAR4 FRET-based biosensor used in this series of 
experiments. (b) Bar graph showing AKAR4 responses in HEK 293T cells following 
treatment with 3.47 (1 μM; n = 11), 3.48 (1 μM; n = 8), 3.49 (1 μM; n = 5), 3.50 (1 μM; 
n = 8), 3.55 (1 μM; n = 24), and alotaketal A (1 μM; n = 13). (c) Representative time 
course graphs depicting AKAR4 responses to the inactive compound 3.47 (left) and 
active compound 3.55 (right). 
 
            We further evaluated the specificity of the alotaketal-induced AKAR4 responses 
by utilizing an AKAR4 T/A mutant probe containing a mutated PKA phosphorylation 
site within the PKA substrate domain. This mutation abolishes PKA phosphorylation 
and the PKA activity-induced FRET changes. No response was detected when cells 
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expressing the AKAR4 T/A mutant were treated with alotaketal A and 3.57, confirming 
that these compounds induce PKA activity via the cAMP/PKA signaling pathway 
(Figure 3.3). 
 
 
Figure 3.3. HEK293 cell expressing AKAR4 T/A mutant (A) were treated with 3.55  
(1 µM, n=6) and (B) alotaketal A (1 µM, n=4) 
 
            To examine further the effects of alotaketal A and 3.55 on cAMP accumulation, 
we used ICUE3, a FRET-based reporter for cAMP.60 The binding of cAMP to ICUE3 
induces a conformational change that results in a decrease in FRET, which is detected as 
an increase in the cyan/yellow emission ratio. When treated with 1 μM alotaketal A and 
3.55, the cells expressing ICUE3 showed 6.5 ± 0.32% (n = 10) and 4.4 ± 1.1% (n = 6) 
increases in the cyan/yellow emission ratio, respectively (Figure 3.4). These data suggest 
that both alotaketal A and 3.55 increase PKA activity by increasing cellular levels of 
cAMP. 
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Figure 3.4. HEK293 cells expressing ICUE3 were (A) treated with 3.55 (1 µM, n = 10) 
and (B) alotaketal A (1 µM, n = 6) 
 
            The mechanisms by which these compounds induce cAMP production and PKA 
activation are unknown. However, the following observation from imaging experiments 
suggested that they exhibited subcellular specificity when activating the pathway in 
living cells. As illustrated in the ratiometric images (Figure 3.5), the nuclear region 
showed a more drastic color change compared to the cytosol upon the addition of 3.55 or 
alotaketal A (Figure 3.5, a). We then quantitated the responses in these two cellular 
compartments. Alotaketal A elicited a response of 6.3 ± 2.5% (n = 6) in the nucleus and 
a mere 2.5 ± 0.21% (n = 6) in the cytosol, while analog 3.55 also had a similar response 
of 7.2 ± 0.71% (n = 5) in the nucleus and 2.5 ± 0.72% (n = 5) in the cytosol (Figure 3.5, 
b). These results are quite different from what has been seen when naïve HEK293 cells 
expressing AKAR4 are treated with forskolin and IBMX. As previously observed, the 
magnitude of the AKAR4 responses is smaller and kinetically slower in the nucleus than 
in the cytosol (Figure 3.5, c), 16.1 ± 0.11% (n = 8) and 70.8 ± 0.09% (n = 8) respectively, 
due to the activation of cytosolic PKA and subsequent translocation of the catalytic 
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domain of cytosolic PKA to the nucleus. 61  These results show that alotaketals are 
possibly targeting a different pool of cAMP/PKA signaling components, more 
specifically those found in the nucleus. 
 
 
 
Figure 3.5. Alotaketal A and 3.55 preferentially activate nuclear cAMP/PKA signaling. 
(a) Representative YFP and ratiometric images of AKAR4-expressing HEK293 cells 
treated with 3.55. (b) Time course graph depicting AKAR4 responses in the nucleus and 
cytoplasm of HEK293 cells after the addition of 3.55 (top panel) and alotaketal A 
(bottom panel). (c) YFP and ratiometric images of AKAR4 response after Fsk (50 μM) 
and IBMX (100 μM) treatment (top panel). Corresponding time course graph depicting 
AKAR4 responses in the nucleus and cytoplasm after the treatment (n = 8) (bottom 
panel). 
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3.9 Summary 
            We accomplished the first enantioselective total synthesis of the tricyclic 
sesterterpenoid (-)-alotaketal A, a potent cAMP signaling agonist that features an 
unprecedented spiroketal ring system. Two Barbier-type SmI2-mediated reductive 
allylation of esters with allyl iodides were employed in this convergent synthetic route: 
an intramolecular reductive coupling was crucial for the preparation of the key bicyclic 
lactone fragment whereas an intermolecular reductive coupling was employed to join the 
fragments and complete the sesterterpenoid molecular skeleton. During the 
spiroketalization to form the unique spiroketal ring system, our study revealed the subtle 
interplay of the structure and functional group stability/reactivity. Also highlighted is the 
Hg(OAc)2-mediated allylic mercuration of β, γ-unsaturated lactone to introduce the C22-
hydroxyl group with high chemo- and regio-selectivity. Using FRET imaging assays 
with genetically encoded AKAR4 reporter genes, we verified that the cAMP signaling 
pathway was activated by alotaketal A. Our preliminary SAR studies revealed the C22-
hydroxyl group to be important to alotaketal A’s bioactivity. On the other hand, 
reduction of the enone moiety to an allyl alcohol was tolerated, suggesting the enone 
moiety to be nonessential. Our FRET imaging studies revealed that alotaketal A and 
analog 3.55 activated the cAMP/PKA pathway in a subcellular specific manner.  
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CHAPTER IV  
TOTAL SYNTHESIS OF AN ANTIFUNGAL O-HYDROXY-P-QUINIONE 
METHIDE DITERPENOID* 
 
4.1 Retrosynthesis of o-Hydroxy-p-Quinone Methide Diterpenoid 1.67 
            The unnamed o-hydroxy-p-quinone methide diterpenoid 1.67 was reported to be 
potently antifungal (MIC=0.19 µM), even more potent than that of the clinical antifungal 
drugs amphotercin B and fluconazole. Although a number of approaches had been 
reported toward the structurally related taxodione prior to 1995,21 no any synthetic 
studies have been reported for this diterpenoid 1.67 since its isolation in 2000 by 
Hostettmann and co-workers from Bobgunnia madagascariensis.20 As part of our efforts 
toward chemical and biological characterization and potential biomedical application of 
this compound, we envisioned a convergent approach to 1.67. This route would serve to 
not only enable access of the natural product itself, but also allow preparation of analogs 
for structure-activity relationship and mode-of-action studies. In this regard, we 
envisioned that the o-hydroxyl-p-quinone methide moiety of 1.67 be prepared by 
oxidation of catechol 4.1 (Scheme 4.1). An intramolecular Friedel-Crafts alkylation of 
4.2 would be relied upon to build the tricyclic molecular framework. The precursor 4.2 
could be assembled by intermolecular coupling of commercially available -cyclocitral 
                                                 
* Reprinted with permission from “Total Synthesis and Biological Evaluation of an 
Antifungal Tricyclic o-Hydroxy-p-Quinone Methide Diterpenoid” by Huang, J.; Foyle. 
D.; Lin, X.; Yang, J. J. Org. Chem. 2013, 78, 9166-9173, Copyright [2013] by American 
Chemical Society 
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4.3 and benzyl chloride 4.4, which in turn could be synthesized from 3, 4-
dimethoxytoluene 4.5. With the intention of developing an asymmetric intramolecular 
Friedel-Crafts alkylation for enantioselective synthesis of 1.67, we initiated our synthetic 
studies.  
 
 
Scheme 4.1. Retrosynthesis of 1.67 
 
4.2 Synthetic Studies Toward Introducing the 2'-Hydroxyethyl Side Chain 
            Since compound 4.6 has been previously synthesized,62 our initial efforts focused 
on introducing a 2'-hydroxyethyl group to access a fully functionalized C ring of 1.67. 
We envisioned that it could be introduced through the coupling of the dianion of 4.7 or 
4.8 and known electrophile 4.1263,64 (Scheme 4.2). The aryl bromide 4.7 was prepared 
by bromination of known carboxylic acid 4.6. Reduction of the carboxyl group of 4.7 
with borane dimethyl sulfide provided benzyl alcohol 4.8 in quantitative yield. With 4.7 
and 4.8 in hand, we tested their coupling with 4.12 through their corresponding dianions 
generated by treatment with n-BuLi. However, only protonated product 4.6 and 4.9 were 
   
60 
 
isolated even when LiCl or HMPA was used as the additive to improve the 
nucleophilicity of the dianions. Since the carbon anion generated through the halogen-
metal exchange might be quenched by the carboxylic acid or benzyl hydroxyl group 
present in the substrate, the benzyl hydroxyl group of 4.7 was protected with TBS to 
give compound 4.10 and subjected to the coupling reaction. Again, only protonated 
product was isolated. We speculated that the congested environment of 4.7 and 4.8 
might be the reason for their low reactivity in the coupling reactions.  
 
4.3 Synthetic Studies Toward Introducing an Ethylene Side Chain 
            Because of the difficulties encountered in direct introduction of the 2'-
hydroxyethyl group, our attention turned to Stille coupling to introduce an ethylene 
group as its surrogate (Scheme 4.3). After extensive screening of reaction conditions, the 
coupling of known 4.13 with tributylvinyltin was achieved using Pd2(dba)3 and P(t-Bu)3 
to give 4.14 in 98% yield.65 DIBAL-H reduction of ester 4.14 yielded benzyl alcohol 
4.15, which was converted to benzyl chloride 4.16 in 92% yield. Whereas complex 
mixtures were obtained when lithium/naphthalene was used for coupling benzyl chloride 
4.16 and -cyclocitral,21c no desired product (i.e. 4.17) could be isolated from our 
attempts of coupling through the corresponding Grignard reagents of 4.16. We 
speculated that the extended conjugation system, the ethylene side chain, likely was 
incompatible with the radical reaction conditions.  
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Scheme 4.2. Studies for introducing the 2'-hydroxyethyl group 
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Scheme 4.3. Studies toward 4.17 
 
           We also tested the coupling of cyclocitral and 4.18, prepared from 4.8 through 
chlorination. The desired coupling did not occur either. (Scheme 4.4).  
 
 
Scheme 4.4. Studies toward 4.19 
 
            Since the ethylene side chain was the likely cause of the difficulty under the 
radical reaction conditions, we explored the possibility of furnishing the 2'-hydroxyethyl 
group prior to the coupling (Scheme 4.5). However, attempts to introduce the 2'-
hydroxyethyl group through hydroboration/oxidation with 4.14 was only partially 
successful as the undesired regio-isomer (i.e. 4.20) was formed as the major product 
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under all conditions except when BH2I•DMS was used,
66 which gave the desired regio-
isomeric product 4.21 slightly preferentially (2:1). 
 
 
Scheme 4.5. Hydroboration/oxidation 
 
4.4 Synthesis of 4.27 
            In order to improve the efficiency of the synthesis, we turn to allyl benzene 4.22 
(Scheme 4.6). We envisioned that the allyl group to be compatible with the 
lithium/naphthalene mediated coupling reaction since the extended conjugation is absent.  
To our glad, Stille coupling conditions proved to be also effective for reaction of 4.13 
and allyltributyltin to give 4.22 in quantitative yield. DIBAL-H reduction of ester 4.22 
followed by chlorination gave the desired benzyl chloride 4.23. As we had expected, the 
coupling of benzyl chloride 4.23 and -cyclocitral went smoothly to give 4.24 in 79% 
yield. IBX oxidation of the benzyl alcohol provided the , -unsaturated ketone 4.25. 
Our next task was to convert the allyl group to the 2'-hydroxyethyl side chain. Following 
the standard oxidative cleavage of the alkene of 4.25, aldehyde 4.26 was obtained in 85% 
yield over two steps. Selective reduction of the aldehyde in the presence of the , -
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unsaturated ketone functionality was achieved with NaBH(OAc)3 to give the primary 
alcohol 4.27. With this key intermediate in hand, our attention turned to the key 
intramolecular Friedel-Crafts alkylation.  
 
 
Scheme 4.6. Synthesis of 4.27 
 
4.5 Model Study of the Intramolecular Friedel-Crafts Alkylation 
            The intramolecular Friedel-Crafts reaction of 4.27 to form the carbon tricycle is 
challenging because it requires simultaneous dearomatization and formation of an all-
carbon quaternary center. Thus, to evaluate the feasibility and elucidate the nuances of 
this transformation, we used 1.69 as a model substrate to test various reaction conditions 
for the cyclization. The aromatic enone 1.69 was synthesized through 
   
65 
 
lithium/naphthalene mediated coupling of the known benzyl chloride 4.28 and -
cyclocitral followed by oxidation with IBX (Scheme 4.7).  
 
 
Scheme 4.7. Synthesis of 1.69 
 
4.5.1 Studies Toward Brønsted and Lewis Acid-Mediated Friedel-Crafts Alkylation 
            With enone 1.69 in hand, we tested both Brønsted and Lewis Acid acid-mediated 
intramolecular asymmetric Friedel-Crafts alkylation. A series of chiral phosphoric acids 
4.29 67  and bisoxazoline ligands 4.30 and 4.31 68  were prepared based on literature 
procedures or bought from Sigma Adrich. As shown in Figure 4.1, different chiral 
phosphoric acids 4.29 were evaluated for the Friedel-Crafts alkylation of 1.69 in various 
solvents at different temperatures. No desired product was favored. We also tested a 
number of Lewis acids as shown in Figure 4.1 with or without ligands (4.30-4.32). The 
desired product was not formed either.  
            The combination of formic acid and phosphoric acid was reported to be suitable 
for cyclization of 1.69 to give 1.70 in 41% yield at 115 oC (Scheme 4.8).21f  Interestingly, 
an extended reaction under such conditions led to formation of the undesired cis-
isomeric 1.71 as the major (38%), suggesting its thermodynamic nature. The BINOL-
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based chiral phosphoric acid 4.29c was also effective for the cyclization. The desired 
trans-isomer 1.70 was obtained in 43% yield, but no enantioselectivity was observed 
under the harsh conditions necessary for the reaction to proceed.  
 
 
Figure 4.1. Acid approach to Friedel-Crafts alkylation 
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Scheme 4.8. Acid-mediated Friedel-Crafts alkylation 
 
4.5.2 Studies Toward Chiral Amine-Mediated Friedel-Crafts Alkylation 
            Aiming to develop a catalytic asymmetric intramolecular Friedel-Crafts reaction 
through iminium catalysis, we also tested a primary-amine based chiral catalyst for the 
reaction with 1.69. Because of the sterically congested nature of the substrate, we 
focused on quinidine-derived primary amine 4.33 as the catalyst.69 Unfortunately, as 
shown in Figure 4.2, no cyclization was observed when enone 1.69 was treated with 
primary amine 4.33 and trifluroacetic acid in various solvents at different temperatures.  
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Figure 4.2. Attempts for Friedel-Crafts alkylation through iminium activation 
 
4.5.3 BBr3-Mediated Friedel-Crafts Alkylation 
            Although the trans-isomeric 1.70 could be synthesized by acid-mediated 
intramolecular Friedel-Crafts alkylation using a combination of formic acid and chiral 
phosphoric acid at elevated temperature, the harsh conditions of the reaction limited its 
substrate scope and rendered enantioselection less likely. To address this difficulty, we 
envisioned that the reaction might be able to proceed under milder conditions upon 
demethylation of 1.69 to give the corresponding catechol, which was expected to be 
more nucleophilic. To our surprise, treatment of enone 1.69 with BBr3 led to 4.34 as the 
only isomeric product (Scheme 4.9). Thus, BBr3 not only initiated bis-demethylation, it 
was also involved in the intramolecular Friedel-Crafts reaction in one-pot to give the 
cyclization product. The cyclization proceeded under much milder conditions than those 
reported by Stevens which was shown in Scheme 4.6 (Temp: 0 oC vs 115 oC; solvent: 
CH2Cl2 vs the mixture of HCO2H and H3PO4). No obvious oxidation of catechol 4.34 
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was observed when it was kept at -20 oC for one month. When 1.69 was treated with 
BF3•Et2O, no cyclization was observed and the starting material was recovered.  
 
 
Scheme 4.9. BBr3-mediated Friedel-Crafts alkylation 
 
            Encouraged by this result, we tested cationic oxazaborolidine 4.35 developed by 
Corey for potential asymmetric Friedel-Crafts cyclization of 1.69.70 However, no desired 
product was formed even when the reaction was warmed to room temperature (Figure 
4.3). With the addition of BBr3, the cyclization did proceed at 0 
oC in less than 30 min to 
give 4.34 in 20% yield, but with less than 20% enantioselectivity.  
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Figure 4.3. Chiral borane-mediated Friedel-Crafts alkylation 
 
4.5.4 TMSI-Mediated Friedel-Crafts Alkylation 
            As part of our efforts of developing an enantioselective Friedel-Crafts cyclization 
of 1.69, we sought to identify reaction conditions that decouple the demethylation 
reaction from the subsequent Friedel-Crafts cyclization process, which occurred in one-
pot when BBr3 was used. As shown in the Scheme 4.10, no desired product was isolated 
when enone 1.69 was treated with thiolate-based demethylating reagents, such as LiSEt 
and PhSK. Surprisingly, subjecting 1.69 to TMSI in toluene at 70 oC gave the cis-
isomeric 4.37 as the only product, with only one of the methoxyl group hydrolyzed.  
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Scheme 4.10. Demethylation of 1.69 
             
4.6 Total Synthesis of o-Hydroxy-p-Quinone Methide Diterpenoid 1.67 and Its 
Analogs 
            We applied the BBr3-mediated Friedel-Crafts alkylation for total synthesis of 
1.67 and analogs (Scheme 4.11). Thus, treatment of 4.27 with BBr3 led to one-pot bis-
demethylation and Friedel-Crafts cyclization to form a tricyclic catechol, which was 
subjected to oxidation with Ag2O to finish the total synthesis of 1.67. Comparison of the 
spectra of 1.67 with those reported for the natural product confirmed its identify. To 
elucidate the structure-activity relationship, analog 4.38 was prepared by protecting the 
2'-hydroxyethyl side chain with methyl chloromethyl ether.  
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Scheme 4.11. Total synthesis of 1.67 and its analog 4.38 
 
            To evaluate the effect of the 2'-hydroxyethyl side chain on the antifungal activity 
of 1.67, we also prepared analog 4.41 from known acid 4.6 (Scheme 4.12). Reduction of 
carboxylic acid 4.6 with borane dimethyl sulfide complex followed by chlorination 
provided the benzyl chloride 4.39. The coupling of benzyl chloride 4.39 and -
cyclocitral went smoothly to give an allyl alcohol, which was oxidized by IBX to give 
enone 4.40. The analog 4.41 was obtained by BBr3-mediated one-pot bis-demethylation 
and intramolecular Friedel-Crafts alkylation to give the tricyclic core, followed by Ag2O 
mediated oxidation of the resulting catechol.  
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Scheme 4.12. Synthesis of 4.41 
 
4.7 Synthesis of Taxodione  
            For further structure-activity relationship studies, we also applied the BBr3-
mediated one-pot bis-demethylation/Friedel-Crafts alkylation to synthesize taxodione (as 
shown in Scheme 4.9). Treatment of catechol 4.34 with Ag2O delivered the taxodione in 
87% yield (Scheme 4.13).  
 
 
Scheme 4.13. Synthesis of taxodione 
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4.8 Investigating the Bioactivity of Taxodione, 1.67 and Its Analogs 
            With taxodione, 1.67 and analogs in hand, we collaborated with Prof. Xiaorong 
Lin of Department of Biology at Texas A&M University to evaluate their antifungal 
activity against strains of pathogenic yeasts (Candida spp. and Cryptococcus spp.) and 
the filamentous fungus Aspergillus fumigatus. Candida, Cryptococcus, and Aspergillus 
species are the major fungal pathogens of global significance (Table 4.1).71 Consistent 
with the original report, the synthetic o-hydroxy-p-quinone methide 1.67 was found to 
be potently cytotoxic toward all the yeast strains tested, with MIC100 values ranging from 
0.4 to 6.4 mg/L. The MIC100 values were found to be similar to those of MFC (minimum 
fungicidal concentration), indicative of fungicidal rather than fungistatic nature of this 
compound. Compound 4.41 was also found to be effective against the yeast strains that 
have been tested, including the Candida glabrata, Candida krusei, and Candida 
parapsilosis strains that are resistant to the commonly used antifungal fluconazole.72 
These results suggest both 1.67 and 4.41 differ in their mode-of-action against fungi 
from fluconazole. Taxodione showed potent activity as well. However, the 
methoxymethyl ether of 1.67 (i.e. 4.38) showed significantly diminished growth 
inhibition activity. None of these compounds were effective against the mold A. 
fumigatus. It appears that the cytotoxicity of these compounds is correlated with the 
fungal growth mode (yeast vs mold) rather than their evolutionary relatedness, given that 
Candida and Aspergillus spp. are closely related while Cryptococcus spp. belongs to a 
different fungal phylum. The cause of the differential cytotoxicity of these compounds 
against yeasts and the filamentous fungal stains is currently unknown. 
   
75 
 
Table 4.1. Taxodione, 1.67 and its analogs exhibiting fungicidal effect (mg/L) 
Yeast/fungal strain 
MIC100 MFC* MIC100 MFC MIC100 MFC MIC100 MFC 
1.67 1.67 4.41 4.41 taxodione taxodione 4.38 4.38 
Cryptococcus gattii R265 0.4 0.4 0.8 0.8 0.8 0.8 6.4 12.8 
Cryptococcus neoformans H99α 0.4 0.8 0.8 0.8 1.6 1.6 6.4 12.8 
Candida albicans SC5314 6.4 12.8 3.2 6.4 6.4 >12.8 >12.8 >100 
Candida glabrata PAT2ISO3 1.6 6.4 1.6 3.2 3.2 >6.4 6.4 >12.8 
Candida krusei DUMC132.91 1.6 1.6 1.6 3.2 3.2 6.4 12.8 >12.8 
Candida parapsilosis 
MMRL1594 
3.2 6.4 1.6 3.2 6.4 12.8 12.8 >100 
Aspergillus fumigatus Af293 25.6 25.6 17.1 17.1 >100 >100 100 >100 
Aspergillus fumigatus CEA10 25.6 25.6 17.1 17.1 >100 >100 100 >100 
 
*: MFC is defined as the lowest drug concentration at which at least 99% of cells were 
killed compared to the original inoculums. Suspensions from the microdilution assay 
after 24 h (Candida species and Aspergillus fumigatus strains) or 48 h (for 
Cryptococcus) of incubation were plated on drug-free medium for obtaining the values 
of  colony forming units (CFU) to determine the minimal fungicidal concentration 
(MFC). Successive 2x serial dilutions of the drugs were used. 
 
4.9 Summary 
            We achieved the first total synthesis of 1.67, an unnamed tricyclic o-hydroxy-p-
quinone methide diterpenoid with potent antifungal activity. Stille coupling was 
employed to introduce the allyl group as a masked 2'-hydroxyethyl side chain. The 
lithium/naphthalene mediated coupling was used to assemble the benzyl chloride 4.23 
and -cyclocitral. We developed a BBr3-mediated one-pot bis-demethylation 
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/intramolecular Friedel-Crafts alkylation to assemble the tricyclic molecular skeleton of 
the diterpenoid, and finished the total synthesis of 1.67 and its analogs 4.38 and 4.41. 
We also applied our BBr3-mediated one-pot cyclization process to synthesize taxodione. 
Cell-proliferation assays in the presence of these compounds showed that 1.67, 4.41, and 
taxodione to be potently cytotoxic against strains of pathogenic yeasts, but etherification 
of the 2'-hydroxyethyl led to significantly attenuated activity. Surprisingly, these 
compounds were found to be ineffective against the fungal strain Aspergillus fumigatus. 
The cause of this discrepancy of activity against the yeasts versus filamentous fungi is 
currently unknown.  
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CHAPTER V  
CONCLUSIONS 
 
5.1 Synthetic Studies of Iriomoteolide-1a 
            Macrolide 2.1 was synthesized as part of our effort to identify the so far unknown 
stereochemical structure of iriomoteolide- 1a. Key features of the synthesis include using 
Evans chiral auxiliary-mediated syn-aldol reaction to deliver alkyne 2.4, a lithium 
acetylide-chloroformate coupling to synthesize 2.16, the ring closing metathesis to form 
the macrocycle 2.19 and a SmI2-mediated intramolecular reductive allylation for 
formation of the cyclic hemiketal (Scheme 5.1). 
            We collaborated with Dr. Jun Liu of Johns Hopkins University to investigate the 
cytotoxicity of 2.1 and previously synthesized diastereomers 1.1-1.3 using cell 
proliferation assays with HeLa and PC3 cell lines. Only diastereomer 2.1 showed a weak 
inhibiting effect on both cell lines at 10 µM. 
            Whereas 2.1 is still different from the natural product, it provides a useful 
reference for our future studies to elucidate the stereochemical structure of 
iriomoteolide-1a by computational methods, and enable the future mode-of-action study 
of the nature product. 
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Scheme 5.1. Synthesis of 2.1 
 
5.2 Total Synthesis of Alotaketal A 
            We accomplished the first enantioselective total synthesis of the potent cAMP 
signaling agonist (-)-alotaketal A. Our synthesis of fragment 3.4 featured a SmI2-
   
79 
 
mediated intramolecular reductive allylation to build the key bicyclic lactone 3.23a and a 
Hg(OAc)2-mediated allylic mercuration of , -unsaturated lactone 3.23a to introduce 
the C22-hydroxyl group of 3.4. The preparation of fragment 3.5 made use of Nagao-
Fujita aldol reaction of aldehyde 1.62 and thiazolidinethione 1.63 to provide excellent 
diastereocontrol of the newly formed C13 hydroxyl group. The aldol product 1.64 was 
converted to allyl iodide 3.5 in five steps.  
 
 
Scheme 5.2. Synthesis of fragment 3.4 and 3.5 
 
            Our total synthesis of alotaketal A also highlighted the Barbier-type SmI2-
mediated intermolecular reductive coupling for joining the fragments 3.4 and 3.5. 
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During the acid-mediated spiroketalization to form the unprecedented spiroketal ring 
system, our study revealed the subtle interplay of the structure and functional group 
stability/reactivity. With C22-deoxy 3.46 as the substrate, a 1:1 mixture of the desired 
spiroketal 3.47 and its Δ10, 11 isomer 3.48 was formed when PPTS was employed. To our 
surprise, no isomerization of Δ11, 23 alkene was observed when 3.53 was treated with 
PPTS. Since 3.46 and 3.53 differ only by the C22 p-methoxybenzyloxy group, we 
speculated that the electron-withdrawing inductive effect of the alkoxy group or the 
cation-π stabilization of the oxocarbenium by the phenyl ring might be responsible for 
their differential reactivity profiles for the spiroketalization.  
 
 
Scheme 5.3. Total synthesis of alotaketal A 
 
            During the total synthesis of alotaketal A, we also synthesized the analogs 3.47-
3.50 and 3.55 to elucidate the structure activity relationship (Figure 5.1). Using live cell 
FRET imaging assays with genetically encoded AKAR4 reporter genes, we verified that 
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the cAMP signaling pathway was activated by alotaketal A. Our preliminary SAR 
studies revealed that the C22-hydroxyl group was essential to alotaketal A’s bioactivity. 
Without the C22-hydroxyl group, the analogs 3.47-3.50 gave no response in the reporter 
gene assay. On the other hand, reduction of the enone moiety to an allyl alcohol was 
tolerated, suggesting that the enone functional group is not important to its activity. Thus, 
this hydroxy group provides a potential site for immobilization for activity-based protein 
target identification. Our FRET imaging studies also revealed alotaketal A’s unique 
activity in selectively targeting PKA signaling in the nucleus of living cells.  
             
 
Figure 5.1. Alotaketal A and its analogs 
 
            Recent studies had suggested that cAMP elicited highly specific cellular response 
to external stimuli via highly compartmentalized cAMP signaling. 73  Evidence of 
subcellular cAMP signaling domains in specific regions such as the nucleus has been 
presented through the identification of a functional pool of nuclear PKA holoenzyme, 
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and its regulators, the phosphodiesterase, PDE4, and scaffolding proteins such as A-
kinase anchoring proteins (AKAPs).74 Therefore, future experiments will focus on the 
identification of cellular targets of alotaketals and elucidation of their functions within 
the nucleus. 
 
5.3 Total Synthesis of o-Hydroxy-p-Quinone Methide Diterpenoid 1.67 
            We achieved the first total synthesis of an unnamed potently antifungal o-
hydroxy-p-quinone methide diterpenoid 1.67 in 10 steps from the known 4.13. Our total 
synthesis featured a Stille coupling to introduce the allyl group as the masked 2'-
hydroxyethyl side chain, a lithium/naphthalene mediated coupling reaction to assemble 
the fragments benzyl chloride 4.23 and -cyclocitral, and BBr3-mediated one-pot bis-
demethylation/intramolecular Friedel-Crafts alkylation to build the tricyclic molecular 
framework of 1.67. To elucidate the effect of the 2'-hydroxyethyl side chain of 1.67 over 
its bioactivity, the analog 4.41 was prepared in 6 steps from known 4.6 employing 
similar strategy. Our preliminary structure-activity relationship study showed that both 
1.67 and 4.41 are effective against yeast strains, including Candida glabrata, Candida 
krusei, and Candida parapsilosis, that are resistant to the commonly used antifungal 
fluconazole. Thus, the 2'-hydroxyethyl side chain of 1.67 is nonessential to its antifungal 
activity. Our future experiments will focus on elucidation of its antifungal mechanism 
and identification of the cellular targets.  
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Scheme 5.4. Total synthesis of 1.67 and 4.41 
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 A.1 General Information 
            All moisture sensitive reactions were carried out in flame-dried flasks under 
nitrogen atmosphere. Dichloromethane and diethyl ether were purified by passing 
through an activated molecular sieve solvent purification system. Tetrahydrofuran was 
freshly distilled over sodium and benzophenone. All other commercial reagents were 
used as received. In general, reactions were magnetically stirred and monitored by TLC 
performed on pre-coated glass-backed TLC plates, Silica Gel 60 F254 (EMD, 250 µm 
thickness). Spots were visualized with UV or through staining with an ethanolic solution 
of phosphomolybdic acid. Flash column chromatography was performed using 60Å 
Silica Gel (Silicycle, 230-400 mesh) as the stationary phase. 1H NMR chemical shifts are 
reported as δ values in ppm relative to CDCl3 (7.26 ppm) or C6D6 (7.16 ppm), coupling 
constants (J) are reported in Hertz (Hz), and multiplicity follows normal convention. 
CDCl3 (77.0 ppm) or C6D6 (128.39 ppm) served as the internal standard for 
13C NMR 
spectra. All 13C NMR spectra were measured with complete proton decoupling. Infrared 
spectra (IR) were recorded on a Bruker TENSOR 27 FT-IR Spectrophotometer. 
Resonance frequencies are given as wavenumbers in cm-1. Optical rotation were 
measured on a Rudolph Autopol II polarimeter and are reported as follows: [α]DT 
(c[10mg/mL], solvent). 
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 A.2 Experimental Procedures for Total Synthesis of 2.1 
 
            (4R,5S)-3-((2R,3S,7S,E)-9-(((tert-butyldimethylsilyl)oxy)methyl)-3-hydroxy-
7-((4-methoxybenzyl)oxy)-2-methyldeca-4,9-dienoyl)-4-methyl-5-phenyloxazolidin-
2-one (2.10). To a stirred solution of Evans chiral auxiliary 2.9 (520 mg, 2.23 mmol) in 
CH2Cl2 (10 mL) was added n-Bu2BOTf (2.44 mL, 2.44 mmol) followed by DIPEA (0.46 
mL, 2.64 mmol) at 0 oC under nitrogen. After being stirred for 30 min, the reaction was 
cooled to -78 oC and a solution of aldehyde 2.7 (820 mg, 2.03 mmol) in CH2Cl2 (2 mL) 
was added. The reaction was stirred at -78 oC for 1h, then warmed to 0 oC, and stirred for 
45 min. The reaction was quenched by the addition of a solution of pH = 7 phosphate 
buffer and MeOH (10 mL, 3:1, v/v). To the resulting slurry was then slowly added a 
mixture of MeOH / 30% aqueous H2O2 (7 mL, 2:1, v/v) and the mixture was stirred 
vigorously for 45 min at room temperature. The reaction was then extracted with ether 
and the combined organic layers were washed with water, saturated aqueous NaHCO3, 
brine and dried over Na2SO4, After concentration in vacuo, the residue was purified by 
flash column chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/5) 
to provide product 2.10 (1.23 g, 95 %) as a colorless oil. [α]D
20 8.55 (c 2.27, CHCl3); IR 
(film) 3020, 2954, 2928, 2851, 1776, 1649, 1607, 1513, 1457, 1247, 1211, 838, 752, 663 
cm-1; 1H NMR (300 MHz, CDCl3) δ 7.45-7.37 (m, 3H), 7.29-7.25 (m, 4H), 6. 87 (d, 
J=8.7 Hz, 2H), 5.86-5.76 (m, 1H), 5.69-5.53 (m, 2H), 5.13 (d, J=1.7 Hz, 1H), 4.90 (s, 
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 1H), 4.79-4.70 (m, 1H), 4.51-4.43 (m, 2H), 4.07 (s, 2H), 3.94-3.86 (m, 1H), 3.79 (s, 3H), 
3.67-3.50 (m, 1H), 2.69 (d, J=2.8 Hz, 1H), 2.38-2.21 (m, 4H), 1.23 (d, J=7.0 Hz, 3H), 
0.91 (s, 9H), 0.87 (d, J=6.6 Hz, 3 H), 0.05 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 176.3, 
159.1, 152.7, 145.6, 133.1, 131.6, 130.7, 129.4, 128.8, 128.7, 125.6, 116.4, 113.7, 111.2, 
78.9, 77.3, 72.8, 70.8, 66.1, 55.3, 54.8, 42.9, 37.8, 36.8, 25.9, 18.37, 14.4, 11.3, -5.4; 
HRMS (ESI): calculated for C36H52NO7Si
+ [M+H+] 638.3513, found 638.3533. 
 
            (2R,3S,7S,E)-3-((tert-butyldimethylsilyl)oxy)-9-(((tert-butyldimethylsilyl)oxy) 
methyl)-N-methoxy-7-((4-methoxybenzyl)oxy)-N,2-dimethyldeca-4,9-dienamide 
(2.11).  To a suspension of MeNHOMe hydrochloride (564 mg, 5.78 mmol) in THF (10 
mL) was cautiously added Me3Al (2M solution in toluene, 2.89 mL, 5.78 mmol) 
dropwise at 0 °C under nitrogen. Gas evolution was noted. After being stirred for 30 
min, the reaction was cooled to –78 °C and a solution of aldol imide 2.10 (1.23 g, 1.93 
mmol) in THF (2 mL) was added via cannula. The reaction was then warmed to room 
temperature, stirred for 1 h before it was quenched with saturated aqueous NH4Cl (25 
mL). The mixture was acidified with 1N HCl (25 mL) and extracted with EtOAc. The 
combined organic layers were washed with 1N HCl, saturated aqueous NaHCO3, brine 
then dried over Na2SO4. After concentration in vacuo, the residue was purified by flash 
column chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/2) to 
provide product weinreb amide (0.86 g, 85 %) as a colorless oil. 
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             To a solution of the above Weinreb amide (0.86 g, 1.65 mmol) in DMF (1.7 mL) 
was added imidazole (169 mg, 2.48 mmol) and TBSCl (298 mg, 1.98 mmol). The 
reaction was stirred at room temperature for 3h before it was diluted with EtOAc. The 
organic layer was washed with H2O, brine, and dried over Na2SO4. After concentration 
in vacuo, the residue was purified by flash column chromatography (silica gel, eluted 
with ethyl acetate/petroleum ether, 1/5 gradient to 1/2) to provide silylated product 2.11 
(1.01 g, 97 %) as a colorless oil. [α]D
20 5.35 (c 2.20, CHCl3); IR (film) 3017, 2952, 2928, 
2854, 1658, 1510, 1459, 1252, 1211, 835, 778, 666 cm-1; 1H NMR (300 MHz, CDCl3) δ 
7.23 (d, J = 8.3 Hz, 2H), 6.85 (d, J=7.7 Hz, 2H), 5.73-5.59 (m, 1H), 5.50 (dd, J = 16.0, 
6.4 Hz, 1H), 5.12 (s, 1H), 4.87 (s, 1H), 4.46 (d, J = 11.1 Hz, 1H), 4.40 (d, J = 11.1 Hz, 
1H), 4.21 (t, J = 7.6 Hz, 1H), 4.05 (s, 2H), 3.79 (d, J = 1.2 Hz, 3H), 3.61 (d, J = 1.2 Hz, 
3H), 3.57-3.45 (m, 1H), 3.10 (s, 3H), 3.03-2.86 (m, 1H), 2.30-2.17 (m, 4H), 1.17 (d, J = 
6.8 Hz, 3H), 0.90 (d, J = 1.2 Hz, 9H), 0.89 (d, J = 1.2 Hz, 9H), 0.06 (d, J = 0.9 Hz, 3H), 
0.04 (d, J = 1.2 Hz, 3H), 0.01 (d, J = 0.8 Hz, 3H), -0.00 (d, J = 1.2 Hz, 3H); 13C NMR 
(75 MHz, CDCl3) δ 159.0, 145.7, 134.2, 130.8, 129.1, 127.7, 113.7, 113.7, 110.8, 77.6, 
75.4, 70.6, 66.0, 61.4, 55.2, 42.8, 37.6, 36.7, 25.9, 25.9, 18.4, 18.2, 14.5, -4.0, -4.7, -5.4; 
HRMS (ESI): calculated for C34H62NO6Si2
+ [M+H+] 636. 4116, found 636.4104. 
 
            (5S,9S,E)-5-((S)-but-3-yn-2-yl)-9-((4-methoxybenzyl)oxy)-2,2,3,3,14,14,15,15-
octamethyl-11-methylene-4,13-dioxa-3,14-disilahexadec-6-ene (2.4). To a well stirred 
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 solution of silylated weinreb amide 2.11 (1.00 g, 1.57 mmol) in THF (15 mL) was added 
DIBAL-H (1 M in hexanes, 2.36 mL, 2.36 mmol) at -78 oC under nitrogen. The reaction 
was stirred at -78 °C for 2h before it was quenched by EtOAc (3 mL) and saturated 
aqueous Rochelle salt (10 mL). The mixture was stirred at room temperature until it 
became clear. The mixture was extracted with EtOAc and the combined organic layers 
were dried over Na2SO4. After concentration in vacuo, the residue was purified by flash 
column chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/10) to 
provide aldehyde (0.86 g, 95 %) as a colorless oil. 
            To a well stirred solution of i-Pr2NH (0.25 mL, 1.79 mmol) in THF (12 mL) was 
added n-BuLi (1.6 M in hexanes, 1.11 mL, 1.79 mmol) at 0 oC under nitrogen. After 
being stirred for 30 min, a solution of TMSCHN2 (2.0 M in hexane, 0.89 mL, 1.79 
mmol) was added dropwise at -78 oC, stirred for 20 min. A solution of the above 
aldehyde (0.86 g, 1.49 mmol) in THF (3 mL) was added. The reaction was slowly 
warmed to room temperature over 2h. After being quenched with aqueous NH4Cl, the 
mixture was extracted with EtOAc. The combined organic layers were dried over 
Na2SO4. After concentration in vacuo, the residue was purified by column 
chromatography (silica gel, ethyl acetate/petroleum ether, 1/60 gradient to 1/20) to 
provide alkyne 2.4 (0.53 g, 62 %) as a pale-yellow oil. [α]D
21 1.48 (c 2.13, CHCl3); IR 
(thin film) 2961, 2931, 2851, 1510, 1460, 1247, 1102, 871, 832, 746 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.26 (d, J = 8.3 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 5.79-5.63 (m, 1H), 
5.57 (dd, J=15.5, 6.5 Hz, 1H), 5.13 (s, 1H), 4.90 (s, 1H), 4.50 (d, J = 11.1 Hz, 1H), 4.44 
(d, J = 11.1 Hz, 1H), 4.08 (s, 2H), 3.98 (t, J=6.4 Hz, 1H), 3.80 (s, 3H), 3.62-3.55 (m, 
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 1H), 2.57-2.41 (m, 1H), 2.38-2.17 (m, 4H), 2.03 (dd, J=2.4, 0.9 Hz, 1H), 1.17 (d, J = 7.0 
Hz, 3H), 0.92 (d, J = 1.0 Hz, 9H), 0.90 (d, J = 1.0 Hz, 9H), 0.08 (s, 3H), 0.06 (d, J = 1.0 
Hz, 3H), 0.03 (s, 3H), 0.01 (d, J = 1.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 159.0, 
145.7, 133.6, 130.8, 129.2, 128.2, 113.7, 111.0, 86.8, 77.6, 76.4, 70.8, 69.7, 66.1, 55.2, 
37.6, 36.5, 33.7, 25.9, 25.9, 18.4, 18.2, 16.7, -4.0, -4.7, -5.4; HRMS (ESI): calculated for 
C33H56O4Si2Li
+ [M+Li+] 579.3877, found 579.3858. 
 
            (3R,4S,6R,7S)-7-((tert-butyldimethylsilyl)oxy)-3,6-dimethyloct-1-en-4-ol 
(A.1). To a solution of 2.12 (ca. 0.4 M in ether/THF, ~39 mL, 15.66 mmol) was added 
boron trifluoride etherate (2.22 mL, 18.01 mmol) followed by aldehyde 2.13 (1.80 g, 
7.83 mmol) at -78 °C. After being stirred at -78 °C for 2.5 h, the mixture was treated 
with 3 N NaOH (7.4 mL) and 35% H2O2 (4.0 mL). The mixture was refluxed for 1 h 
before it was cooled to room temperature and extracted with EtOAc. The combined 
organic extracts were washed with H2O, brine, and dried over Na2SO4. After 
concentration in vacuo, the residue was purified by column chromatography (silica gel, 
ether/petroleum ether = 1/10) to provide alcohol  A.1 (1.70 g, 76 %) as a colorless oil. 1H 
NMR (300 MHz, CDCl3) δ 5.86-5.74 (m, 1H), 5.08 (s, 1H), 5.05-5.02 (m,1H), 3.80-3.73 
(m, 1H), 3.57-3.50 (m, 1H), 2.79 (d, J=3.5Hz, 1H), 2.28-2.17 (m, 1H), 1.76-1.66 (m, 
1H), 1.54-1.35 (m, 2H), 1.11 (d, J = 6.3 Hz, 3H), 1.04 (d, J = 6.9 Hz, 3H), 0.94 (d, J 
=7.0 Hz, 3H), 0.89 (s, 9H), 0.06 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 140.4, 115.3, 
100
 72.0, 71.5, 43.7, 37.3, 36.2, 25.8, 20.3, 18.0, 16.3, 15.9, -4.5, -4.9; HRMS (ESI): 
calculated for C16H34O2SiLi
+ [M+Li+] 293.2488, found 293.2480. 
 
            tert-butyl(((2S,3R,5S,6R)-5-((4-methoxybenzyl)oxy)-3,6-dimethyloct-7-en-2-
yl)oxy)dimethylsilane (2.14). To a solution of alcohol A.1 (1.70 g, 5.94 mmol) and p-
methoxybenzyl trichloro-acetimidate (3.36 g, 11.88 mmol) in CH2Cl2 (10 mL) was 
added pTSA (114 mg, 0.6 mmol) and PPTS (141 mg, 0.6 mmol) at room temperature. 
After being stirred for 5 h, the reaction was diluted with ether (100 mL) and washed with 
water (30 mL). The aqueous layer was extracted with ether and the combined organic 
layers were dried over Na2SO4. After concentration in vacuo, the residue was purified by 
column chromatography (silica gel, ether/petroleum ether = 1/20) to provide product 
2.14 (1.43 g, 79 %) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.28 (d, J = 8.7 Hz, 
2H), 6.87 (d, J = 8.4 Hz, 2H), 5.88-5.76 (m, 1H), 5.06 (s, 1H), 5.01 (d, J = 7.2 Hz, 1H), 
4.46 (s, 2H), 3.80 (s, 3H), 3.72-3.64 (m, 1H), 3.37-3.32 (m, 1H), 2.51-2.46 (m, 1H), 
1.66-1.47 (m, 2H), 1.34-1.19 (m, 1H), 1.04 (d, J = 6.9 Hz, 3H), 1.01 (d, J = 6.3 Hz, 3H),  
0.89 (d, J = 0.6 Hz, 9H), 0.87 (d, J = 2.2 Hz, 3H), 0.03 (s, 3H), 0.03 (s, 3H); 13C NMR 
(75 MHz, CDCl3) δ 159.0, 140.5, 131.1, 129.3, 114.8, 113.6, 81.1, 71.7, 70.9, 55.2, 40.3, 
37.2, 33.5, 25.9, 19.1, 18.1, 15.3, 15.1, -4.4, -4.8; HRMS (ESI): calculated for 
C24H42O3SiLi
+ [M+Li+] 413.3063, found 413.3064. 
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             (3R,4S,6R,7S)-7-((tert-butyldimethylsilyl)oxy)-4-((4-methoxybenzyl)oxy)-
3,6-dimethyloctan-1-ol (A.2). To an ice cold solution of PMB ether 2.14 (1.40 g, 3.45 
mmol) in dry THF (10 mL) was added BH3∙THF (1.0 M in THF, 4.2 mL, 4.14 mmol) 
under nitrogen. The mixture was stirred at 0 °C for 1.5 h. After successive addition of 
water (0.8 mL), 3 N NaOH (1.1 mL), and 30% H2O2 (1.1 mL), the resulting mixture was 
stirred for an additional hour. The mixture was extracted with EtOAc (3x30 mL). The 
combined organic extracts were washed with brine (10 mL) and dried over anhydrous 
Na2SO4. After concentration in vacuo, the residue was purified by column 
chromatography (silica gel, ethyl acetate/petroleum ether = 1/5) to provide the alcohol 
A.2 (1.18 g, 81 %) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.25 (d, J = 8.7 Hz, 
2H), 6.86 (d, J = 8.7 Hz, 2H), 4.48 (d, J = 11.0 Hz, 1H), 4.41 (d, J = 11.1 Hz, 1H), 3.79 
(s, 3H), 3.73-3.65 (m, 2H), 3.61-3.53 (m, 1H), 3.35-3.30 (m, 1H), 2.41 (brs, 1H), 1.98-
1.89 (m, 1H), 1.67-1.52 (m, 4H), 1.36-1.27 (m, 1H), 1.04 (d, J = 6.3 Hz, 3H), 0.96 (d, J 
= 6.9 Hz, 3H), 0.89-0.87 (m, 12H), 0.04 (s, 3H), 0.03 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 159.0, 130.6, 129.3, 113.7, 81.6, 71.9, 71.0, 60.1, 55.2, 37.4, 34.3, 33.1, 32.2, 
25.8, 19.4, 18.0, 15.6, 15.3, -4.4, -4.8; HRMS (ESI): calculated for C24H44O4SiLi
+ 
[M+Li+] 431.3169, found 431.3166. 
 
            (3R,4S,6R,7S)-7-((tert-butyldimethylsilyl)oxy)-4-((4-methoxybenzyl)oxy)-
3,6-dimethyloctanal (A.3). To a solution of alcohol A.2 (1.50 g, 3.54 mmol) in DMSO 
(6 mL) was added IBX (1.49 g, 5.31 mmol) at room temperature. After being stirred for 
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 2h, the reaction was quenched with H2O (6 mL). The mixture was filtered and the 
aqueous phase was extracted with EtOAc. The combined organic layers were washed 
with brine, and dried over Na2SO4. After concentration in vacuo, the residue was 
purified by column chromatography (silica gel, eluted with ethyl acetate/petroleum ether 
= 1/4) to provide the aldehyde A.3 (1.36 g, 90 %) as a colorless oil. 1H NMR (300 MHz, 
CDCl3) δ 9.74 (s, 1H), 7.24 (d, J = 9.0 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 4.45 (t, J = 9.3 
Hz, 1H), 4.36 (d, J = 11.0 Hz, 1H), 3.80 (s, 3H), 3.70-3.63 (m, 1H), 3.28-3.23 (m, 1H), 
2.53-2.41 (m, 1H), 2.38-2.26 (m, 2H), 1.64-1.50 (m, 2H), 1.36-1.23 (m, 1H), 1.04 (d, J = 
6.2 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H), 0.91-0.88 (m, 12H), 0.03 (s, 3H), 0.03 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 202.3, 159.0, 130.6, 129.3, 113.6, 81.3, 71.9, 70.9, 55.2, 46.8, 
37.3, 33.6, 31.5, 25.8, 19.6, 18.0, 16.9, 15.7, -4.4, -4.8; HRMS (ESI): calculated for 
C24H42O4SiLi
+ [M+Li+] 429.3012, found 429.3018. 
 
            tert-butyl(((2S,3R,5S,6R)-5-((4-methoxybenzyl)oxy)-3,6-dimethylnon-8-en-2-
yl)oxy)dimethylsilane (2.15). To a stirred suspension of methyltriphosphonium iodide 
(2.61 g, 6.4 mmol) in THF (60 mL) was added dropwise n-BuLi (1.6 M in THF, 3.80 ml, 
6.1 mmol) until it became a clear yellow solution. Aldehyde A.3 (1.36 g, 3.2 mmol) in 
dry THF (2 mL) was added slowly. The reaction mixture was stirred at room 
temperature for 2 h before it was quenched with saturated aqueous NH4Cl (10 mL). The 
mixture was extracted with EtOAc (3x50 mL). The combined organic extracts were 
washed with H2O (10 mL) and brine (20 mL), and dried over Na2SO4. After 
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 concentration in vacuo, the residue was purified by column chromatography (silica gel, 
ethyl acetate/petroleum ether, 1/15) to provide alkene 2.15 (1.26 g, 94%) as a colorless 
oil. 1H NMR (300 MHz, CDCl3) δ 7.27 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 
5.85-5.71 (m, 1H), 5.03 (d, J = 9.8 Hz, 1H), 4.98 (s, 1H), 4.53-4.31 (m, 2H), 3.80 (s, 
3H), 3.75-3.67 (m, 1H), 3.33-3.29 (m, 1H), 2.19-2.12 (m, 1H), 1.98-1.83 (m, 2H), 1.69-
1.49 (m, 2H), 1.32-1.20 (m, 1H), 1.03 (d, J = 6.2 Hz, 3H), 0.9-0.89 (m, 15H), 0.03 (s, 
3H), 0.03 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 158.9, 137.8, 131.2, 129.2, 115.6, 
113.6, 81.3, 71.6, 70.7, 55.2, 37.6, 36.9, 35.2, 33.0, 25.9, 19.0, 18.1, 15.4, 14.8, -4.4, -
4.8; HRMS (ESI): calculated for C25H45O3Si
+ [M+H+] 421.3138, found 421.3135.  
 
            (4R,5S,7R,8S)-8-((tert-butyldimethylsilyl)oxy)-4,7-dimethylnon-1-en-5-ol 
(A.4). To a mixture of PMB ether 2.15 (1.26 g, 3.0 mmol) in CH2Cl2 (18 mL) and H2O 
(1 mL) was added DDQ (817 mg, 3.6 mmol). The resulting mixture was stirred at room 
temperature for 0.5 h before it was quenched by saturated aqueous NaHCO3 (10 mL). 
After being stirred for a further 15 min, the reaction mixture was extracted with EtOAc. 
The organic phase was washed with water, saturated aqueous NaHCO3, brine, and dried 
over anhydrous Na2SO4. After concentration in vacuo, the residue was purified by 
column chromatography (silica gel, ethyl acetate/petroleum ether, 1/10) to provide 
alcohol A.4 (757 mg, 84 %) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 5.87-5.72 
(m, 1H), 5.05-4.95 (m, 2H), 3.83-3.75 (m, 1H), 3.57-3.50 (m, 1H), 3.27 (d, J=3.2 Hz, 
1H), 2.30-2.20 (m, 1H), 1.97-1.86 (m, 1H), 1.78-1.70 (m, 1H), 1.67-1.61 (m, 1H), 1.50 
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 (t, J = 5.7 Hz, 2H), 1.16 (d, J = 6.3 Hz, 3H), 0.96 (d, J = 7.1 Hz, 3H), 0.93-0.87 (m, 
12H), 0.07 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 137.8, 115.6, 72.3, 71.1, 38.4, 37.5, 
37.0, 34.8, 25.8, 25.8, 20.8, 18.1, 16.7, 15.2 -4.4, -4.9; HRMS (ESI): calculated for 
C17H37O2Si
+ [M+H+] 301.2563, found 301.2567. 
 
            (4R,5S,7R,8S)-8-((tert-butyldimethylsilyl)oxy)-4,7-dimethylnon-1-en-5-yl 
carbonochloridate (2.6). To a stirred solution of alcohol A.4 (388 mg, 1.29 mmol) in 
carbon tetrachloride (5 mL) was added pyridine (120 μL, 1.49 mmol) followed by 
triphosgene (153 mg, 0.52 mmol). The resulting mixture was stirred at room temperature 
for 4 h before it was diluted with hexanes (60 mL). The solids were removed by 
filtration and the filtrate was evaporated to afford chloroformate 2.6 (459 mg, 98%) as a 
colorless oil. It was used directly for the next step without further purification. 
 
            (2E,4S,5S,6E,9S)-(4R,5S,7R,8S)-8-((tert-butyldimethylsilyl)oxy)-4,7-
dimethylnon-1-en-5-yl 5-((tert-butyldimethylsilyl)oxy)-11-(((tert-butyldimethylsilyl) 
oxy)methyl)-9-((4-methoxybenzyl)oxy)-3,4-dimethyldodeca-2,6,11-trienoate (2.17). 
To a solution of alkyne 2.4 (490 mg, 0.86 mmol) in THF (3.5 mL) was added n-BuLi 
(1.6 M in hexanes, 0.56 mL, 0.90 mmol) dropwise at −78 °C. After being stirred at −78 
°C for 45 min, HMPA (0.30 mL, 1.72 mmol) was added, stirred for 5 min, and then a 
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 solution of chloroformate 2.6 (310 mg, 0.86 mmol) in THF (0.8 mL) was added 
dropwise at −78 °C. After being stirred at −78 °C for 1 h, the reaction mixture was 
warmed to 0 °C over a period of 2 h and subsequently quenched by addition of saturated 
aqueous NH4Cl. The layers were separated and the aqueous phase was extracted with 
EtOAc (3x30 mL). The combined organic layers were dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by flash chromatography 
(silica gel, ethyl acetate/petroleum ether, 1/60 gradient to 1/5) to provide alkyne 2.4 (193 
mg) and alkynoate 2.16 (411 mg, 88% based on recovering staring material) as a clear oil.  
            To an ice-cold suspension of CuI (644 mg, 3.38 mmol) in THF (7 mL) was added 
MeLi (1.5 M in Et2O, 4.51 mL, 6.76 mmol) dropwise to give a clear solution. After 
being stirred at 0 °C for 1 h, the solution was cooled to −78 °C, treated with TMSCl 
(0.43 mL, 3.38 mmol), and stirred at this temperature for 5 min. A solution of alkynoate 
2.16 (304 mg, 0.33 mmol) in THF (2 mL) was added. The bright yellow solution was 
slowly warmed to 0 °C over a period of 3 h and quenched by addition of saturated 
aqueous NH4Cl (5 mL) and H2O (2 mL). The resulting biphasic solution was stirred 
vigorously for 20 min. The layers were separated and the aqueous phase was extracted 
with EtOAc (3x30 mL). The combined organic layer was washed with brine (10 mL), 
dried over Na2SO4. After concentration in vacuo, the residue was purified by column 
chromatography (silica gel, ethyl acetate/petroleum ether, 1/60 gradient to 1/20) to 
afford the alkenoate 2.17 (299 mg, 99%) as a light yellow oil. [α]D 
18 4.89 (c 2.15, 
CHCl3); IR (thin film) 2961, 2925, 2860, 1706, 1640, 1513, 1463, 1247, 1075, 832, 770 
cm-1; 1H NMR (300 MHz, CDCl3) δ 7.24 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 
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 5.83-5.57 (m, 3H), 5.45 (dd, J = 15.5, 6.6 Hz, 1H), 5.13 (d, J = 1.8 Hz, 1H), 5.03 (d, J = 
6.2 Hz, 1H), 4.98 (s, 1H), 4.96-4.89 (m, 1H), 4.88 (s, 1H), 4.45 (s, 2H), 4.12-4.07 (m, 
3H), 3.80 (s, 3H), 3.75-3.67 (m, 1H), 3.60-3.47 (m, 1H), 2.31-2.13 (m, 6H), 2.16 (d, J = 
1.1 Hz, 3H), 1.94-1.75 (m, 2H), 1.70-1.50 (m, 1H), 1.39-1.23 (m, 2H), 1.07 (d, J = 6.9 
Hz, 3H), 1.01 (d, J = 6.2 Hz, 3H), 0.94-0.84(m, 33H), 0.06-0.03 (m, 18H); 13C NMR (75 
MHz, CDCl3) δ 166.5, 161.5, 159.1, 145.6, 137.2, 134.5, 130.8, 129.2, 127.1, 117.0, 
116.0, 113.7, 111.0, 77.6, 75.1, 75.0, 70.9, 70.7, 66.1, 55.2, 50.7, 37.6, 37.2, 36.6, 36.5, 
36.2, 33.2, 25.9, 25.9, 25.9, 18.8, 18.4, 18.4, 18.2, 18.0, 15.1, 15.1, 13.6, -4.0, -4.5, -4.8, 
-4.9, -5.4; HRMS (ESI): calculated for C52H94O7Si3Li
+ [M+Li+] 921.6467, found 
921.6451. 
 
            (2E,4S,5S,6E,9S)-(4R,5S,7R,8S)-8-((tert-butyldimethylsilyl)oxy)-4,7-
dimethylnon-1-en-5-yl 5-((tert-butyldimethylsilyl)oxy)-11-(((tert-butyldimethylsilyl) 
oxy)methyl)-9-hydroxy-3,4-dimethyldodeca-2,6,11-trienoate (A.5). To a solution of 
the 2.17 (300 mg, 0.33 mmol) in CH2Cl2 (9.90 mL) and H2O (0.55 mL) was added DDQ 
(112 mg, 0.49 mmol). The resulting mixture was stirred at room temperature for 0.5 h 
before it was quenched by saturated aqueous NaHCO3 (4 mL). After being stirred for a 
further 15 min, the reaction mixture was extracted with EtOAc. The organic phase was 
washed with water, saturated aqueous NaHCO3, brine, and dried over Na2SO4. After 
concentration in vacuo, the residue was purified by column chromatography (silica gel, 
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 ether/petroleum ether, 1/10 to 1/7) to provide A.5 (214 mg, 82 %) as colorless oils. 
[α]D
19 4.76 (c 2.04, CHCl3); IR (thin film) 3020, 2958, 2934, 2857, 1709, 1643, 1463, 
1247, 1217, 832, 746 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.85-5.67 (m, 1H), 5.65 (s, 
1H), 5.63-5.56 (m, 1H), 5.44 (dd, J = 15.5, 6.6 Hz, 1H), 5.12 (d, J=1.5 Hz, 1H), 5.02 (d, 
J = 6.2 Hz, 1H), 4.98 (s, 1H), 4.93 (s, 2H), 4.15-4.04 (m, 1H), 4.09 (s, 2H), 3.75-3.66 
(m, 2H), 2.73 (d, J=3.0 Hz, 1H), 2.32-2.04 (m, 7H), 2.14 (s, 3H), 1.91-1.78 (m, 2H), 
1.60-1.51 (m, 1H), 1.34-1.24 (m, 1H), 1.07 (d, J = 6.9 Hz, 3H), 1.01 (d, J = 6.2 Hz, 3H), 
0.95-0.78 (m, 33H), 0.08 (s, 6H), 0.02-0.01(m, 12H); 13C NMR (75 MHz, CDCl3) δ 
166.5, 161.4, 145.4, 137.2, 134.9, 127.2, 117.0, 115.9, 113.7, 75.2, 75.0, 71.0, 69.8, 
66.7, 50.7, 41.5, 39.9, 37.2, 36.5, 36.2, 33.2, 25.9, 18.8, 18.3, 18.2, 18.0, 15.1, 15.1, 
13.9, -4.0, -4.5, -4.8, -4.9, -5.4; HRMS (ESI): calculated for C44H86O6Si3Na
+ [M+Na+] 
817.5624, found 817.5655. 
 
            (2E,4S,5S,6E,9R)-(4R,5S,7R,8S)-8-((tert-butyldimethylsilyl)oxy)-4,7-
dimethylnon-1-en-5-yl 5-((tert-butyldimethylsilyl)oxy)-11-(((tert-butyldimethylsilyl) 
oxy)methyl)-9-(((S)-2-hydroxy-2-methylbut-3-enoyl)oxy)-3,4-dimethyldodeca-
2,6,11-trienoate (2.18). To a solution of alcohol A.5 (180 mg, 0.22 mmol), acid 2.5 (79 
mg, 0.68 mmol), and PPh3 (178 mg, 0.68 mmol) in THF (3 mL) was added DEAD (40% 
in toluene, 0.31 mL, 0.68 mmol) dropwise under nitrogen. After being stirred for 
overnight at room temperature, the reaction mixture was extracted with EtOAc (3x30 
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 mL). The combined organic layers were washed with water, brine, and dried over 
Na2SO4. After concentration in vacuo, the residue was purified by column 
chromatography (silica gel, ethyl acetate/petroleum ether, 1/15 gradient to 1/12) to 
provide ester 2.18 (148 mg, 73%) as a clear oil. [α]D
20 -6.05 (c 2.11, CHCl3); IR (thin 
film) 3020, 2961, 2931, 2857, 1720, 1706, 1640, 1466, 1250, 1214, 1104,, 838, 770, 669 
cm-1; 1H NMR (300 MHz, CDCl3) δ 5.97 (dd, J = 17.1, 10.5 Hz, 1H), 5.83-5.69 (m, 1H), 
5.65 (s, 1H), 5.54-5.42 (m, 3H), 5.17-5.07 (m, 3H), 5.02 (d, J=5.6 Hz, 1H), 4.98 (s, 1H), 
4.95-4.88(m, 1H), 4.85 (s, 1H), 4.12-4.05 (m, 1H), 4.07 (s, 2H), 3.78-3.65 (m, 1H), 3.32 
(s, 1H), 2.36-2.27 (m, 4H), 2.24-2.11 (m, 3H), 2.14 (d, J=1.1, 3H), 1.92-1.73 (m, 2H), 
1.70-1.50 (m, 1H), 1.44 (s, 3H), 1.37-1.22 (m, 1H), 1.04 (d, J = 6.9 Hz, 3H), 1.02 (d, 
J=6.2 Hz, 3H), 0.94-0.83 (m, 33H), 0.15--0.15 (m, 18H); 13C NMR (75 MHz, CDCl3) δ 
174.9, 166.4, 161.1, 143.8, 139.5, 137.2, 136.1, 124.5, 117.1, 116.0, 114.5, 112.4, 75.0, 
74.6, 74.4, 73.7, 70.9, 65.6, 50.4, 37.2, 37.0, 36.5, 36.4, 36.2, 33.2, 25.9, 18.8, 18.5, 
18.3, 18.1, 18.0, 15.1, 15.1, 13.4, –4.1, -4.5, –4.8, –4.9, –5.4; -5.4 HRMS (ESI): 
calculated for C49H92O8Si3Na
+ [M+Na+] 915.5991, found 915.5959. 
 
            (3S,4E,7R,8S,11E,13S,14S,15E,18R)-14-((tert-butyldimethylsilyl)oxy)-8-
((2R,3S)-3-((tert-butyldimethylsilyl)oxy)-2-methylbutyl)-18-(2-(((tert-butyldimethyl 
silyl) oxy) methyl)allyl)-3-hydroxy-3,7,12,13-tetramethyl-1,9-dioxacyclooctadeca-4, 
11,15 -triene-2,10-dione (2.19). To a solution of Grubbs' 2nd generation catalyst (20 
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 mg, 0.024 mmol) in CH2Cl2 (50 mL) was added a solution of diene 2.18 (140 mg, 0.16 
mmol) in CH2Cl2 (7 mL) and the resulting solution was refluxed for 4 h under nitrogen. 
The solvent was removed under reduced pressure and the residue was purified by flash 
chromatography (silica gel, ether/petroleum ether, 1/8 to 1/5) to afford compound 2.19 
(98 mg, 72%) as a colorless oil. [α]D
20 -35.64 (c 2.10, CHCl3); IR (thin film) 3023, 2961, 
2928, 2857, 1703, 1643, 1466, 1256, 1214, 829, 767 cm-1; 1H NMR (300 MHz, CDCl3) 
5.88-5.79 (m, 1H), δ 5.62 (d, J=1.2 Hz, 1H), 5.53 (d, J = 15.2 Hz, 1H), 5.43-5.37 (m, 
2H), 5.22-5.15 (m, 1H), 5.08 (s, 1H), 4.99-4.93 (m, 1H), 4.83 (s, 1H), 4.13-4.01 (m, 2H), 
3.87-3.82 (m, 1H), 3.75-3.67 (m, 1H), 3.39 (s, 1H),  2.41-1.97 (m, 7H), 2.07 (s, 3H), 
1.89-1.80 (m, 1H), 1.77-1.67 (m, 1H), 1.42 (s, 3H), 1.35-1.26 (m, 2H), 1.15 (d, J = 6.8 
Hz, 3H), 1.02 (d, J = 6.2 Hz, 3H), 0.96-0.81 (s, 30H), 0.71 (d, J=6.7 Hz, 3H), 0.18--0.13 
(m, 18H); 13C NMR (75 MHz, CDCl3) δ 175.2, 166.6, 162.0, 143.9, 136.4, 133.7, 128.2, 
124.9, 116.6, 112.1, 79.0, 75.3, 74.0, 72.7, 71.2, 65.5, 50.5, 37.1, 36.7, 36.4, 36.1, 35.0, 
33.0, 25.9, 25.8, 25.5, 21.1, 19.1, 18.3, 18.2, 18.0, 17.7, 16.7, 15.5, -3.8, -4.5, -4.6, -4.8, -
5.4, -5.4; HRMS (ESI): calculated for C47H89O8Si3
+ [M+H+] 865.5865, found 865.5846. 
 
            (3S,4E,7R,8S,11E,13S,14S,15E,18R)-14-((tert-butyldimethylsilyl)oxy)-8-
((2R,3S)-3-((tert-butyldimethylsilyl)oxy)-2-methylbutyl)-3-hydroxy-18-(2-(hydroxy 
methyl)allyl)-3,7,12,13-tetramethyl-1,9-dioxacyclooctadeca-4,11,15-triene-2,10-
dione (A.6). To a solution of 2.19 (77 mg, 0.093 mmol) in anhydrous EtOH (5 mL) was 
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 added PPTS (2.33 mg, 0.010 mmol) and the reaction mixture was refluxed for 1.5 h 
under nitrogen. The solvent was removed under reduced pressure and the residue was 
purified by flash chromatography (silica gel, ethyl acetate/petroleum ether, 1/2) to afford 
2.19 (33.7 mg) and the primary alcohol A.6 (33.7 mg, 90% based on recovered starting 
material) as a colorless oil: [α]D
20 -34.40 (c 1.85, CHCl3); IR (thin film) 3449, 2961, 
2931, 2851, 1723, 1649, 1460, 1385, 1060, 1253, 838, 776 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 5.89-5.80 (m, 1H), 5.60 (s, 1H), 5.54 (d, J = 15.2 Hz, 1H), 5.47-5.34 (m, 2H), 
5.22-5.15 (m, 1H), 5.08 (s, 1H), 4.97-4.87 (m, 1H), 4.86 (s, 1H), 4.08 (s, 2H), 3.87-3.80 
(m, 1H), 3.77-3.59 (m, 1H), 3.41 (s, 1H), 2.46-1.95 (m, 7H), 2.07 (s, 3H), 1.87-1.78 (m, 
1H), 1.77-1.67 (m, 1H), 1.64-1.52 (m, 1H), 1.42 (s, 3H), 1.35-1.21 (m, 1H), 1.14 (d, 
J=6.8 Hz, 3H), 1.00 (d, J=6.1 Hz, 3H), 0.93-0.81 (m, 21H), 0.74 (d, J=6.8 Hz, 3H), 0.12 
(s, 3H), 0.06 (s, 3H), 0.01 (s, 3H), -0.01 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 175.6, 
166.5, 162.4, 144.2, 136.5, 133.7, 128.1, 124.9, 116.4, 113.5, 79.0, 75.1, 74.1, 73.2, 
71.2, 65.9, 50.5, 37.6, 36.9, 36.4, 35.1, 33.3, 25.8, 25.8, 25.7, 21.3, 19.0, 18.2, 18.0, 
17.7, 16.7, 15.5, -3.8, -4.5, -4.6, -4.8; HRMS (ESI): calculated for C41H75O8Si2
+[M+H+] 
751.5001, found 751.5016. 
 
            (3S,4E,7R,8S,11E,13S,14S,15E,18R)-14-((tert-butyldimethylsilyl)oxy)-8-
((2R,3S)-3-((tert-butyldimethylsilyl)oxy)-2-methylbutyl)-18-(2-(chloromethyl)allyl)-
3-hydroxy-3,7,12,13-tetramethyl-1,9-dioxacyclooctadeca-4,11,15-triene-2,10-dione 
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 (2.20). To an ice-cold solution of alcohol A.6 (60 mg, 0.080 mmol) in anhydrous CH2Cl2 
(3 mL) was added Et3N (17 μL, 0.12 mmol) followed by MsCl (7.5 μL, 0.096 mmol). 
The reaction mixture was stirred for 5 min at 0 °C before it was directly purified by flash 
chromatography (silica gel, ethyl acetate/petroleum ether, 1/3) to afford the crude 
mesylate (60.4 mg) as a colorless oil, which was dissolved in HMPA (1 mL) and treated 
with LiCl (31 mg, 0.73 mmol). The resulting mixture was stirred at room temperature for 
4 h and extracted with EtOAc (3x20 mL). The combined organic layers were washed 
with water, brine, and dried over Na2SO4. After concentration in vacuo, the residue was 
purified by column chromatography (silica gel, ethyl acetate/petroleum ether, 1/5) to 
provide chloride 2.20 (52.5 mg, 85% for two steps) as a clear oil: [α]D 
19 -36.80 (c 1.22, 
CHCl3); IR (thin film) 2961, 2928, 2857, 1717, 1640, 1457, 1380, 1256, 1217, 1105, 
835, 776 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.89-5.79 (m, 1H), 5.62 (d, J=1.3 Hz, 1H), 
5.54 (d, J=15.1 Hz, 1H), 5.46-5.39 (m, 2H), 5.28-5.20 (m, 1H), 5.19 (s, 1H), 4.99-4.93 
(m, 2H), 4.09 (d, J = 11.2 Hz, 1H), 4.00 (d, J = 12.3 Hz, 1H), 3.90-3.83 (m, 1H), 3.75-
3.64 (m, 1H), 3.34 (s, 1H), 2.52-2.29 (m, 3H), 2.25-2.13 (m, 3H), 2.08 (d, J=1.3, 3H), 
2.04-1.96 (m, 1H), 1.87-1.80 (m, 1H), 1.80-1.69 (m, 1H), 1.63-1.51 (m, 1H), 1.42 (s, 
3H), 1.35-1.24 (m, 1H), 1.16 (d, J=6.8 Hz, 3H), 1.02 (d, J=6.2 Hz, 3H), 0.95-0.81 (m, 
21H), 0.71 (d, J=6.8 Hz, 3H), 0.14 (s, 3H), 0.09 (s, 3H), 0.02 (s, 3H), 0.00 (s,3H); 13C 
NMR (75 MHz, CDCl3) δ 175.3, 166.6, 162.1, 140.8,. 136.7, 133.6, 128.4, 124.6, 117.5, 
116.6, 78.9, 75.3, 74.1, 72.2, 71.2, 50.5, 47.7, 37.1, 36.9, 36.4, 36.3, 35.0, 33.0, 29.7, 
25.9, 25.8, 25.5, 21.1, 19.1, 18.2, 18.0, 17.7, 16.7, 15.5, -3.8, -4.5, -4.6, -4.8; HRMS 
(ESI): calculated for C41H74ClO7Si2
+ [M+H+] 769.4662, found 769.4658. 
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            (3S,4E,7R,8S,11E,13S,14S,15E,18R)-18-(2-(chloromethyl)allyl)-3,14-
dihydroxy-8-((2R,3S)-3-hydroxy-2-methylbutyl)-3,7,12,13-tetramethyl-1,9-
dioxacyclooctadeca-4,11,15-triene-2,10-dione (A.7). To a stirred solution of TBS ether 
2.20 (52.5 mg, 0.068 mmol) in THF (2.4 mL) was added a solution of HF·py complex 
(0.80 mL). The reaction mixture was stirred for 20 h at room temperature and quenched 
by saturated aqueous NaHCO3 (5 mL). After stirring for a further 15 min, the reaction 
mixture was extracted with EtOAc. The organic phase was washed with water, saturated 
aqueous NaHCO3, brine, and dried over Na2SO4. After concentration in vacuo, the 
residue was purified by column chromatography (silica gel, ethyl acetate/petroleum 
ether, 1/2 to 1/1) to provide triol A.7 (34.5 mg, 94%) as a colorless oil: [α]D
19 -74.22 (c 
0.6, CHCl3); IR (thin film) 3446, 2958, 2928, 2848, 1729, 1709, 1640, 1460, 1377, 1214, 
1093, 870, 832, 752 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.89-5.79 (m, 1H), 5.65 (d, 
J=1.4 Hz, 1H), 5.63-5.44 (m, 3H), 5.25-5.18 (m, 2H), 5.05-4.98 (m, 2H), 4.10 (d, J = 
11.7 Hz, 1H), 4.01 (d, J = 11.1 Hz, 1H), 3.97-3.90 (m, 1H), 3.72-3.64 (m, 1H), 3.31 (s, 
1H), 2.46-2.31 (m, 3H), 2.26-2.15 (m, 3H), 2.12 (d, J=1.3 Hz, 3H), 2.07-1.96 (m, 1H), 
1.86-1.70 (m, 2H), 1.63-1.52 (m, 1H), 1.47-1.37 (m, 1H), 1.42 (s, 3H), 1.25 (d, J = 7.0 
Hz, 3H), 1.12 (d, J = 6.3 Hz, 3H), 0.90 (d, J = 6.8 Hz, 3H), 0.73 (d, J = 6.9 Hz, 3H); 13C 
NMR (125 MHz, CDCl3) δ 175.3, 166.9, 162.1, 140.7, 135.4, 133.6, 128.3, 126.7, 117.9, 
116.5, 78.2, 75.5, 74.1, 72.1, 71.5, 49.5, 47.8, 37.0, 36.7, 36.6, 36.1, 36.0, 33.1, 25.5, 
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 21.2, 19.7, 17.2, 16.6, 16.2; HRMS (ESI): calculated for C29H46ClO7
+ [M+H+] 541.2932, 
found 541.2958. 
 
            (3S,4E,7R,8S,11E,13S,14S,15E,18R)-18-(2-(chloromethyl)allyl)-3,7,12,13-
tetramethyl-8-((2R,3S)-2-methyl-3-((trimethylsilyl)oxy)butyl)-3,14-bis((trimethyl 
silyl)oxy)-1,9-dioxacyclooctadeca-4,11,15-triene-2,10-dione (2.21). To an ice-cold 
solution of alcohol A.7 (34.5 mg, 0.06 mmol) in anhydrous CH2Cl2 (1 mL) was added 
pyridine (46 μL, 0.58 mmol) followed by TMSOTf (52 μL, 0.29 mmol). The reaction 
mixture was stirred at 0 °C for 10 min before it was directly purified by flash 
chromatography (silica gel, petroleum ether/EtOAc, 20/1) to afford TMS silyl ether 2.21 
(45 mg, 93%) as a colorless oil: [α]D
19 -45.76 (c 0.54, CHCl3); IR (thin film) 2961, 2925, 
2857, 1744, 1714, 1649, 1252, 1211, 1105, 835, 752 cm-1; 1H NMR (300 MHz, CDCl3) 
δ 5.78-5.68 (m, 1H), 5.63 (d, J=1.3 Hz, 1H), 5.53 (d, J=15.1 Hz, 1H), 5.45-5.40 (m, 2H), 
5.29-5.22 (m, 1H), 5.17 (s, 1H), 5.03-4.97 (m, 1H), 4.95 (s, 1H), 4.08 (d, J = 10.9 Hz, 
1H), 3.99 (d, J = 11.8 Hz, 1H), 3.86 (dd, J = 9.6, 7.0 Hz, 1H), 3.72-3.64 (m, 1H), 2.49-
2.28 (m, 3H), 2.23-2.04 (m, 4H), 2.08 (d, J=1.3, 3H), 1.97-1.86 (m, 1H), 1.82-1.73 (m, 
2H), 1.45 (s, 3H), 1.36-1.25 (m, 1H), 1.14 (d, J = 6.8 Hz, 3H), 1.05 (d, J = 6.1 Hz, 3H), 
0.89 (d, J = 6.8 Hz, 3H), 0.68 (d, J = 6.7 Hz, 3H), 0.18 (s, 9H), 0.15 (s, 9H), 0.09 (s, 
9H); 13C NMR (75 MHz, CDCl3) δ 173.3, 166.7, 161.6, 141.2, 136.1, 134.7, 128.4, 
124.9, 117.0, 116.7, 78.9, 77.1, 75.7, 71.5, 70.3, 50.2, 47.8, 37.3, 36.8, 36.4, 36.1, 35.1, 
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 32.9, 26.9, 21.0, 19.5, 17.5, 16.7, 15.6, -2.3, -0.6, -0.2; HRMS (ESI): calculated for 
C38H69ClO7SiLi
+ [M+Li+] 763.4200, found 763.4241. 
 
            (1R,2S,3E,6R,7S,10E,12S,13S,14E,17R)-1,2,13-trihydroxy-7-((2R,3S)-3-
hydroxy-2-methylbutyl)-2,6,11,12-tetramethyl-19-methylene-8,21-dioxabicyclo 
[15.3.1] henicosa-3,10,14-trien-9-one (2.1). To a stirred solution of chloride 2.21 (43 
mg, 0.057 mmol) in acetone (2 mL) was added NaI (85 mg, 0.57 mmol). The reaction 
mixture was stirred at room temperature for 10 h before it was diluted with Et2O (50 
mL) and filtered by a short pad of silica gel. After concentration in vacuo, the crude 
iodide was used directly without further purification.  
            To an ice-cold solution of SmI2 (3.8 mL, 0.1 M in THF, 0.38 mmol) was added 
dropwise a solution of the above iodide (15.2 mg, 0.018 mmol) in THF (0.7 mL) under 
nitrogen. The deep blue mixture was stirred at 0 °C for 10 min before it was quenched 
by a mixture of saturated aqueous NaHCO3 (2 mL) and sodium potassium phosphate 
buffer solution (pH = 7). After stirring for a further 15 min, the reaction mixture was 
extracted with EtOAc. The organic phase was washed with water, saturated aqueous 
NaHCO3, brine, and dried over anhydrous Na2SO4. After concentration in vacuo, the 
residue was dissolved in THF (1.0 mL), to which was added a mixture of HF·py 
complex (20 μL ) and HF/TBAF/Py (20 μL). The reaction mixture was stirred at room 
temperature for 3 h and quenched by saturated aqueous NaHCO3 (1 mL). After stirring 
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 for a further 15 min, the reaction mixture was extracted with EtOAc. The organic phase 
was washed with water, saturated aqueous NaHCO3, brine, and dried over Na2SO4. After 
concentration in vacuo, the residue was purified by column chromatography (silica gel, 
petroleum ether/acetone, 2/1) to provide the diastereomeric iriomoteolide 1a 1 (4.6 mg, 
49% for three steps) as a colorless oil consisting of an equilibrating mixture of hemiketal 
2.1 and its ketol form. [α]D
19 -11.07 (c 0.6, CHCl3); IR (thin film) 2967, 2928, 2854, 
1661 1638, 1427, 1013, 871 cm-1; 1H NMR (500 MHz, CDCl3) δ= 5.72 (s, 1 H), 5.72-
5.70 (m, 2 H), 5.62-5.57 (m, 1 H), 5.45 (dd, J = 16.2, 9.1 Hz, 1 H), 4.87 (s, 1 H), 4.85-
4.80 (m, 1 H), 4.83 (s, 1 H), 3.77 (t, J = 9.1 Hz, 1 H), 3.64(dd, J = 11.9, 2.4 Hz, 1 H), 
3.61-3.53 (m, 1 H), 3.03 (s, 1 H),2.50-2.46 (m, 1 H), 2.44-2.35 (m, 1 H), 2.33 (d, J = 8.1 
Hz, 1 H), 2.25 (dd, J = 13.6, 10.3 Hz, 1 H), 2.17-2.11 (m, 3 H), 2.08 (s, 3 H), 2.06-1.98 
(m, 1 H), 1.93-1.88 (m, 1 H), 1.84-1.79 (m, 1 H), 1.51-1.45 (m, 1 H), 1.28 (d, J = 6.8 Hz, 
3 H), 1.15 (s, 3 H), 1.17-1.11 (m, 1 H), 1.07 (d, J = 6.3 Hz, 3 H), 1.02 (d, J = 7.1 Hz, 3 
H), 0.85 (d, J = 6.8 Hz, 3 H). 13C NMR (75 MHz, CDCl3) δ 168.1, 162.6, 141.2, 139.0, 
135.0, 128.0, 120.7, 115.7, 111.3, 97.0, 79.9, 75.8, 75.6, 73.7, 72.4, 48.4, 45.9, 43.8, 
38.0, 37.0, 36.2, 35.4, 33.6, 23.2, 21.5, 20.4, 17.7, 16.9, 15.9; HRMS (ESI): calculated 
for C29H46O7Na
+ [M+Na+] 529.3141, found 529.3152. 
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 Table A.1. Comparison of NMR data for natural iriomoteolide-1a and synthetic 2.1 
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 A.3 Experimental Procedures for Total Synthesis of Alotaketal A 
 
            (4S,5R)-4-Hydroxy-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-enone (3.7). To a 
solution of nitrosobenzene (10.80 g, 100.7 mmol) in CH2Cl2 (210 mL) were added acetic 
acid (5.76 mL, 100 mmol) and (5-isopropenyl-2-methyl-cyclohexa-1,3-dienyloxy)-
trimethyl silane 3.81 (9.33 g, 42.0 mmol) at −78 °C. The solution was stirred at this 
temperature for 12 h before being warmed to room temperature and further stirred for 4 
h. The solvent was removed under reduced pressure and the residue was purified by 
flash column chromatography (silica gel, ethyl acetate/petroleum ether, 1/2) to provide 
3.7 (4.12 g, 59%) as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 6.71-6.70 (m, 1H), 
4.98-4.97 (m, 1H), 4.95-4.94 (m, 1H), 4.46-4.42 (m, 1H), 2.72-2.67 (m, 1H), 2.50 (dd, J 
= 16.3, 3.9 Hz, 1H), 2.38 (dd, J = 16.4, 13.8 Hz, 1H), 1.79-1.78 (m, 3H), 1.76-1.75 (m, 
3H); 13C NMR (125 MHz, CDCl3) δ 198.5, 147.4, 143.0, 135.1, 114.8, 68.4, 52.7, 40.8, 
19.0, 15.4. 
 
           (1R,6R)-3-Methyl-4-oxo-6-(prop-1-en-2-yl)cyclohex-2-en-1-ylacrylate (3.10a). 
To a solution of 5β-hydroxycarvone 3.7 (83 mg, 0.5 mmol), acrylic acid (103 μL, 1.5 
mmol) and triphenylphosphine (394 mg, 1.5 mmol) in THF (2.5 mL) was added diethyl 
                                                 
(1)  Sarabèr,F. C. E.; Baranovsky, A.; Jansen, B. J. M.; Posthumus,  M. A.; Groot, A. d.  
       Tetrahedron 2006, 62, 1726.    
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 azodicarboxylate (0.68 mL, 40% in toluene, 1.5 mmol) dropwise at 0 °C under nitrogen. 
The resulting mixture was stirred at room temperature for 3 h, diluted with EtOAc (30 
mL), and washed with H2O and brine. The organic layer was dried over Na2SO4, 
concentrated and purified by flash column chromatography (silica gel, ethyl 
acetate/petroleum ether, 1/5) to provide 3.10a (52 mg, 47%) as a light yellow oil. [α]D
21 -
98.3 (c 1.96, CHCl3); IR (film, cm
-1) 2976, 2919, 1729, 1685, 1407, 1262, 1182, 1042, 
900, 809; 1H NMR (500 MHz, CDCl3) δ 6.79 (dd, J = 5.6, 1.5 Hz, 1H), 6.38 (dd, J = 
17.3, 1.4 Hz, 1H), 6.07 (dd, J = 17.3, 10.4 Hz, 1H), 5.84 (dd, J = 10.4, 1.4 Hz, 1H), 5.63-
5.61 (m, 1H), 4.94 (s, 1H), 4.75 (s, 1H), 2.86 (d, J = 12.6 Hz, 2H), 2.55 (dd, J = 12.5, 0.9 
Hz, 1H), 1.83 (dd, J = 1.4, 0.8 Hz, 3H), 1.78 (s, 3H); 13C NMR (125 MHz, CDCl3) 
199.2, 165.4, 142.8, 138.9, 138.6, 131.4, 128.0, 113.0, 66.4, 44.3, 37.9, 21.9, 15.6; 
HRMS (ESI): calculated for C13H16O3 [M+Li
+] 227.1259, found 227.1249. 
 
            (E)-(1R,6R)-3-methyl-4-oxo-6-(prop-1-en-2-yl)cyclohex-2-en-1-ylpent-2-
enoate (3.10b). To a solution of 5β-hydroxycarvone 3.7 (50 mg, 0.3 mmol), 2-pentenoic 
acid (0.09 mL, 0.9 mmol) and triphenylphosphine (237 mg, 0.9 mmol) in THF (2 mL) 
was added diethyl azodicarboxylate (0.42 mL, 40% in toluene, 0.9 mmol) dropwise at 0 
°C under nitrogen. The resulting mixture was stirred at room temperature for 3 h, diluted 
with EtOAc (30 mL) and washed with H2O and brine. The organic layer was dried over 
Na2SO4, concentrated and purified by flash column chromatography (silica gel, ethyl 
acetate/petroleum ether, 1/5) to provide product 3.10b (61.8 mg, 83%) as a light yellow 
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 oil. [α]D
21 -287.77 (c 2.14, CHCl3); IR (film, cm
-1) 2970, 2919, 1720, 1679, 1649, 1244, 
1176, 1116, 1025, 971; 1H NMR (300 MHz, CDCl3) δ 7.05-6.96 (m, 1H), 6.79 (dd, J = 
5.6, 1.5 Hz, 1H), 5.76 (dt, J =15.7, 1.7 Hz, 1H), 5.61-5.58 (m, 1H), 4.94 (s, 1H), 4.75 (s, 
1H), 2.88-2.80 (m, 2H), 2.60-2.47 (m, 1H), 2.27-2.17 (m, 2H), 1.83 (dd, J = 1.5, 0.8 Hz, 
3H), 1.78 (s, 3H), 1.06 (t, J = 7.4 Hz, 3H);13C NMR (75 MHz, CDCl3) δ 199.3, 166.0, 
151.8, 142.9, 139.0, 138.7, 119.7, 112.9, 66.1, 44.3, 37.9, 25.4, 21.9, 15.6, 12.0; HRMS 
(ESI): molecular ion was not observed. 
 
            (E)-4,4-diethyl 1-((1R,6R)-3-methyl-4-oxo-6-(prop-1-en-2-yl)cyclohex-2-en-
1-yl) hepta-1,6-diene-1,4,4-tricarboxylate (3.10c). To a solution of triethyl pent-4-ene-
1,2,2-tricarboxylate2 (5.0 g, 16 mmol) in EtOH (20 mL) was added 1 N NaOH (19.2 mL, 
19.2 mmol) at room temperature. The resulting mixture was stirred for 4 h before it was 
acidified with 2 N HCl. The aqueous layer was extracted with EtOAc. The combined 
organic layer was dried over Na2SO4, concentrated and purified by flash column 
chromatography (silica gel, ethyl acetate/petroleum ether, 1/2) to provide 3,3-
bis(ethoxycarbonyl)hex-5-enoic acid A.8 (3.51 g, 77%) as a colorless oil. IR (film, cm-1) 
2985, 1735, 1700, 1652, 1282, 1208, 1096, 927, 856; 1H NMR (500 MHz, CDCl3) δ 
6.92 (dt, J = 15.5, 7.7 Hz, 1H), 5.87 (dd, J = 15.5, 0.8 Hz, 1H), 5.66-5.58 (m, 1H), 5.15 
(dd, J = 2.8, 0.9 Hz, 1H), 5.12 (d, J = 0.9 Hz, 1H), 4.20 (q, J = 7.1 Hz, 4H), 2.78 (d, J = 
                                                 
(2)  De Riggi, I.; Gastaldi, S.; Surzur, J.-M.; Bertrand, M. P. J. Org. Chem. 1992, 57,    
       6118.   
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 7.7 Hz, 2H), 2.65 (d, J = 7.4 Hz, 2H), 1.25 (t, J = 7.1 Hz, 6H); 13C NMR (125 MHz, 
CDCl3) δ 171.1, 170.1, 145.8, 131.7, 124.2, 119.8, 61.6, 56.9, 37.4, 35.3, 14.1; HRMS 
(ESI): calculated for C14H20O6
 [M+Li+] 291.1420, found 291.1433. 
            To a solution of 5-hydroxycarvone 3.7 (83 mg, 0.5 mmol), 3,3-bis(ethoxy 
carbonyl)hex-5-enoic acid A.8 (426 mg, 1.5 mmol) and triphenylphosphine (394 mg, 1.5 
mmol) in THF (2.5 mL) was added diethyl azodicarboxylate (0.68 mL, 40% in toluene, 
1.5 mmol) dropwise at 0 °C under nitrogen. The resulting mixture was stirred at room 
temperature for 3 h, diluted with EtOAc (30 mL), washed with H2O and brine. The 
organic layer was dried over Na2SO4, concentrated and purified by flash column 
chromatography (silica gel, ethyl acetate/petroleum ether, 1/5) to provide 3.10c (121 mg, 
56%) as light yellow oil. [α]D
19 -174.17 (c 1.81, CHCl3); IR (film, cm
-1) 2985, 1726, 
1685, 1649, 1448, 1173, 1045, 915; 1H NMR (500 MHz, CDCl3) δ 6.82-6.76 (m, 2H), 
5.81 (d, J = 15.6 Hz, 1H), 5.65-5.56 (m, 2H), 5.13 (d, J =1.2, 1H), 5.10 (dd, J = 9.3, 1.9 
Hz, 1H), 4.92 (s, 1H), 4.73 (s, 1H), 4.19-4.16 (m, 4H), 2.88-2.77 (m, 2H), 2.74 (dd, J = 
7.7, 1.3 Hz, 2H), 2.62 (d, J = 7.5 Hz, 2H), 2.53 (dd, J = 15.2, 2.6 Hz, 1H), 1.83 (s, 3H), 
1.76 (s, 3H), 1.29-1.18 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 199.2, 170.1, 170.1, 
165.0, 143.9, 142.9, 138.8, 138.7, 131.7, 124.3, 119.7, 112.9, 66.3, 61.6, 56.9, 44.3, 
37.9, 37.3, 35.3, 21.9, 15.6, 14.1; HRMS (ESI): calculated for C24H32O7
 [M+Li+] 
439.2308, found 439.2288. 
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             (E)-(1R,4R,6R)-4-Hydroxy-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl 
pent-2-enoate (3.12a). To a solution of enone 3.10b (19 mg, 0.076 mmol) in MeOH 
(1.5 mL) was added CeCl3∙7H2O (43 mg, 0.12 mmol) at room temperature under 
nitrogen. The resulting suspension was stirred for 10 min, and cooled to -78 °C, then 
NaBH4 (3.5 mg, 0.092 mmol) was added in one portion. Once the reaction was complete 
(typically <10 min), it was immediately quenched with saturated aqueous NaHCO3. The 
aqueous phase was extracted with EtOAc. The combined organic layers were dried over 
Na2SO4, concentrated and purified by flash column chromatography (silica gel, ethyl 
acetate/petroleum ether, 1/4) to provide 3.12a (17.5 mg, 92 %) as yellow oil. [α]D
19 -
261.6 (c 2.02, CHCl3); IR (film) 2967, 2875, 2854, 1714, 1694, 1653, 1448, 1285, 1178, 
1119, 1093, 1045, 974, 918, 885; 1H NMR (300 MHz, CDCl3) δ 6.95 (dt, J = 15.6, 6.3 
Hz, 1H), 5.80-5.65 (m, 2H), 5.44-5.32 (m, 1H), 4.85 (s, 1H), 4.74 (s, 1H), 4.14 (brs, 1H), 
2.31 (d, J = 13.1 Hz, 1H), 2.25-2.03 (m, 3H), 1.95-1.84 (m, 1H), 1.83 (s, 3H), 1.75 (s, 
3H), 1.04 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 166.3, 150.7, 144.6, 143.5, 
121.9, 120.4, 111.6, 70.8, 66.8, 43.3, 32.2, 25.3, 22.0, 18.8, 12.1; HRMS (ESI): 
calculated for C15H22O3
 [M+Li+] 257.1729, found 257.1724. 
 
             (E)-(1R,4R,6R)-4-((tert-Butyldimethylsilyl)oxy)-3-methyl-6-(prop-1-en-2-
l)cyclohex-2-en-1-yl pent-2-enoate (3.12b): To a solution of allyl alcohol 3.12a (12 mg, 
0.048 mmol) in CH2Cl2 (1 mL) was added 2,6-lutidine (14 µL, 0.12 mmol) and TBSOTf 
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 (22 µL, 0.096 mmol) at 0 °C. After 15 min, the reaction was quenched with a sodium 
potassium phosphate buffer solution (pH = 7, 1 mL) and extracted with CH2Cl2 (3x10 
mL). The combined organic layers were washed with saturated aqueous NaHCO3 and 
dried over Na2SO4. After concentration in vacuo, the residue was purified by flash 
column chromatography (silica gel, ethyl acetate/petroleum ether, 1/15) to provide 3.12b 
(16.7 mg, 97 %) as yellow oil. [α]D
19 -188.8 (c 1.58, CHCl3); IR (film, cm
-1) 2958, 2928, 
2854, 1717, 1646, 1253, 1179, 1105, 891, 832; 1H NMR (300 MHz, CDCl3) δ 6.96 (dt, J 
= 15.7, 6.3 Hz, 1H), 5.74 (dt, J = 15.6, 1.6 Hz, 1H), 5.65-5.63 (m, 1H), 5.36-5.33 (m, 
1H), 4.85 (s, 1H), 4.73 (s, 1H), 4.14 (t, J = 8.0 Hz, 1H), 2.34-2.23 (m, 1H), 2.22-2.14 (m, 
2H), 1.94-1.82 (m, 2H), 1.75 (s, 6H), 1.04 (t, J = 7.4 Hz, 3H), 0.92 (s, 9H), 0.11 (s, 3H), 
0.11 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 166.4, 150.5, 144.9, 144.8, 121.0, 120.5, 
111.5, 71.4, 66.8, 43.3, 32.5, 25.9, 25.6, 25.3, 22.1, 19.6, 12.1, -4.1, -4.9; HRMS (ESI): 
calculated for C21H36O3Si
 [M+Li+] 371.2594, found 371.2606. 
 
            (4S,5R)-5-(3-Chloroprop-1-en-2-yl)-4-hydroxy-2-methylcyclohex-2-enone 
(3.16). To a suspension of calcium hypochlorite (1.50 g, 70% purity, 7.4 mmol) in water 
(3.4 mL) was added a solution of 5-hydroxycarvone 3.7 (1.88 g, 11.3 mmol) in 
dichloromethane (34 mL). Approximately 10 g of dry ice was added in small portions to 
this mixture with stirring over a period of 2 h. At the end of this period, the reaction 
mixture was filtered to remove insoluble salts. The organic layer was separated, dried 
over Na2SO4 and concentrated under reduced pressure. Purification by flash column 
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 chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/2) provided 
product 3.16 (1.45 g, 64 %) as a yellow oil. [α]D
21 106 (c 1.98, CHCl3); IR (film) 2964, 
2919, 1673, 1448, 1368, 1262, 1116, 1028, 891; 1H NMR (300 MHz, CDCl3) δ 6.70 (t, J 
= 1.8, 1H), 5.42 (s, 1H), 5.23 (s, 1H), 4.59 (d, J = 9.7 Hz, 1H), 4.16 (d, J = 11.8 Hz, 1H), 
4.11 (d, J = 11.8 Hz, 1H), 2.91-2.82 (m, 1H), 2.60 (dd, J = 16.3, 4.0 Hz, 1H), 2.48-2.38 
(m, 2H), 1.79 (t, J = 1.8, 3H); ); 13C NMR (75 MHz, CDCl3) 197.9, 147.6, 144.1, 135.3, 
118.2, 70.4, 48.4, 47.1, 41.7, 15.3; HRMS (ESI): calculated for C10H13ClO2 [M+Cl
+] 
235.0293, found 235.0288. 
 
            (1R,6R)-6-(3-Chloroprop-1-en-2-yl)-3-methyl-4-oxocyclohex-2-en-1-yl 
formate (3.17). To a solution of hydroxycarvone 3.16 (1.27 g, 6.3 mmol), formic acid 
(0.48 mL, 12.7 mmol) and triphenylphosphine (3.33 g, 12.7 mmol) in THF (63 mL) was 
added diethyl azodicarboxylate (5.78 mL, 40% in toluene, 12.7 mmol) dropwise at 0 °C 
under nitrogen. The resulting mixture was stirred at room temperature for 3h and then 
diluted with EtOAc (100 mL), washed with H2O and brine. The organic lay was dried 
over Na2SO4, concentrated and purified by flash column chromatography (silica gel, 
eluted with ethyl acetate/petroleum ether = 1/5) to provide product 3.17 (1.01 g, 70 %) 
as a light yellow oil. [α]D
21 -245 (2.05, CHCl3); IR (film) 2961, 2928, 1720, 1679, 1451, 
1359, 1261, 1158, 912; 1H NMR (300 MHz, CDCl3) δ 8.02 (d, J = 0.9 Hz, 1H), 6.76 (d, 
J = 5.8 Hz, 1H), 5.68 (brs, 1H), 5.38 (s, 1H), 5.06 (s, 1H), 4.18 (d, J = 12.0 Hz, 1H), 
4.07 (d, J = 12.0 Hz, 1H),  3.28 (d, J = 12.9 Hz, 1H), 2.90-2.80 (m, 1H), 2.55(dd, J = 
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 16.4, 3.9 Hz, 1H), 1.85 (s, 3H); 13C NMR (75 MHz, CDCl3) 198.1, 160.1, 142.4, 139.6, 
137.3, 118.1, 65.4, 47.2, 39.7, 37.4, 15.6; HRMS (ESI, MALDI): molecular ion was not 
observed. 
 
            (1R,4R,6R)-6-(3-chloroprop-1-en-2-yl)-4-hydroxy-3-methylcyclohex-2-en-1-
yl formate (3.18). To a solution of ester 3.17 (920 mg, 4.0 mmol) in MeOH (80 mL) 
was added CeCl3∙7H2O (2.26 g, 6.1 mmol) at room temperature under nitrogen. The 
resulting suspension was stirred for 10 min and cooled to -78 °C, then NaBH4 (185 mg, 
4.8 mmol) was added in one portion. Once the reaction was complete (typically <10 
min), it was immediately quenched with saturated aqueous NaHCO3. The aqueous phase 
was extracted with EtOAc. The combined organic layers were dried over Na2SO4, 
concentrated and purified by flash column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/2) to provide product 3.18 (857 mg, 92 %) as a yellow oil. 
[α]D
19-117 (c 2.35, CHCl3); IR (film) 2952, 2925, 2872, 1712, 1451, 1170, 1042, 924, 
888; 1H NMR (300 MHz, CDCl3) δ 7.96 (s, 1H), 5.69-5.65 (m, 1H), 5.44 (brs, 1H), 5.30 
(s, 1H), 5.05 (s, 1H), 4.25-4.02 (m, 3H), 2.76 (d, J = 13.2 Hz, 1H), 2.14-2.07 (m, 1H), 
1.94-1.79 (m, 1H), 1.86 (s, 3H), 1.74 (d, J = 7.1 Hz, 1H); 13C NMR (75 MHz, CDCl3); 
160.5, 144.8, 144.0, 120.6, 117.1, 70.4, 66.2, 47.5, 38.6, 31.8, 18.8; HRMS (MALDI): 
calculated for C11H15ClO3
 [M+Cl+] 266.0471, found 266.0482.  
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            (1R,4R,6R)-4-((tert-Butyldimethylsilyl)oxy)-6-(3-chloroprop-1-en-2-yl)-3-
methylcyclohex-2-en-1-yl formate (3.21a). To a solution of allyl alcohol 3.18 (857 mg, 
3.7 mmol) in DMF (3.7 mL) was added imidazole (507 mg, 7.5 mmol) and TBSCl (841 
mg, 5.6 mmol). The reaction was stirred at room temperature for 3h before it was diluted 
with EtOAc. The organic layer was washed with H2O, brine, and dried over Na2SO4. 
After concentration in vacuo, the residue was purified by flash column chromatography 
(silica gel, eluted with ethyl acetate/petroleum ether = 1/20) to provide 3.21a (1.23 g, 96 
%) as a yellow oil. [α]D
19 -152 (c 2.19, CHCl3); IR (film) 2958, 2934, 2860, 1717, 1256, 
1173, 1096, 1060, 903, 838; 1H NMR (300 MHz, CDCl3) δ 7.97 (s, 1H), 5.62 (d, J = 5.4 
Hz, 1H), 5.43-5.40 (m, 1H), 5.29 (s, 1H), 5.04 (s, 1H), 4.22-4.02 (m, 3H), 2.73 (t, J = 9.5 
Hz, 1H), 1.95-1.88 (m, 2H), 1.78 (s, 3H), 0.92 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H); 13C 
NMR (75 MHz, CDCl3); 160.5, 146.0, 144.3, 119.7, 116.9, 70.9, 66.2, 47.5, 38.6, 32.1, 
25.8, 19.6, 18.1, -4.1, -4.9; HRMS (ESI): calculated for C17H29ClO3Si
 [M+Li+] 
351.1735, found 351.1739.  
 
            (1R,4R,6R)-6-(3-Chloroprop-1-en-2-yl)-4-(methoxymethoxy)-3-methylcyclo 
hex-2-en-1-yl formate (3.21b): To a solution of allyl alcohol 3.18 (400 mg, 1.73 mmol) 
in dichloromethane (11 mL) was added N, N-diisopropylethylamine (0.58 mL, 3.46 
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 mmol). The reaction mixture was cooled to 0 °C before methyl chloromethyl ether (2.1 
mL, 2.1 M in toluene, 4.35 mmol) was introduced. The solution was stirred at room 
temperature for 12 h before it was poured into water (20 mL) and extracted with ethyl 
acetate. The combined organic layers were dried over Na2SO4. After concentration in 
vacuo, the residue was purified by flash column chromatography (silica gel, ethyl 
acetate/petroleum ether, 1/5) to provide 3.21b (450 mg, 95 %) as yellow oil. [α]D
21 -
209.4 (c 0.71, CHCl3); IR (film, cm
-1) 2949, 2931, 2890, 1720, 1173, 1143, 1101, 1034, 
927; 1H NMR (500 MHz, CDCl3) δ 7.97 (s, 1H), 5.70 (d, J = 5.5Hz, 1H), 5.43 (brs, 1H), 
5.30 (s, 1H), 5.06 (s, 1H), 4.82 (d, J = 6.9 Hz, 1H), 4.70 (d, J = 6.9 Hz, 1H), 4.16 (d, J = 
11.9, 1H), 4.14-4.10 (m, 1H), 4.04 (d, J = 11.9, 1H), 3.44 (s, 3H), 2.73 (d, J = 13.5 Hz, 
1H), 2.17-2.12 (m, 1H), 1.96-1.88 (m, , 1H), 1.83 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 160.5, 144.2, 143.8, 121.2, 117.1, 95.8, 75.5, 65.9, 55.7, 47.5, 38.4, 28.9, 19.3; HRMS 
(ESI): molecular ion not observed.  
 
            (4aR,6R,8aR)-6-((tert-Butyldimethylsilyl)oxy)-7-methyl-4-methylene-
3,4,4a,5,6,8a-hexahydro-2H-chromen-2-one (3.23a). To a solution of allyl chloride 
3.21a (0.98 g, 2.8 mmol) in acetone (28 mL) was added anhydrous NaI (4.29 g, 28 
mmol) at room temperature. The resulting mixture was stirred overnight before it was 
concentrated. The mixture was suspended in ether (20 mL) and filtered through a short 
pad of silica gel. After concentration in vacuo, the crude allyl iodide was used without 
further purification. 
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             To an ice-cold solution of SmI2 (200 mL, 0.1 M in THF, 18.9 mmol) was added a 
solution of the above allyl iodide (1.19 g, 2.7 mmol) in dry THF (10 mL) via cannula 
under nitrogen. The deep blue mixture was stirred at 0 °C for 10 min before it was 
quenched by a mixture of saturated aqueous NaHCO3 (40 mL) and sodium potassium 
phosphate buffer solution (pH = 7, 40 mL). After 15 min, the reaction mixture was 
extracted with EtOAc. The combined organic layers were washed with water, saturated 
aqueous NaHCO3, brine, and dried over Na2SO4. After concentration in vacuo, the 
residue was purified by flash column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/2) to provide lactols 3.22a (1:1 mixture of epimers, 643 mg, 
73%) as a colorless oil.  
            To a solution of lactols 3.22a (100 mg, 0.32 mmol) in DMSO (3 mL) was added 
IBX (180 mg, 0.64 mmol) at room temperature. The resulting mixture was stirred at 40 
°C. The reaction was quenched with H2O (3 mL) when it was complete (monitored by 
1H NMR due to similar Rf of 3.22a and 3.23a on TLC). The mixture was filtered and the 
aqueous phase was extracted with EtOAc. The combined organic layers were washed 
with brine, and dried over Na2SO4. After concentration in vacuo, the residue was 
purified by column chromatography (silica gel, eluted with ethyl acetate/petroleum ether 
= 1/2) to provide the product 3.23a (72 mg, 72%) as a light yellow oil. [α]D
21 -0.23 (c 
1.5, CHCl3); IR (film) 2955, 2925, 2851, 1750, 1643, 1250, 1096, 832; 
1H NMR (300 
MHz, CDCl3) δ 5.59 (d, J = 5.0 Hz, 1H), 5.05 (s, 1H), 5.03 (s, 1H), 4.66 (t, J = 4.5 Hz, 
1H), 4.20-4.15 (m, 1H), 3.26 (s, 2H), 2.71 (d, J = 13.0 Hz, 1H), 1.92-1.70 (m, 2H), 1.79 
(s, 3H), 0.89 (s, 9H), 0.10 (s, 3H), 0.08 (s, 3H); 13C NMR (75 MHz, CDCl3) 170.3, 
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 146.7, 140.1, 118.9, 112.9, 73.4, 69.9, 37.9, 37.3, 34.5, 25.8, 19.8, 18.0, -4.1, -4.9; 
HRMS (ESI): calculated for C17H28O3Si
 [M+H+] 309.1886, found 309.1874.  
 
            (4aR,6R,8aR)-6-(Methoxymethoxy)-7-methyl-4-methylene-3,4,4a,5,6,8a-
hexahydro-2H-chromen-2-one (3.23b): To a solution of allyl chloride 3.21b (450 mg, 
1.64 mmol) in acetone (16 mL) was added anhydrous NaI (2.46 g, 16.4 mmol) at room 
temperature. The resulting mixture was stirred overnight before it was concentrated. The 
mixture was suspended in ether (20 mL) and filtered through a short pad of silica gel. 
After concentration in vacuo, the crude allyl iodide was used without further 
purification.  
            To an ice-cold solution of SmI2 (93 mL, 0.1 M in THF, 9.28 mmol) was added a 
solution of the above allyl iodide (485 mg, 1.32 mmol) in dry THF (5 mL) via cannula 
under nitrogen. The deep blue mixture was stirred at 0 °C for 10 min before it was 
quenched by a mixture of saturated aqueous NaHCO3 (30 mL) and a sodium potassium 
phosphate buffer solution (pH = 7, 30 mL). After 15 min, the reaction mixture was 
extracted with EtOAc. The combined organic layers were washed with water, saturated 
aqueous NaHCO3, brine, and dried over Na2SO4. After concentration in vacuo, the 
residue was purified by flash column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/2) to provide lactols 3.22b (1:1 mixture of epimers, 258 mg, 
76%) as colorless oil.  
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             To a solution of lactols 3.22b (113 mg, 0.47 mmol) in DMSO (4 mL) was added 
2-iodoxybenzoic acid (266 mg, 0.95 mmol) at room temperature. The resulting mixture 
was stirred at 45 °C. The reaction was quenched with H2O (3 mL) when it was complete. 
The mixture was filtered and the aqueous phase was extracted with EtOAc. The 
combined organic layers were washed with brine and dried over Na2SO4. After 
concentration in vacuo, the residue was purified by column chromatography (silica gel, 
eluted with ethyl acetate/petroleum ether = 1/2) to provide 3.23b (84 mg, 75%) as light 
yellow oil. [α]D
21 -27.12 (c 2.12, CHCl3); IR (film, cm
-1) 2949, 2925, 2889, 1741, 1448, 
1241, 1152, 1102, 1028, 968, 906; 1H NMR (500 MHz, CDCl3) δ 5.69-5.66 (m, 1H), 
5.08-5.06 (m, 2H), 4.79 (d, J = 7.0 Hz, 1H), 4.69-4.67 (m, 1H), 4.67 (d, J = 7.0 Hz, 1H), 
4.12-4.09 (m, 1H), 3.41 (s, 3H), 3.31 (d, J = 17.6 Hz, 1H), 3.25 (d, J = 17.6 Hz, 1H), 
2.72 (d, J = 13.2 Hz, 1H), 2.23-2.09 (m, 1H), 1.85 (s, 3H), 1.80-1.73 (m, 1H); 13C NMR 
(125 MHz, CDCl3) δ 170.2, 144.5, 139.8, 120.2, 113.1, 95.8, 74.6, 73.0, 55.7, 37.9, 36.9, 
31.2, 19.4; HRMS (ESI): calculated for C13H18O4 [M+H
+] 239.1284, found 239.1288. 
 
            (4aR,6R,8aR)-6-((tert-Butyldimethylsilyl)oxy)-4-(iodomethyl)-7-methyl-
4a,5,6,8a-tetrahydro-2H-chromen-2-one (3.31). To a solution of , -unsaturated 
lactone 3.23a (320 mg, 1.0 mmol) in toluene (20 mL) was added Hg(OAc)2 (364 mg, 1.1 
mmol) under nitrogen. The mixture was stirred at 80 °C for 2 h. The reaction was cooled 
to room temperature and treated with aqueous KCl (619 mg, 8.3 mmol) in 5 mL of H2O. 
The mixture was stirred for 30 min, diluted with EtOAc, washed with brine, and dried 
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 over Na2SO4. After concentration in vacuo, the residue was dissolved in CH2Cl2 (10 
mL). To this mixture was added a solution of I2 (527 mg, 2.1 mmol) in CH2Cl2 (10 mL) 
under nitrogen. The resulting mixture was stirred for 30 min, quenched with saturated 
aqueous Na2S2O3 (10 mL), diluted with EtOAc, washed with water, and dried over 
Na2SO4. After concentration in vacuo, the residue was purified by column 
chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/5) to provide 
allyl iodide 3.31 (367 mg, 81%) as a white solid. [α]D
21 -3.24 (c 1.03, CHCl3); IR (film) 
2955, 2922, 2854, 1709, 1250, 1090, 974, 832; 1H NMR (300 MHz, CDCl3) δ 6.07 (s, 
1H), 5.65 (d, J = 5.0 Hz, 1H), 4.70 (t, J = 4.3 Hz, 1H), 4.17 (dd, J = 9.9, 5.8 Hz, 1H), 
4.05 (d, J = 9.8 Hz, 1H), 4.00 (d, J = 9.8 Hz, 1H), 2.67 (dt, J = 13.3, 3.3 Hz, 1H), 2.02-
1.94 (m, 1H), 1.82 (s, 3H), 1.80-1.67 (m, 1H), 0.90 (s, 9H), 0.12 (s, 3H), 0.10 (s, 3H); 
13C NMR (75 MHz, CDCl3) 163.7, 158.2, 146.3, 119.1, 117.3, 72.9, 69.8, 34.8, 32.2, 
25.7, 19.8, 18.0, 2.9, -4.1, -4.9; HRMS (ESI): calculated for C17H27IO3Si [M+H
+] 
435.0853, found 435.0861. 
 
            (4aR,6R,8aR)-6-((tert-Butyldimethylsilyl)oxy)-4-(hydroxymethyl)-7-methyl-
4a,5,6,8a-tetrahydro-2H-chromen-2-one (3.32). To a solution of allyl iodide 3.31 (367 
mg, 0.80 mmol) in DMF (10 mL) was added NaHCO3 (852 mg, 10.1 mmol) and formic 
acid (64 µl, 1.7 mmol) at room temperature under nitrogen. The mixture was stirred for 3 
h before MeOH (12 mL) and H2O (8 mL) were added. After additional 1 h, the mixture 
was concentrated. The residue was taken into EtOAc, washed with H2O, brine, and dried 
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 over Na2SO4. After concentration in vacuo, the residue was purified by column 
chromatography (silica gel, eluted with acetate/petroleum ether = 2/1) to provide the 
product 3.32 (237 mg, 86%) as a white solid. [α]D
18 -113 (c 2.02, CHCl3); IR (film) 
2958, 2925, 2854, 1682, 1253, 1105, 980, 888, 935; 1H NMR (300 MHz, CDCl3) δ 6.05 
(s, 1H), 5.63 (d, J = 5.0 Hz, 1H), 4.67 (t, J = 4.3 Hz, 1H), 4.41-4.26 (m, 2H), 4.14 (dd, J 
= 9.4, 5.8 Hz, 1H), 2.34 (dt, J = 13.4, 3.3 Hz, 1H), 1.97-1.90 (m, 1H), 1.80 (s, 3H), 1.76-
1.64 (m, 1H), 0.88 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
164.6, 162.1, 146.4, 119.1, 113.9, 72.7, 69.9, 62.6, 33.2, 32.2, 25.7, 19.8, 18.0, -4.2, -4.9; 
HRMS (ESI): calculated for C17H28O4Si
 [M+H+] 325.1835, found 325.1823. 
 
            (4aR,6R,8aR)-6-((tert-Butyldimethylsilyl)oxy)-4-(((4-methoxybenzyl) 
oxy)methyl)-7-methyl-4a,5,6,8a-tetrahydro-2H-chromen-2-one (3.4). To a solution of 
allyl alcohol 3.32 (160 mg, 0.49 mmol) in CH2Cl2 (10 mL) was added freshly prepared 
p-(methoxybenzyl)-trichloroacetimidate (PMBTCA) (180 mg, 0.64 mmol) and pTSA 
(28 mg, 0.15 mmol). The mixture was stirred at room temperature for 5 h before it was 
diluted with EtOAc. The organic layer was washed with saturated aqueous NaHCO3, 
H2O, brine, and dried over Na2SO4. After concentration in vacuo, the residue was 
purified by column chromatography (silica gel, eluted with ethyl acetate/petroleum ether 
= 1/2) to give 3.4 (200 mg, 93%) as a white solid.  [α]D
18 -65.6 (c 0.26, CHCl3); IR 
(film) 2958, 2928, 2857, 1703, 1516, 1247, 1108, 977, 835; 1H NMR (300 MHz, CDCl3) 
δ 7.26 (d, J = 8.6 Hz, 2H), 6.90 (d, J = 8.1 Hz, 2H), 6.03 (s, 1H), 5.63 (d, J = 5.1 Hz, 
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 1H), 4.65 (t, J = 4.3, 1H), 4.54 (d, J = 11.6 Hz, 1H), 4.45 (d, J = 11.5 Hz, 1H), 4.21-4.08 
(m, 3H), 3.82 (s, 3H), 2.37 (dt, J = 13.3, 3.1 Hz, 1H), 2.00-1.85 (m, 1H), 1.80 (s, 3H), 
1.77-1.61 (m, 1H), 0.89 (s, 9H), 0.09 (s, 3H), 0.05 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
164.2, 159.5, 159.1, 146.4, 129.5, 129.2, 119.2, 115.7, 114.0, 72.6, 72.6, 70.0, 69.1, 
55.3, 33.3, 32.0, 25.7, 19.7, 18.0, -4.2, -4.9; HRMS (ESI): calculated for C25H36O5Si
 
[M+H+] 445.2410, found 445.2397 
 
            (Z)-Ethyl 7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)octa-2,7-dienoate (3.35)  
A well-stirred solution of 3.3446a (7.93 g, 40 mmol) in hexanes (200 mL, 0.2 M) was 
cooled with an ice bath to 5-10 °C (internal temperature) and treated with a saturated 
aqueous solution of LiOH (60 mL, ~300 mmol) slowly. The resulting biphasic mixture 
was vigorously stirred at 5-10°C for ~ 5 minutes before dropwise addition of triflic 
anhydride (16.82 mL, 100 mmol) at a rate that maintained the internal temperature 
between 5-15 ºC. Upon completion of the reaction (as judged by TLC, typically <10 
min), triethylamine (20 mL) was added slowly followed by H2O (50 mL). The layers 
were separated and the aqueous layer was extracted with EtOAc (2x100 mL). The 
combined organic layers were washed with H2O, brine, and dried over Na2SO4. After 
concentration in vacuo, the residue was purified by flash column chromatography (silica 
gel, eluted with EtOAc/petroleum ether = 1/10) to provide product 3.35 (12.99 g, 98 %) 
as a light yellow liquid. IR (film) 3079, 2987, 2946, 1732, 1673, 1427, 1211, 1137, 
1027, 921 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.76 (s, 1H), 4.77 (s, 1H), 4.68 (s, 1H), 
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 4.24 (q, J = 7.1 Hz, 2H), 2.37(t, J = 7.6 Hz, 2H), 2.07 (t, J = 7.4 Hz, 2H), 1.77-1.69 (m, 
5H), 1.30 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 162.4, 158.6, 143.8, 118.3 
(q, J = 319 Hz), 112.0, 111.3, 61.2, 35.4, 33.8, 23.5, 22.0, 14.0; HRMS (ESI): calculated 
for C12H17F3O5S
+ [M+H+] 331.0827, found 331.0824. 
 
            (E)-Ethyl 3,7-dimethylocta-2,7-dienoate (3.36). To a stirred suspension of 
CuCN (3.46 g, 38.6 mmol) in dry ether (80 mL), methylmagnesium bromide (3M in 
ether, 7.8 mL, 23.2 mmol) was added dropwise at –78 °C under nitrogen and the 
resulting suspension was stirred at 0 °C for 5 min. The suspension was re-cooled to –78 
°C and a solution of enol triflate 3.35 (5.10 g, 15.5 mmol) in ether (10 mL) was added 
dropwise. After 15 min at –78 °C, the reaction mixture was quenched with saturated 
aqueous NH4Cl. The aqueous layer was extracted with ethyl acetate and the combined 
organic layers were dried with Na2SO4 and concentrated. The residue was purified by 
flash column chromatography (silica gel, eluted with EtOAc/petroleum ether = 1/20) to 
provide product 3.36 (2.88 g, 95 %) as a light yellow liquid. IR (film) 3076, 2981, 2934, 
1712, 1643, 1371, 1226, 1143, 1030, 885 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.65 (s, 
1H), 4.70 (s, 1H), 4.65 (s, 1H),, 4.12 (q, J = 6.9 Hz, 2H), 2.13-2.08 (m, 5H), 1.98 (t, J = 
7.7 Hz, 2H), 1.68 (s, 3H), 1.64-1.54 (m, 2H), 1.25 (t, J = 6.5 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 166.8, 159.8, 145.1, 115.6, 110.3, 59.4, 40.3, 37.1, 25.2, 22.2, 18.7, 
14.3; HRMS (ESI): calculated for C12H20O2
 [M+H+] 197.1542, found 197.1550. 
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             (E)-N-Methoxy-N,3,7-trimethylocta-2,7-dienamide (3.37). To a solution of E-
alkenoic ester 3.36 (904 mg, 4.61 mmol) and N,O-dimethylhydroxyamine hydrochloride 
(899 mg, 9.22 mmol) in THF (12 mL) was added i-PrMgCl (10.4 mL, 2 M in THF, 
20.75 mmol) dropwise at -5 °C. The mixture was stirred for 30 min and quenched with 
sat. aq. NH4Cl (30 mL). The mixture was extracted with ethyl acetate. The combined 
organic layers were washed with brine and dried over Na2SO4. After concentration in 
vacuo, the residue was purified by flash column chromatography (silica gel, ethyl 
acetate/petroleum ether = 1/5) to give Weinreb amide 3.37 (896 mg, 92% yield) as 
colorless oil. IR (film, cm-1) 2970, 2940, 1658, 1635, 1436, 1362, 1173, 1099, 980, 883; 
1H NMR (300 MHz, CDCl3) δ 6.10 (s, 1H), 4.71 (s, 1H), 4.67 (s, 1H), 3.65 (s, 3H), 3.20 
(s, 3H), 2.15-2.10 (m, 5H), 2.01 (t, J = 7.5, 2H), 1.70 (s, 3H), 1.66-1.56 (m, 2H); 13C 
NMR (75 MHz, CDCl3) 145.3, 114.0, 110.2, 61.3, 40.6, 37.2, 25.4, 22.3, 18.6; HRMS 
(ESI): calculated for C12H21NO2
 [M+H+] 212.1651, found 212.1653. 
 
            (E)-2-(((4-Methoxybenzyl)oxy)methyl)-6,10-dimethylundeca-1,5,10-trien-4-
one (3.39). To a well-stirred suspension of magnesium turnings (1.38 g, 57.0 mmol) in 
anhydrous THF (12 mL) was added 1,2-dibromoethane (0.17 mL, 1.97 mmol) under 
nitrogen. The reaction mixture was stirred at room temperature for 30 min and a solution 
of the corresponding allyl chloride (1.77 g, 7.86 mmol) in anhydrous THF (4 mL) was 
introduced dropwise in 30 min. After an additional 1.5 h, the freshly prepared Grignard 
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 reagent was transferred to Weinreb amide 3.37 (565 mg, 2.68 mmol) in THF (10 mL) at 
-78 °C via cannula. The reaction mixture was stirred at -78 °C for 30 min and quenched 
with aqueous NH4Cl. After warming to room temperature, the aqueous layer was 
extracted with ethyl acetate. The combined organic layers were washed with H2O, brine 
and dried over Na2SO4. After concentration in vacuo, the residue was purified by flash 
column chromatography (silica gel, ethyl acetate/petroleum ether, 1/10) to give 3.39 
(910 mg, 98% yield) as colorless oil. IR (film, cm-1) 2937, 2854, 1679, 1611, 1513, 
1244, 1173, 1099, 1028, 883, 814; 1H NMR (300 MHz, CDCl3) δ 7.28 (d, J = 8.1 Hz, 
2H), 6.90 (d, J = 8.7 Hz, 2H), 6.14 (s, 1H), 5.27 (s, 1H), 5.07 (s, 1H), 4.76 (s, 1H), 4.71 
(s, 1H), 4.44 (s, 2H), 4.01 (s, 2H), 3.83 (s, 3H), 3.24 (s, 2H), 2.16-2.11 (m, 5H), 2.03 (t, J 
= 7.6 Hz, 2H), 1.74 (s, 3H), 1.68-1.58 (m, 2H); 13C NMR (75 MHz, CDCl3) 198.2, 
159.6, 159.1, 145.2, 140.4, 130.3, 129.3, 122.7, 115.9, 113.7, 110.4, 72.7, 71.8, 55.3, 
48.8, 40.7, 37.2, 25.3, 22.3, 18.4; HRMS (ESI): calculated for C22H30O3
 [M+H+] 
343.2273, found 343.2278. 
 
            (E)-2-(((4-Methoxybenzyl)oxy)methyl)-6,10-dimethylundeca-1,5,10-trien-4-
ol (3.6): A solution of (R)-(+)-2-methyl-CBS-oxazaborolidine (60 µL, 0.06 mmol) in 
THF (0.3 mL) was treated with BH3∙DMS (30 µL, 2 M in THF, 0.06 mmol) at room 
temperature. After stirring for 15 min, the mixture was cooled to -78 °C and a solution of 
enone 3.39 (17 mg, 0.05 mmol) in THF (0.3 mL) was added through cannula. The 
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 reaction was stirred at -78 °C for 3 h before it was slowly warmed to room temperature. 
The reaction was quenched by the addition of MeOH followed by H2O. The aqueous 
phase was extracted with ethyl acetate. The combined organic layers were dried over 
Na2SO4. After concentration in vacuo, the residue was purified by flash column 
chromatography (silica gel, ethyl acetate/petroleum ether, 1/2) to give racemic 3.6 (14.6 
mg, 85% yield) as colorless oil.. IR (film, cm-1) 2935, 2854, 1649, 1617, 1513, 1442, 
1247, 1170, 1037, 891, 820; 1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 8.6 Hz, 2H), 
6.88 (d, J = 8.7 Hz, 2H), 5.20 (d, J = 8.4 Hz, 1H), 5.16 (s, 1H), 5.05 (s, 1H), 4.70 (s, 
1H), 4.67 (s, 1H), 4.52-4.48 (m, 1H), 4.47 (d, J = 11.7 Hz, 1H), 4.45 (d, J = 11.5 Hz, 
1H), 3.99 (d, J = 11.3 Hz, 1H), 3.95 (d, J = 11.9 Hz, 1H), 3.80 (s, 3H), 2.35-2.26 (m, 
2H), 1.98 (t, J = 7.7 Hz, 4H), 1.71 (s, 3H), 1.66 (d, J = 1.3 Hz, 3H), 1.58-1.51 (m, 2H); 
13C NMR (125 MHz, CDCl3) 159.2, 145.8, 142.8, 138.2, 129.9, 129.5, 127.3, 116.3, 
113.8, 109.9, 73.2, 72.0, 67.2, 55.3, 42.7, 39.0, 37.3, 25.6, 22.4, 16.6; HRMS (ESI): 
calculated for C22H32O3
 [M+Li+] 351.2511, found 351.2503. 
 
            (E)-3,7-Dimethylocta-2,7-dienal (1.62). To a well-stirred solution of E-alkenoic 
ester 3.36 (3.29 g, 16.7 mmol) in THF (110 mL) was added DIBAL-H (1 M in Hexane, 
50.1 mL, 50.1 mmol) at -78 °C under N2. The reaction was stirred at -78 °C for 2h 
before it was quenched by EtOAc (5 mL) and saturated aqueous Rochelle salt (50 mL). 
The mixture was stirred at room temperature until it became clear. The mixture was 
extracted with CH2Cl2 and the combined organic layers were dried over Na2SO4. After 
concentration in vacuo, the residue was purified by flash column chromatography (silica 
137
 gel, eluted with EtOAc/petroleum ether = 1/2) to provide allyl alcohol (2.51 g, 97 %) as 
a light yellow liquid. IR (film) 3073, 2966, 2931, 1649, 1442, 1371, 1001, 886; 1H NMR 
(300 MHz, CDCl3) δ 5.42 (t, J = 6.3 Hz, 1H), 4.71 (s, 1H), 4.67 (s, 1H), 4.15 (d, J = 6.9 
Hz, 2H), 2.11-1.91 (m, 4H), 1.71 (s, 3H), 1.67 (s, 3H), 1.63-1.49 (m, 2H), 1.39-1.21 (brs, 
1H); 13C NMR (75 MHz, CDCl3) δ 145.8, 139.6, 123.4, 109.9, 59.3, 39.1, 37.4, 25.6, 
22.4, 16.2; HRMS (ESI): molecular ion was not observed. 
            To a well stirred solution of allyl alcohol (2.30 g, 14.9 mmol) in CH2Cl2 (75 mL) 
was added Dess-Martin periodinane (7.59 g, 17.9 mmol) at 0 °C. The mixture was 
stirred at this temperature for 2 h and quenched with saturated aqueous NaHCO3 (30 
mL). It was extracted with CH2Cl2, dried over Na2SO4, filtered and concentration in 
vacuo. The residue was purified by flash column chromatography (silica gel, eluted with 
ether/petroleum ether = 1/2) to provide product 1.62 (2.18 g, 96 %) as a light yellow 
liquid. IR (film) 3073, 2937, 2860, 1676, 1442, 1374, 1193, 1116, 883 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 9.98 (d, J = 8.1 Hz, 1H), 5.88 (d, J = 8.1 Hz, 1H), 4.73 (s, 1H), 
4.67 (s, 1H), 2.22-2.15 (m, 5H), 2.02 (t, J = 7.5 Hz, 2H), 1.70 (d, J = 0.7 Hz, 3H), 1.70-
1.57 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 191.3, 164.0, 144.8, 127.4, 110.5, 40.0, 
37.1, 24.9, 22.2, 17.5; HRMS (ESI): calculated for C10H16O
 [M+H+] 153.1279, found 
153.1283. 
 
            (S,E)-3-Hydroxy-1-((R)-4-isopropyl-2-thioxothiazolidin-3-yl)-5,9-dimethyl 
deca-4,9-dien-1-one (1.64). To a suspension of tin (II) triflate (5.84 g, 14.0 mmol) in 
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 CH2Cl2 (29 mL) was added N-ethylpiperidine (1.93 mL, 14.0 mmol) at -78 °C under 
nitrogen. From a separate flask, thione 1.63 (2.44 g, 12.0 mmol) in CH2Cl2 (12 mL) was 
added to the cold tin triflate mixture via a cannula. The reaction was allowed to warm to 
–50 ºC and was stirred for 4 h before cooling back to –78 ºC. In a separate flask, 
aldehyde 1.62 (1.52 g, 10 mmol) was dissolved in CH2Cl2 (9 mL) and cooled to –78 ºC 
before it was added to the enolate solution over 15 minutes. After being stirred for an 
additional hour, the reaction mixture was quenched with pH = 7 phosphate buffer (30 
mL). The organic layer was separated and the aqueous layer was extracted with CH2Cl2. 
The combined organic layers were washed with saturated aqueous NaHCO3 and dried 
over Na2SO4. After concentration in vacuo, the residue was purified by flash column 
chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/5) to provide 
product 1.64 (2.86 g, 80 %) as a yellow oil. [α]D
22 -319 (c 2.00, CHCl3); IR (film) 2964, 
2934, 1691, 1368, 1252, 1155, 1039, 880; 1H NMR (300 MHz, CDCl3) δ 5.25 (d, J = 
8.6, 1H), 5.18-5.13 (m, 1H), 4.91 (td, J = 8.7, 3.0 Hz, 1H), 4.69 (s, 1H), 4.66 (s, 1H), 
3.57-3.49 (m, 2H), 3.32 (dd, J = 17.7, 8.8 Hz, 1H), 3.03 (d, J = 11.5, 1H), 2.65 (brs, 1H), 
2.43-2.31 (m, 6.8 Hz, 1H), 2.01-1.95 (m, 4H), 1.71 (s,  6H), 1.60-1.50 (m, 2H), 1.06 (d, 
J = 6.8 Hz, 3H), 0.98 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 202.9, 172.8, 
145.7, 139.4, 125.3, 110.0, 71.4, 65.1, 45.7, 39.0, 37.3, 30.8, 30.6, 25.5, 22.4, 19.1, 17.8, 
16.7; HRMS (ESI): calculated for C18H29NO2S2
 [M+H+] 356.1718, found 356.1731. 
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             (S,E)-3-((tert-Butyldimethylsilyl)oxy)-1-((R)-4-isopropyl-2-thioxothiazolidin-
3-yl)-5,9-dimethyldeca-4,9-dien-1-one (3.40). To a solution of aldol product 1.64 (2.80 
g, 7.9 mmol) in CH2Cl2 (74 mL) at 0 °C was added 2,6-lutidine (2.29 mL, 19.7 mmol) 
and TBSOTf (3.62 mL, 15.8 mmol). After being stirred for 15 min, the reaction was 
quenched with a pH = 7 sodium potassium phosphate buffer solution (50 mL) and 
extracted with CH2Cl2. The combined organic extracts were washed with saturated 
aqueous NaHCO3 and dried over Na2SO4. After concentration in vacuo, the residue was 
purified by flash column chromatography (silica gel, eluted with ethyl acetate/petroleum 
ether = 1/20) to provide product 3.40 (3.66 g, 99 %) as a yellow oil. [α]D
22 -238 (c 2.21, 
CHCl3); IR (film) 2961, 2934, 2860, 1670, 1466, 1362, 1250, 1155, 1078, 826; 
1H NMR 
(300 MHz, CDCl3) δ 5.17 (d, J = 8.9 Hz, 1H), 5.02-4.95 (m, 2H), 4.70 (s, 1H), 4.66 (s, 
1H), 3.72 (dd, J = 16.1, 8.7 Hz, 1H), 3.45 (dd, J = 11.4, 7.8 Hz, 1H), 3.04-2.93 (m, 2H), 
2.44-2.33 (m,  1H), 2.00-1.92 (m, 4H), 1.70 (s, 3H), 1.66 (s, 3H), 1.58-1.47 (m, 2H), 
1.05 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 6.9 Hz, 3H), 0.83 (s, 9H), 0.03 (s, 3H), 0.01 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 202.8, 171.4, 145.8, 135.9, 127.8, 109.9, 71.8, 67.0, 
46.1, 38.9, 37.3, 31.0, 30.8, 25.8, 25.5, 22.4, 19.1, 18.0, 17.8, 16.6, -4.2, -4.9; HRMS 
(ESI): calculated for C24H43NO2S2Si2
 [M+Li+] 476.2650, found 476.2628. 
 
            (S,E)-Methyl 3-((tert-butyldimethylsilyl)oxy)-5,9-dimethyldeca-4,9-dienoate 
(3.41). To a solution of thione 3.40 (3.38 g, 7.21 mmol) in MeOH (36 mL) at 0 °C was 
added K2CO3 (300 mg, 2.16 mmol). After 3 h, the solution was allowed to warm to room 
temperature and stirred for an additional 3 h during which the yellow color disappeared. 
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 The reaction mixture was diluted with saturated aqueous NH4Cl (50 mL) and extracted 
with Et2O (3x50 mL). The combined organic extracts were washed with brine and dried 
over Na2SO4. After concentration in vacuo, the residue was purified by flash column 
chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/20) to provide 
product 3.41 (2.40 g, 98 %) as a clear oil. [α]D
22 -6.79 (c 1.99, CHCl3); IR (film) 2958, 
2937, 2863, 1738, 1439, 1250, 1149, 1075, 835; 1H NMR (300 MHz, CDCl3) δ 5.14 (d, 
J = 8.8 Hz, 1H), 4.87-4.79 (m, 1H), 4.70 (s, 1H), 4.66 (s, 1H), 3.64 (s, 3H), 2.53 (dd, J = 
14.2, 8.6 Hz, 1H), 2.34 (dd, J = 14.2, 4.9 Hz, 1H), 1.99-1.92 (m, 4H), 1.70 (s, 3H), 1.65 
(d, J = 1.1 Hz, 3H), 1.57-1.47 (m, 2H), 0.84 (s, 9H), 0.02 (s, 3H), 0.00 (s, 3H); 13C NMR 
(75 MHz, CDCl3) 171.6, 145.7, 136.0, 127.7, 109.9, 66.9, 51.4, 43.7, 38.9, 37.2, 25.7, 
25.5, 22.4, 18.0, 16.4, -4.3, -5.1; HRMS (ESI): calculated for C19H36O3Si
 [M+Li+] 
347.2594, found 347.2587. 
 
            (S,E)-tert-Butyl((6,10-dimethyl-2-((trimethylsilyl)methyl)undeca-1,5,10-trien 
-4-yl)oxy) dimethylsilane (3.42). Powdered CeC13·7H2O (2.80 g, 7.5 mmol) was dried 
in a flask at 130-140 °C overnight before it was cooled to room temperature, and 
maintained in a dry-nitrogen atmosphere. Dry THF (6 mL) was added, and the mixture 
was stirred at room temperature for 2 h before the slurry was cooled to -78 °C and 
treated with trimethylsilylmethyllithium (1 M in pentane, 7.5 mL, 7.5 mmol). The 
suspension was stirred at -78 °C for 1 h, at which time the ester 3.41 (0.51 g, 1.5 mmol) 
was added over 2-3 minutes. Stirring was continued for 2 h at -78 °C. Then the reaction 
was allowed to warm to room temperature overnight. After quenching with 1 M HCl (30 
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 mL), the crude bis(trimethylsilylmethy1)carbinol was isolated by extraction with 
CH2Cl2, drying over Na2SO4, and concentrated in vacuo. The subsequent Petersen 
elimination was accomplished by stirring the crude with 1.5 g of silica gel (column 
chromatography grade) and 15 mL of CH2C12 for 2-3 h. After concentration in vacuo, 
the residue was purified by flash chromatography to provide the allylsilane 3.42 (0.51 g, 
86%) as a light yellow oil. [α]D
22 -0.51 (c 2.3, CHCl3); IR (film) 2955, 2928, 2857, 1250, 
1066, 832; 1H NMR (300 MHz, CDCl3) δ 5.14 (d, J = 7.4 Hz, 1H), 4.70 (s, 1H), 4.67 (s, 
1H), 4.60 (s, 1H), 4.54 (s, 1H), 4.52-4.44 (m, 1H), 2.18 (dd, J = 13.4, 7.2 Hz, 1H), 2.04-
1.93 (m, 5H), 1.71 (s, 3H), 1.61 (s, 3H), 1.56-1.49 (m, 4H), 0.87 (s, 9H), 0.03 (s, 3H), 
0.02-0.01 (m, 12H); 13C NMR (75 MHz, CDCl3) 145.9, 144.0, 134.3, 129.5, 109.8, 
109.7, 69.2, 47.3, 39.0, 37.3, 27.3, 25.9, 25.6, 22.4, 18.2, 16.5, -1.4, -4.3, -4.8; HRMS 
(ESI): molecular ion was not observed. 
 
            (S,E)-4-((tert-Butyldimethylsilyl)oxy)-6,10-dimethylundeca-5,10-dien-2-one 
(3.44) was formed as the major product during synthesis of 3.42 when less stringently 
prepared TMSCH2Li-CeC13 reagent was used. Isolate by flash column chromatography 
(silica gel, ethyl acetate/petroleum ether = 1/20) as light yellow oil. [α]D
21 -24.28 (c 2.72, 
CHCl3); IR (film) 2955, 2931, 2860, 1362, 1256, 1075, 838; 
1H NMR (300 MHz, 
CDCl3) δ 5.13 (dd, J = 8.8, 1.2 Hz, 1H), 4.87-4.80 (m, 1H), 4.70 (s, 1H), 4.66 (s, 1H), 
2.69 (dd, J = 14.3, 8.4 Hz, 1H), 2.34 (dd, J = 14.3, 4.6 Hz, 1H), 2.15 (s, 3H), 1.96 (dd, J 
= 15.1, 7.4 Hz, 4H), 1.70 (s, 3H), 1.64 (d, J = 1.3 Hz, 3H), 1.57-1.47 (m, 2H), 0.84 (s, 
9H), 0.01 (s, 3H), 0.00 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 207.7, 145.7, 135.7, 127.9, 
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 109.9, 67.0, 51.8, 38.9, 37.3, 31.9, 25.8, 25.5, 22.4, 18.0, 16.5, -4.3, -5.0; HRMS (ESI): 
calculated for C19H36O2Si [M+Li
+] 331.2645, found 331.2637. 
 
            (S,E)-tert-Butyl((6,10-dimethyl-2-((trimethylsilyl)methyl)undeca-1,5,10-
trien-4-yl)oxy) dimethylsilane (3.42). A solution of methyl ketone 3.44 (1.50 g, 4.62 
mmol) in THF (10 mL) was cooled to –78 °C and treated with a solution of potassium 
bis(trimethylsilyl)amide (5.55 mL, 1.0 M in THF, 5.55 mmol) dropwise. After stirring 
for 1 h, a solution of N-phenyltrifluoromethanesulfonimide (1.98 g, 5.55 mmol) in 4 mL 
of THF was added dropwise. After 2 h, the solution was poured over 20 mL of saturated 
aqueous NaHCO3 and extracted with ethyl acetate (2x50 mL). The combined organic 
layers were dried with Na2SO4 and concentrated in vacuo. Purification of the residue by 
flash column chromatography (silica gel, ethyl acetate/petroleum ether = 1/20) provided 
3.44-enol triflate (2.06 g, 98 %) as clear oil. [α]D
21 -9.56 (c 2.38, CHCl3); IR (film, cm
-1) 
2955, 2937, 2863, 1673, 1649, 1418, 1247, 1208, 1146, 1069, 954, 891, 838; 1H NMR 
(300 MHz, CDCl3) δ 5.14-5.11 (m, 2H), 4.97 (d, J = 3.2 Hz, 1H), 4.71 (s, 1H), 4.67 (s, 
1H), 4.64-4.58 (m, 1H), 2.50 (dd, J = 14.8, 8.0 Hz, 1H), 2.39 (dd, J = 14.9, 4.9 Hz, 1H), 
2.00-1.94 (m, 4H), 1.71 (s, 3H), 1.63 (d, J = 1.3 Hz, 3H), 1.61-1.48 (m, 2H), 0.85 (s, 
9H), 0.03 (s, 3H), 0.01 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 153.8, 145.7, 136.7, 127.4, 
109.9, 106.8, 66.3, 43.3, 38.9, 37.3, 25.7, 25.5, 22.4, 18.1, 16.4, -4.4, -5.1; HRMS (ESI): 
molecular ion not observed. 
            A round-bottom flask was charged with LiCl (783 mg, 18.48 mmol), flame-dried 
under reduced pressure, and purged with argon. The anhydrous LiCl thus prepared was 
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 taken into diethyl ether (20 mL) followed by a solution of 3.44-enol triflate (2.06 g, 4.52 
mmol) in 10 mL of diethyl ether. The suspension was cooled to 0 °C and 
tetrakis(triphenylphosphine)palladium(0) (267 mg, 0.23 mmol) was added. This was 
followed by a solution of (trimethylsilyl)methylmagnesium chloride (1.0 M in Et2O, 
9.24 mL, 9.24  mmol). After 2 h, the yellow suspension was filtered through a pad of 
celite and eluted with diethyl ether (50 mL). The ether solution was washed with 50 mL 
of saturated aqueous NaHCO3, which was back-extracted with Et2O (3x50 mL). The 
combined organic fractions were dried with Na2SO4 and concentrated in vacuo. 
Purification of the residue by flash column chromatography (silica gel, ethyl 
acetate/petroleum ether, 1/20) gave 3.42 (1.51 g, 85 %) as clear oil. 
 
            (S,E)-((2-(Bromomethyl)-6,10-dimethylundeca-1,5,10-trien-4-yl)oxy)(tert-
butyl)dimethylsilane (3.43). To a solution of allylsilane 3.42 (417 mg, 1.05 mmol) in 
THF (10.5 mL) was added propylene oxide (0.19 mL, 2.6 mmol) and NBS (207 mg, 1.2 
mmol) at -78 °C under nitrogen. The resulting mixture was stirred in the dark for 1 h. 
After the reaction was complete (TLC), the mixture was diluted with EtOAc, washed 
with H2O and brine. The organic layer was dried over Na2SO4 and concentrated in 
vacuo. Purification by flash column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/20) to provide product 3.43 (389 mg, 93 %) as a clear oil. 
[α]D
21 -3.02 (c 1.33, CHCl3); IR (film) 2961, 2934, 2857, 1253, 1208, 1069, 832; 
1H 
NMR (300 MHz, CDCl3) δ 5.21 (s, 1H), 5.14 (d, J = 9.2 Hz, 1H), 4.98 (s, 1H), 4.71 (s, 
1H); 4.67 (s, 1H), 4.56-4.49 (m, 1H), 4.03 (q, J = 9.9 Hz, 2H), 2.35 (d, J = 6.6 Hz, 2H), 
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 2.00-1.93 (m, 4H), 1.71 (s, 3H), 1.63 (s, 3H), 1.58-1.48 (m, 2H), 0.86 (s, 9H), 0.02 (s, 
3H), 0.00 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 145.8, 142.6, 135.1, 128.7, 117.7, 
109.8, 69.0, 42.1, 39.0, 37.7, 37.3, 25.8, 25.6, 22.4, 18.1, 16.5, -4.2, -4.8; HRMS (ESI): 
molecular ion was not observed. 
 
            (S,E)-tert-Butyl((2-(iodomethyl)-6,10-dimethylundeca-1,5,10-trien-4-yl)oxy) 
dimethylsilane (3.5). To a solution of allyl bromide 3.43 (160 mg, 0.4 mmol) in acetone 
(4 mL) was added anhydrous NaI (600 mg, 4 mmol) at room temperature. The resulting 
mixture was stirred overnight before it was concentrated. The residue was suspended in 
ether (20 mL) and filtered through a short pad of silica gel. After concentration in vacuo, 
the crude allyl iodide 3.5 (171 mg, 95%) was used without further purification. [α]D
21 -
2.95 (c 1.27, CHCl3); IR (film) 2952, 2934, 2857, 1247, 1152, 1072, 936, 883, 835; 
1H 
NMR (300 MHz, CDCl3) δ 5.27 (s, 1H), 5.14 (d, J =8.5 Hz, 1H), 4.92 (s, 1H), 4.70 (s, 
1H), 4.67 (s, 1H), 4.55-4.48 (m, 1H), 4.00 (q, J = 9.0 Hz, 2H), 2.36 (d, J = 6.3 Hz, 2H), 
2.01-1.93 (m, 4H), 1.71 (s, 3H), 1.64 (s, 3H), 1.59-1.48 (m, 2H), 0.86 (s, 9H), 0.02 (s, 
3H), 0.01 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 145.8, 143.8, 135.1, 128.7, 116.4, 
109.8, 69.1, 42.8, 39.0, 37.3, 25.8, 25.6, 22.4, 18.1, 16.6, 12.1, -4.2, -4.8; HRMS (ESI): 
calculated for C20H37IOSi
 [M+Li+] 455.1805, found 455.1816. 
 
            (4aR,6R,8aR)-6-((tert-Butyldimethylsilyl)oxy)-4,7-dimethyl-4a,5,6,8a-
tetrahydro-2H-chromen-2-one (3.28). To a solution of , -unsaturated lactone 3.23a 
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 (154 mg, 0.5 mmol) in CH2Cl2 (5 mL) was added 1,8-diazabicycloundec-7-ene (0.12 
mL, 0.75 mmol) at room temperature under nitrogen. After 10 min, the mixture was 
concentrated and the residue was purified by column chromatography (silica gel, eluted 
with ethyl acetate/petroleum ether = 1/2) to provide product 3.28 (146 mg, 95%) as a 
light yellow oil. [α]D
21 -100 (c 2.33, CHCl3); IR (film) 2958, 2931, 2857, 1720, 1244, 
1099, 968, 835; 1H NMR (300 MHz, CDCl3) δ 5.81 (s, 1H), 5.62 (d, J = 3.9 Hz, 1H), 
4.65 (t, J = 4.3 Hz, 1H), 4.17-4.11 (m, 1H), 2.17 (dt, J = 13.4, 3.2 Hz, 1H), 2.00 (s, 3H), 
1.97-1.90 (m, 1H), 1.80 (s, 3H), 1.72-1.58 (m, 1H), 0.89 (s, 9H), 0.10 (s, 3H), 0.09 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 164.3, 159.4, 146.1, 119.3, 116.4, 72.2, 70.2, 37.6, 
31.6, 25.7, 21.3, 19.7, 18.0, -4.2, -4.9; HRMS (ESI): calculated for C17H28O3Si
 [M+H+] 
309.1886, found 309.1896. 
 
            (2S,4aR,6R,6'S,8aR)-6'-((E)-2,6-Dimethylhepta-1,6-dien-1-yl)-4,7-dimethyl-
4'-methylene-3',4a,4',5,5',6,6',8a-octahydrospiro[chromene-2,2'-pyran]-6-ol (3.47) 
and (2S,4aR,6R,6'S,8aR)-6'-((E)-2,6-Dimethylhepta-1,6-dien-1-yl)-4,4',7-trimethyl-
4a,5,5',6,6',8a-hexahydrospiro[chromene-2,2'-pyran]-6-ol (3.48). To an ice-cold 
solution of SmI2 (8.6 mL, 0.1 M in THF, 0.86 mmol) was added a mixture of the allyl 
iodide 3.5 (93 mg, 0.21 mmol) and , -unsaturated lactone 3.28 (53 mg, 0.17 mmol) in 
dry THF (2 mL) under nitrogen. The deep blue mixture was stirred at 0 °C for 15 min 
before it was quenched with saturated aqueous NaHCO3 (10 mL). The mixture was 
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 extracted with EtOAc (modified with 1% Et3N). The combined organic layers were dried 
over Na2SO4. After concentration in vacuo, the residue was dissolved in THF (10 mL), 
treated with TBAF (0.86 mL, 1M in THF, 0.86 mmol), and stirred at room temperature 
under nitrogen. After 4h, the mixture was diluted with EtOAc (modified with 1% Et3N). 
The organic layer was washed with saturated aqueous NH4Cl, and dried over Na2SO4. 
After concentration in vacuo, the residue was dissolved in CH2Cl2 (10 mL). To this 
mixture was added pTSA (36 mg, 0.19 mmol) at room temperature. The mixture was 
stirred for 30 min before it was diluted with CH2Cl2. The organic layer was washed with 
water, brine, and dried over Na2SO4. After concentration in vacuo, the residue was 
purified by column chromatography (silica gel, eluted with ethyl acetate/petroleum ether 
= 1/5) to provide the spiroketal 3.47 and the isomeric spiroketal 3.48 (18.9 mg, 29% for 
three steps, ratio varies from 1:3 to 1:6) as colorless oils.  
            Spiroketal 3.47. [α]D
19 -69.7 (c 0.50, MeOH); IR (film) 3073, 2937, 2854, 1679, 
1649, 1442, 1377, 1250, 1232, 1037, 1016, 980, 965, 886; 1H NMR (500 MHz, C6D6) δ 
5.61 (d, J = 5.1 Hz, 1H), 5.48 (d, J = 8.4 Hz, 1H), 5.45 (s, 1H), 4.94-4.88 (m, 1H), 4.90-
4.88 (m, 2H), 4.78 (s, 1H), 4.77 (s, 1H), 4.38 (s, 1H), 3.66 (brs, 1H), 2.47-2.19 (m, 4H), 
1.95-1.89 (m, 4H), 1.80-1.76 (m, 1H), 1.71 (d, J = 1.2 Hz, 3H), 1.68 (d, J = 1.3 Hz, 3H), 
1.59 (s, 3H), 1.58-1.43 (m, 4H), 1.48 (d, J = 1.4 Hz, 3H); 13C NMR (75 MHz, C6D6) δ 
146.0, 143.7, 142.3, 139.1, 139.0, 127.2, 126.2, 123.6, 111.0, 110.8, 96.7, 70.7, 68.2, 
64.2, 44.9, 41.0, 39.7, 38.1, 38.0, 32.9, 26.3, 22.8, 21.2, 19.5, 17.1;  HRMS (ESI): 
calculated for C25H36O3
 [M+Li+] 391.2824, found 391.2809.  
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             Migrated spiroketal 3.48. [α]D
19 -146 (c 0.50, MeOH); IR (film) 2967, 2937, 
2854, 1679, 1649, 1445, 1377, 1164, 1119, 968, 886; 1H NMR (500 MHz, C6D6) δ 5.71 
(d, J = 5.2 Hz, 1H), 5.56 (s, 1H), 5.52 (s, 2H), 5.09-5.04 (m, 1H), 4.80 (s, 1H), 4.79 (s, 
1H), 4.55 (s, 1H), 3.72 (brs. 1H), 2.09-2.02 (m, 2H), 1.98-1.91 (m, 4H), 1.84-1.80 (m, 
1H), 1.80 (s, 3H), 1.72 (s, 3H), 1.62 (s, 3H), 1.59 (s, 3H), 1.57-1.47 (m, 4H), 1.54 (s, 
3H); 13C NMR (75 MHz, C6D6) δ 146.0, 143.5, 139.6, 138.6, 136.0, 126.9, 125.5, 125.0, 
124.0, 110.8, 94.9, 70.7, 65.9, 64.6, 39.7, 38.1, 38.0, 36.3, 32.9, 26.4, 23.2, 22.8, 21.3, 
19.5, 17.0; HRMS (ESI): calculated for C25H36O3
 [M+Li+] 391.2824, found 391.2809. 
 
            (2S,4aR,6'S,8aR)-6'-((E)-2,6-Dimethylhepta-1,6-dien-1-yl)-4,7-dimethyl-4'-
methylene-3',4a,4',5,5',6'-hexahydrospiro[chromene-2,2'-pyran]-6(8aH)-one (3.49). 
To a solution of allyl alcohol 3.47 (2.9 mg, 0.0075 mmol) in DMSO (0.6 mL) was added 
IBX (4.3 mg, 0.015 mmol) at room temperature. The resulting mixture was stirred for 1h 
before H2O (1 mL) was added. The resulting mixture was filtered. The aqueous layer 
was extracted with EtOAc. The combined organic phase was washed with brine, and 
dried over Na2SO4. After concentration in vacuo, the residue was purified by column 
chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/10) to provide 
the product 3.49 (2.5 mg, 87%) as a light yellow oil. [α]D
18 -61.6 (c 0.24, MeOH); IR 
(film) 2925, 2851, 1685, 1445, 1377, 1250, 1122, 983, 880; 1H NMR (500 MHz, C6D6) δ 
6.32 (dd, J = 5.7, 1.5 Hz, 1H), 5.49 (d, J = 8.3 Hz, 1H), 5.32 (s, 1H), 4.89 (d, J = 1.9 Hz, 
1H), 4.87 (d, J = 1.8 Hz, 1H), 4.85-4.83 (m, 1H), 4.81 (s, 1H), 4.80 (s, 1H), 4.38-4.37 
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 (m, 1H), 2.48-2.18 (m, 6H), 1.99-1.92 (m, 4H), 1.77-1.70 (m, 1H), 1.72 (s, 3H), 1.68 (d, 
J = 1.3 Hz, 3H), 1.62 (s, 3H), 1.58-1.51 (m, 2H), 1.31 (d, J = 1.4 Hz, 3H); 13C NMR (75 
MHz, C6D6) δ 197.8, 145.9, 141.8, 139.7, 139.0, 138.9, 138.6, 127.0, 125.8, 111.2, 
110.9, 97.2, 68.5, 63.5, 44.3, 40.8, 39.7, 38.2, 38.0, 30.6, 26.3, 22.8, 20.7, 17.1, 16.4; 
HRMS (ESI): calculated for C25H34O3
 [M+H+] 383.2586, found 383.2599. 
 
            (2S,4aR,6'S,8aR)-6'-((E)-2,6-dimethylhepta-1,6-dien-1-yl)-4,4',7-trimethyl-
4a,5,5',6'-tetrahydrospiro[chromene-2,2'-pyran]-6(8aH)-one (3.50). To a solution of 
allyl alcohol 3.48 (6.2 mg, 0.018 mmol) in DMSO (0.8 mL) was added IBX (10.2 mg, 
0.036 mmol) at room temperature. The resulting mixture was stirred for 1 h before H2O 
(1 mL) was added. The resulting mixture was filtered. The aqueous layer was extracted 
with EtOAc. The combined organic phase was washed with brine, and dried over 
Na2SO4. After concentration in vacuo, the residue was purified by column 
chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/10) to provide 
the product 3.50 (6.2 mg, 89%) as a light yellow oil. [α]D
18 -111 (c 0.60, MeOH); IR 
(film) 2967, 2931, 2857, 1679, 1445, 1377, 1170, 1128, 1004, 977, 927, 877; 1H NMR 
(500 MHz, C6D6) δ 6.40 (dd, J = 5.7, 1.5 Hz, 1H), 5.50 (d, J = 8.0, 1H), 5.41 (s, 1H), 
5.37 (s, 1H), 4.97 (ddd, J = 11.2, 8.0, 3.4 Hz, 1H), 4.81 (s, 1H), 4.80 (s, 1H), 4.53-4.51 
(m, 1H), 2.50-2.44 (m, 2H), 2.05-1.93 (m, 5H), 1.81 (s, 3H), 1.79-1.71 (m, 2H), 1.68 (d, 
J = 1.3 Hz, 3H), 1.63 (s, 3H), 1.59-1.52 (m, 2H), 1.56 (s, 3H), 1.35 (d, J = 1.4 Hz, 3H); 
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 13C NMR (75 MHz, C6D6) δ 198.1, 145.9, 140.3, 139.6, 138.7, 138.3, 136.4, 126.7, 
125.2, 124.1, 110.9, 95.3, 66.1, 63.8, 39.7, 38.3, 38.0, 38.0, 36.2, 26.4, 23.1, 22.8, 20.8, 
17.0, 16.4; HRMS (ESI): calculated for C25H34O3
 [M+H+] 383.2586, found 383.2599. 
 
            (2S,4aR,6R,6'S,8aR)-6'-((E)-2,6-Dimethylhepta-1,6-dien-1-yl)-4-(((4-methoxy 
benzyl)oxy)methyl)-7-methyl-4'-methylene-3',4a,4',5,5',6,6',8a-octahydrospiro 
[chromene-2,2'-pyran]-6-ol (3.54). To an ice-cold solution of SmI2 (2.5 mL, 0.1 M in 
THF, 0.25 mmol) was added a mixture of the allyl iodide 3.5 (25 mg, 0.055 mmol) and 
lactone 3.4 (23 mg, 0.05 mmol) in dry THF (1 mL) under nitrogen. The deep blue 
mixture was stirred at 0 °C for 15 min before it was treated with saturated aqueous 
NaHCO3 (1 mL). The mixture was extracted with EtOAc (modified with1% Et3N). The 
combined organic layers were dried over Na2SO4. After concentration in vacuo, the 
residue was dissolved in THF (2 mL) and treated with TBAF (0.25 mL, 1M in THF, 
0.25 mmol) at room temperature under nitrogen. After 4 h, the mixture was diluted with 
EtOAc (modified with 1% Et3N), washed with saturated aqueous NH4Cl, and dried over 
Na2SO4. After concentration in vacuo, the residue was dissolved in CH2Cl2 (2 mL) and 
treated with PPTS (12 mg, 0.05 mmol) at room temperature under nitrogen. The mixture 
was stirred for 30 min before it was diluted with CH2Cl2. The organic layer was washed 
with water, brine, and dried over Na2SO4. After concentration in vacuo, the residue was 
purified by column chromatography (silica gel, eluted with ethyl acetate/petroleum ether 
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 = 1/1) to provide the product 3.54 (10.4 mg, 40%) as a colorless oil. [α]D
18 -42.5 (c 0.21, 
MeOH); IR (film) 2931, 2854, 1614, 1510, 1445, 1250, 1039, 974; 1H NMR (500 MHz, 
C6D6) δ 7.20 (d, J = 8.7 Hz, 2H), 6.78 (d, J = 8.7 Hz, 2H), 5.83 (s, 1H), 5.63 (d, J = 5.2, 
1H), 5.49 (d, J = 8.4, 1H), 4.94 (ddd, J = 11.2, 8.4, 2.8 Hz, 1H), 4.89-4.88 (m, 2H), 4.78 
(s, 1H), 4.77 (s, 1H), 4.43 (s,1H), 4.34 (d, J = 11.6 Hz, 1H), 4.25 (d, J = 11.6 Hz, 1H), 
3.88 (d, J = 12.8 Hz, 1H), 3.73 (d, J = 12.7 Hz, 1H), 3.69 (brs, 1H), 3.28 (s, 3H), 2.46-
2.20 (m, 4H), 1.95-1.84 (m, 5H), 1.69 (d, J = 1.1 Hz, 3H), 1.67 (d, J = 1.3 Hz, 3H), 1.65-
1.55 (m, 2H), 1.59 (s, 3H), 1.53-1.48 (m, 2H); 13C NMR (125 MHz, C6D6) δ 160.2, 
145.9, 143.9, 142.1, 140.5, 139.1, 131.2, 129.9, 127.5, 127.0, 123.4, 114.5, 111.1, 110.8, 
96.7, 72.4, 71.2, 70.6, 68.3, 64.4, 55.1, 44.6, 40.9, 39.7, 38.0, 34.2, 33.1, 26.3, 22.8, 
19.5, 17.1; HRMS (ESI): calculated for C33H44O5
 [M+H+] 521.3267, found 521.3273. 
 
            (2S,4aR,6R,6'S,8aR)-6'-((E)-2,6-Dimethylhepta-1,6-dien-1-yl)-4-
(hydroxymethyl)-7-methyl-4'-methylene-3',4a,4',5,5',6,6',8a-octahydrospiro 
[chromene-2,2'-pyran]-6-ol (3.55). To a mixture of PMB ether 3.57 (4.1 mg, 0.008 
mmol) in CH2Cl2 (1.8 mL) and H2O (0.1 mL) was added DDQ (2.8 mg, 0.012 mmol). 
The resulting mixture was stirred at room temperature for 2 h before it was quenched by 
saturated aqueous NaHCO3 (1 mL). After being stirred for 15 min, the reaction mixture 
was extracted with EtOAc. The organic phase was washed with water, saturated aqueous 
NaHCO3, brine, and dried over anhydrous Na2SO4. After concentration in vacuo, the 
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 residue was purified by column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 2/1) to provide the product 3.55 (2.9 mg, 92%) as a colorless 
oil. [α]D
20 -104 (c 0.18, MeOH); IR (film) 3076, 2931, 2857, 1454, 1371, 1259, 1034, 
963, 883; 1H NMR (500 MHz, C6D6) δ 5.64 (s, 1H), 5.63-5.61 (m, 1H), 5.48 (d, J = 8.4 
Hz, 1H), 4.94-4.91 (m, 1H), 4.90-4.88 (m, 2H), 4.78 (s, 1H), 4.76 (s, 1H), 4.36 (s, 1H), 
3.72 (s, 2H), 3.67 (dd, J = 11.1, 6.1 Hz, 1H), 2.45-2.20 (m, 4H), 1.95-1.89 (m, 4H), 1.80-
1.77 (m, 1H), 1.70 (s, 3H), 1.68 (d, J = 1.3 Hz, 3H), 1.59 (s, 3H), 1.55-1.46 (m, 4H); 13C 
NMR (125 MHz, C6D6) δ 145.2, 143.2, 142.4, 141.3, 138.6, 126.3, 125.0, 122.7, 110.5, 
110.1, 95.9, 69.8, 67.5, 63.7, 63.6, 43.9, 40.2, 39.0, 37.3, 33.1, 32.5, 25.6, 22.1, 18.8, 
16.3; HRMS (ESI): calculated for C25H36O4
 [M+H+] 401.2692, found 401.2708. 
 
            Alotaketal A. To a solution of alcohol 3.54 (8.3 mg, 0.016 mmol) in DMSO (1.5 
mL) was added IBX (9 mg, 0.032 mmol) at room temperature. The resulting mixture 
was stirred for 1h before H2O (1.5 mL) was added. The resulting mixture was filtered. 
The aqueous phase was extracted with EtOAc. The combined organic phase was washed 
with brine, and dried over Na2SO4. After concentration in vacuo, the residue was 
purified by column chromatography (silica gel, eluted with ethyl acetate/petroleum ether 
= 1/5) to provide the enone A.9 (7.4 mg, 89%) as a light yellow oil. [α]D
16 -35.7 (c 0.15, 
MeOH); IR (film) 2925, 2851, 1679, 1608, 1510, 1448, 1247, 1122, 1039, 980, 880; 1H 
NMR (500 MHz, C6D6) δ 7.17 (d, J = 8.5 Hz, 2H), 6.78 (d, J = 8.3 Hz, 2H), 6.30 (d, J = 
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 5.7 Hz, 1H), 5.71 (s, 1H), 5.47 (d, J = 8.3 Hz, 1H), 4.90-4.71 (m, 5H), 4.40 (s, 1H), 4.26 
(d, J = 11.7 Hz, 1H), 4.19 (d, J = 11.6 Hz, 1H), 3.66 (d, J = 13.1 Hz, 1H), 3.58 (d, J = 
12.8 Hz, 1H), 3.28 (s, 3H), 2.59 (dd, J = 15.6, 4.2 Hz, 1H), 2.45 (dd, J = 15.6, 13.3 Hz, 
1H), 2.34-2.16 (m, 4H), 2.03 (dd, J = 14.7, 7.3 Hz, 1H), 1.97-1.90 (m, 4H), 1.68 (s, 3H), 
1.65 (s, 3H), 1.61 (s, 3H), 1.56-1.50 (m, 2H); 13C NMR (125 MHz, C6D6) δ 197.7, 166.2, 
160.2, 145.9, 141.5, 140.1, 139.6, 139.1, 139.0, 130.9, 129.9, 126.9, 126.8,  114.5, 
111.4, 110.9, 97.2, 72.7, 70.8, 68.6, 63.7, 55.2, 44.1, 40.8, 39.7, 38.6, 38.0, 34.5, 26.3, 
22.8, 17.1, 16.4; HRMS (ESI): calculated for C33H42O5
 [M+H+] 519.3110, found 
519.3126. 
            To a mixture of the above enone A.9 (7.4 mg, 0.014 mmol) in CH2Cl2 (2.7 mL) 
and H2O (0.15 mL) was added DDQ (5 mg, 0.022 mmol). The resulting mixture was 
stirred at room temperature for 2 h before it was quenched with saturated aqueous 
NaHCO3 (1 mL). After being stirred for 15 min, the reaction mixture was extracted with 
EtOAc. The organic phase was washed with water, saturated aqueous NaHCO3, brine, 
and dried over anhydrous Na2SO4. After concentration in vacuo, the residue was purified 
by column chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/1) 
to provide the natural product alotaketal A (5.1 mg, 92%) as a colorless oil. [α]D
20 -40.2 
(c 0.15, MeOH); IR (film) 2925, 2857, 1684, 1445, 1252, 1122, 974, 882; 1H NMR (500 
MHz, C6D6) δ 6.32 (dd, J = 6.0, 1.5 Hz, 1H), 5.56 (s, 1H), 5.48 (d, J = 8.5 Hz, 1H), 4.89 
(brs, 1H), 4.87 (brs, 1H), 4.86-4.83 (m, 1H), 4.81 (brs, 1H), 4.80 (brs, 1H), 4.36 (dd, J = 
5.5, 4.5 Hz, 1H), 3.55-3.49 (m, 2H), 2.47 (dd, J = 15.5, 5.0 Hz, 1H), 2.39 (dd, J = 15.5, 
13.0 Hz, 1H), 2.35-2.27 (m, 3H), 2.20 (t, J = 13.0, 1H), 2.06 (dt, J = 12.0, 4.5, 1H), 1.98 
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 (t, J = 7.5 Hz, 2H), 1.94 (t, J = 7.5 Hz, 2H), 1.71 (s, 3H), 1.68 (s, 3H), 1.62 (s, 3H), 1.57-
1.52 (m, 2H); 13C NMR (125 MHz, C6D6) δ 197.7, 145.9, 142.5, 141.5, 139.7, 139.2, 
139.0, 126.8, 125.1, 111.4, 110.9, 97.2, 68.5, 63.8, 63.6, 44.1, 40.7, 39.7, 38.6, 38.0, 
34.0, 26.3, 22.8, 17.1, 16.4; HRMS (ESI): calculated for C25H34O4
 [M+Li+] 405, 2417, 
found 405.2630. 
            Cell Culture and Imaging. HEK293 cells were plated in 35 mm glass-bottom 
dishes and grown to ~60% confluency in DMEM with 10% FBS at 37 °C with 5% CO2. 
The cells were transfected with AKAR4, ICUE3, or AKAR4 T/A mutant using 
Lipofectamine 2000 (Invitrogen) for 24 hours. The next day, the cells were washed with 
and maintained in Hanks’ balanced salt solution (HBSS) in the dark. The cells were 
imaged on a Zeiss Aioxvert 200M microscope with a 40x/1.3NA oil-immersion 
objective lens and cooled charged-coupled device (CCD) camera controlled by 
METAFLUOR software (Molecular Devices, Sunnyvale, CA). Dual emission ratio 
imaging was used with 420DF20 excitation filter, a 450DRLP dichroic mirror and two 
emission filters (475DF40 for cyan and 535DF25 for yellow). First baseline emission 
ratios were acquired and then the compounds were added to the cells as indicated. The 
ratios of yellow-to-cyan were calculated at different time points and normalized by 
dividing all ratios by the baseline emission ratio, setting basal emission ratio as 1. 
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 A.4 Experimental Procedures for Total Synthesis of 1.67 
 
           3-bromo-4,5-dimethoxy-2-methylbenzoic acid (4.7). To a solution of carboxylic 
acid 4.6 (3.77 g, 19.22 mmol) in CHCl3 (50 mL) was added Br2 (1.19 mL, 23.07 mmol) 
dropwise at 0 oC. The mixture was slowly warmed to room temperature and stirred 
overnight. The reaction was quenched with saturated aqueous Na2S2O3 solution (50 mL). 
The resulting two phases were separated and the aqueous layer was extracted with 
EtOAc (2x50 mL). The combined organic layers were washed with brine, dried over 
Na2SO4. After concentration, the residue was purified by flash column chromatography 
(silica gel, eluted with ethyl acetate/petroleum ether = 1/1) to provide product 4.7 (210 
mg, 92 %) as a light yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.56 (s, 1H), 3.92 (s, 
3H), 3.91 (s, 3H), 2.70 (s, 3H); 13C NMR (125 MHz, CDCl3) 172.6, 150.6, 150.2, 134.2, 
125.1, 123.1, 114.1, 60.5, 56.1, 20.6.  
 
            (3-bromo-4,5-dimethoxy-2-methylphenyl)methanol (4.8). To a solution of 
carboxylic acid 4.7 (240 mg, 0.88 mmol) in THF (2 mL) was added borane dimethyl 
sulfide (0.70 mL, 1.40 mmol, 2M in THF) at 0 °C. The resulting solution was allowed to 
warm to room temperature overnight. The reaction was carefully quenched with H2O 
and the resulting solution was diluted with EtOAc. Organic Phase was separated, washed 
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 with H2O, dried over Na2SO4. After concentration, the residue was purified by flash 
column chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/1) to 
provide product 4.8 (210 mg, 92 %) as a white solid. IR (film, cm-1) 2940, 1596, 1557, 
1484, 1430, 1309, 1108, 1045, 1010, 971; 1H NMR (500 MHz, CDCl3) δ 6.91 (s, 1H), 
4.63 (s, 2H), 3.83 (s, 3H), 3.80 (s, 3H), 2.31 (s, 3H); 13C NMR (125 MHz, CDCl3) 151.0, 
145.4, 135.4, 128.2, 121.6, 111.1, 63.8, 60.4, 56.0, 17.9; HRMS (ESI): molecular ion 
was not observed. 
 
            ((3-bromo-4,5-dimethoxy-2-methylbenzyl)oxy)(tert-butyl)dimethylsilane 
(4.10). To a solution of benzyl alcohol 4.8 (173 mg, 0.66 mmol) in DMF (0.7 mL) was 
added imidazole (90 mg, 1.32 mmol) and TBSCl (149 mg, 0.99 mmol). The reaction was 
stirred at room temperature for 3h before it was diluted with EtOAc. The organic layer 
was washed with H2O, brine, and dried over Na2SO4. After concentration in vacuo, the 
residue was purified by flash column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/20) to provide 4.10 (233 mg, 94 %) as a colorless oil. IR 
(film, cm-1) 2958, 2931, 2848, 1602, 1487, 1312, 1253, 1205, 1122, 1048, 835; 1H NMR 
(500 MHz, CDCl3) δ 7.07 (s, 1H), 4.67 (s, 2H), 3.87 (s, 3H), 3.83 (s, 3H), 2.26 (s, 3H), 
0.96 (s, 9H), 0.12 (s, 6H); 13C NMR (125 MHz, CDCl3) 151.1, 144.9, 135.9, 126.7, 
121.2, 109.9, 63.4, 60.4, 56.0, 25.9, 18.3, 17.5, 5.3; HRMS (ESI): molecular ion was not 
observed. 
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            methyl 4,5-dimethoxy-2-methyl-3-vinylbenzoate (4.14). To a suspension of 
ester 4.13 (1.57 g, 5.45 mmol), Pd2dba3 (113 mg, 0.11mmol), tributylvinyltin (1.75 mL, 
6.0 mmol) in toluene (11 mL) was added P(t-Bu)3 (0.22 mL, 0.22 mmol, 1M in toluene) 
under nitrogen. The reaction was stirred at 60 °C for overnight. Pd2dba3 (56 mg, 
0.055mmol) was added to the reaction. When the reaction was complete (monitored by 
TLC, ethyl acetate/petroleum ether = 1:10 for 2~3 times), KF (4 g) was added followed 
by Et2O (30 mL) and activated carbon (4 g). The mixture was stirred for 5 min, and then 
it was filtered through a short pad of silica (washed with ethyl acetate). After 
concentration, the residue was purified by flash column chromatography (silica gel, 
eluted with ethyl acetate/petroleum ether = 1/5) to provide product 4.14 (1.26 g, 98 %) 
as a yellow oil. IR (film, cm-1) 2999, 2955, 2842, 1723, 1590, 1478, 1427, 1324, 1199, 
1167, 1110, 983; 1H NMR (500 MHz, CDCl3) δ 7.32 (s, 1H), 6.71 (dd, J = 17.9, 11.6 
Hz, 1H), 5.61 (dd, J = 11.6, 2.0 Hz, 1H), 5.52 (dd, J = 17.9, 2.0 Hz, 1H), 3.90 (s, 3H), 
3.89 (s, 3H), 3.79 (s, 3H), 2.47 (s, 3H); 13C NMR (125 MHz, CDCl3) 168.4, 150.0, 
149.7, 133.8, 131.2, 131.1, 126.3, 121.1, 112.9, 60.1, 55.9, 52.0, 17.6; GCMS (EI): 
retention time, 15.60 min; calculated for C13H16O4 [M]
+ 236.1, found 236.1. 
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             (4,5-dimethoxy-2-methyl-3-vinylphenyl)methanol (4.15). To a well stirred 
solution of ester 4.14 (1.24 g, 5.25 mmol) in THF (30 mL) was added DIBAL-H ( 15.75 
mL, 1 M in hexanes, 15.75 mmol) at 0 °C under N2. The reaction was stirred at 0 
oC for 
2h, then quenched by ethyl acetate (3 mL) followed by saturated aqueous Rochelle salt 
(30 mL). The reaction was stirred for another 1h at room temperature. The organic layer 
was separated and aqueous phase was extracted with ethyl acetate. The combined 
organic layers were washed with brine, dried over Na2SO4. After concentration, the 
residue was purified by flash column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/1) to provide product 4.15 (992 mg, 91 %) as a colorless oil. 
IR (film, cm-1) 2934, 1587, 1475, 1318, 1235, 1116, 974, 921, 944; 1H NMR (500 MHz, 
CDCl3) δ 6.92 (s, 1H), 6.74 (dd, J = 17.9, 11.7 Hz, 1H), 5.58 (dd, J = 11.7, 2.1 Hz, 1H), 
5.54 (dd, J = 17.9, 2.1 Hz, 1H), 4.67 (s, 2H), 3.86 (s, 3H), 3.75 (s, 3H), 2.25 (s, 3H); 13C 
NMR (125 MHz, CDCl3) 150.4, 146.3, 134.6, 132.9, 131.5, 126.6, 120.5, 111.2, 63.9, 
60.2, 55.9, 15.1; HRMS (ESI): calculated for C12H16O3 [M+Li
+] 215.1259, found 
215.1266. 
 
            1-(chloromethyl)-4,5-dimethoxy-2-methyl-3-vinylbenzene (4.16). To a 
solution of alcohol 4.15 (832 mg, 4.0 mmol) in CH2Cl2 (20 mL) was added SOCl2 (0.35 
mL, 4.8 mmol) dropwise at 0 °C under nitrogen. The reaction was stirred at room 
temperature for 30 min before it was carefully quenched by the addition of saturated 
aqueous NaHCO3. The mixture was diluted with CH2Cl2. The organic layer was 
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 separated and washed with water, brine, dried over Na2SO4. After concentration, the 
residue was purified by flash column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/20) to provide product 4.16 (832 mg, 92 %) as a yellow oil. 
IR (film, cm-1) 3005, 2970, 2934, 2837, 1590, 1478, 1318, 1238, 1116, 1045, 980, 927, 
853; 1H NMR (500 MHz, CDCl3) δ 6.84 (s, 1H), 6.73 (dd, J = 17.9, 11.7 Hz, 1H), 5.60 
(dd, J = 11.7, 2.0 Hz, 1H), 5.54 (dd, J = 17.9, 2.1 Hz, 1H), 4.62 (s, 2H), 3.88 (s, 3H), 
3.76 (s, 3H), 2.34 (s, 3H); 13C NMR (125 MHz, CDCl3) 150.5, 147.4, 133.4, 131.3, 
131.2, 128.2, 120.7, 113.0, 60.2, 55.9, 45.8, 15.4; GCMS (EI): retention time, 15.34 min; 
calculated for C12H15ClO2 [M]
+ 226.1, found 226.1.  
 
            3-bromo-1-(chloromethyl)-4,5-dimethoxy-2-methylbenzene (4.18). To a 
solution of alcohol 4.9 (52 mg, 0.2 mmol) in CH2Cl2 (1 mL) was added SOCl2 (0.018 
mL, 0.24 mmol) dropwise at 0 °C under nitrogen. The reaction was stirred at room 
temperature for 30 min before it was carefully quenched by the addition of saturated 
aqueous NaHCO3. The mixture was diluted with EtOAc. The organic layer was 
separated and washed with water, brine, dried over Na2SO4. After concentration, the 
residue was purified by flash column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/20) to provide product 4.18 (52.2 mg, 94 %) as a colorless 
oil. IR (film, cm-1) 2934, 1599, 1487, 1395, 1318, 1270, 1108, 1045, 1013, 980, 812; 1H 
NMR (300 MHz, CDCl3) δ 6.85 (s, 1H), 4.60 (s, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 2.44 (s, 
3H); 13C NMR (75 MHz, CDCl3) 151.2, 146.8, 131.8, 130.0, 122.1, 113.2, 60.4, 56.2, 
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 45.6, 18.5; GCMS (EI): retention time, 15.96 min; calculated for C10H12BrClO2 [M]
+ 
280.0, found 280.0.  
 
            ethyl 3-allyl-4,5-dimethoxy-2-methylbenzoate (4.22). To a suspension of ester 
4.13 (2.88 g, 10 mmol), Pd2dba3 (275 mg, 0.30 mmol), allyltributyltin (3.72 mL, 12 
mmol) in toluene (15 mL) was added P(t-Bu)3 (0.60 mL, 0.60 mmol, 1M in toluene) 
under nitrogen. The reaction was stirred at 60 °C for overnight. When the reaction was 
complete (monitored by TLC, ethyl acetate/petroleum ether = 1:10 for 2~3 times), KF (5 
g) was added followed by Et2O (30 mL) and activated carbon (5 g). The mixture was 
stirred for 5 min, and then it was filtered through a short pad of silica (washed with ethyl 
acetate). After concentration, the residue was purified by flash column chromatography 
(silica gel, eluted with ethyl acetate/petroleum ether = 1/5) to provide product 4.22 in 
quantitative yield as a yellow oil. IR (film, cm-1) 2949, 2842, 1717, 1596, 1484, 1330, 
1211, 1099, 1045, 989, 1H NMR (500 MHz, CDCl3) δ 7.29 (s, 1H), 5.95-5.89 (m, 1H), 
5.00 (dd, J = 10.2, 1.8 Hz, 1H), 4.86 (dd, J = 17.1, 1.8 Hz, 1H), 3.88 (s, 3H), 3.87 (s, 
3H), 3.83 (s, 3H), 3.49 (dt, J = 5.6, 1.8 Hz, 2H), 2.41 (s, 3H); 13C NMR (125 MHz, 
CDCl3) 168.6, 150.2, 150.0, 136.0, 133.3, 132.1, 126.1, 115.1, 112.2, 60.9, 55.7, 51.9, 
30.8, 16.1; HRMS (ESI): calculated for C14H18O4 [M+H
+] 251.1283, found 251.1274. 
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             (3-allyl-4,5-dimethoxy-2-methylphenyl)methanol (A.10). To a well stirred 
solution of ester 4.22 (2.50 g, 10 mmol) in THF (50 mL) was added DIBAL-H ( 30 mL, 
1 M in hexanes, 30 mmol) at 0 °C under N2. The reaction was stirred at 0 
oC for 4h, then 
quenched by ethyl acetate (5 mL) followed by saturated aqueous Rochelle salt (50 mL). 
The reaction was stirred for another 1h at room temperature. The organic layer was 
separated and aqueous phase was extracted with ethyl acetate. The combined organic 
layers were washed with brine, dried over Na2SO4. After concentration, the residue was 
purified by flash column chromatography (silica gel, eluted with ethyl acetate/petroleum 
ether = 1/1) to provide corresponding allyl alcohol A.10 (2.01 g, 90 %) as a colorless 
liquid. IR (film, cm-1) 3414, 2937, 1640, 1599, 1487, 1309, 1232, 1111, 1042, 906, 850; 
1H NMR (500 MHz, CDCl3) δ 6.87 (s, 1H), 5.92 (ddt, J = 17.1, 10.1, 5.8 Hz, 1H)., 4.99 
(dd, J = 10.2, 1.8 Hz, 1H), 4.90 (dd, J = 17.1, 1.9 Hz, 1H), 4.64 (d, J = 4.5 Hz, 2H), 3.84 
(s, 3H), 3.78 (s, 3H), 3.47 (dt, J = 5.8, 1.8 Hz, 2H), 2.18 (s, 3H); 13C NMR (125 MHz, 
CDCl3) 150.4 146.7, 136.5, 134.4, 132.6, 127.5, 115.0, 110.5, 63.9, 60.9, 55.7, 30.9, 
13.9; HRMS (ESI): calculated for C13H18O3 [M+Li
+] 229.1416, found 229.1406. 
 
            3-allyl-1-(chloromethyl)-4,5-dimethoxy-2-methylbenzene (4.23). To a solution 
of the above allyl alcohol (1.85 g, 8.32 mmol) in CH2Cl2 (40 mL) was added SOCl2 
(0.73 mL, 9.99 mmol) dropwise at 0 °C under nitrogen. The reaction was stirred at room 
temperature for 30 min before it was carefully quenched by the addition of saturated 
aqueous NaHCO3. The mixture was diluted with CH2Cl2. The organic layer was 
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 separated and washed with water, brine, dried over Na2SO4. After concentration, the 
residue was purified by flash column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/10) to provide product 4.23 (1.93 g, 97 %) as a white solid. 
IR (film, cm-1) 2940, 1602, 1484, 1330, 1226, 1108, 1045, 986, 912; 1H NMR (500 
MHz, CDCl3) δ 6.79 (s, 1H), 5.92 (ddt, J = 17.1, 10.2, 5.8 Hz, 1H), 5.01 (dd, J = 10.2, 
1.8 Hz, 1H), 4.89 (dd, J = 17.1, 1.8 Hz, 1H), 4.60 (s, 2H), 3.86 (s, 3H), 3.80 (s, 3H), 3.48 
(dt, J = 5.8, 1.8 Hz, 2H), 2.26 (s, 3H); 13C NMR (125 MHz, CDCl3) 150.5, 147.7, 136.2, 
133.1, 131.0, 129.1, 115.1, 112.2, 60.9, 55.7, 45.9, 31.0, 14.3; HRMS (ESI): calculated 
for C13H17ClO2 [M+H
+] 241.0995, found 241.1003. 
 
            2-(3-allyl-4,5-dimethoxy-2-methylphenyl)-1-(2,6,6-trimethylcyclohex-1-en-1-
yl) ethanol (4.24). A mixture of naphthalene (3.61 g, 28.13 mmol) and lithium (196 mg, 
28.13 mmol) in THF (30 mL) was stirred at room temperature under nitrogen for 1.5h. 
To which, a solution of -cyclocitral (1.26 g, 8.25 mmol) and benzyl chloride 4.23 (1.80 
g, 7.50 mmol) in THF (10 mL) was added dropwise via syringe at 0 °C. The mixture was 
then stirred at room temperature for 2h, diluted with ether and then quenched with 
saturated aqueous NH4Cl. The organic phase was separated. The aqueous phase was 
extracted with EtOAc. The combined organic layers were washed with brine, dried over 
Na2SO4. After concentration, the residue was purified by flash column chromatography 
(silica gel, eluted with ethyl acetate/petroleum ether = 1/4) to provide product 4.24 (2.13 
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 g, 79%) as a colorless liquid. IR (film, cm-1) 3500, 2931, 1593, 1484, 1291, 1229, 1111, 
1048, 989, 906; 1H NMR (500 MHz, CDCl3) δ 6.70 (s, 1H), 5.94 (dd, J = 17.1, 10.1 Hz, 
1H), 5.01 (dq, J = 10.1, 1.7 Hz, 1H), 4.93 (dq, J = 17.1, 1.8 Hz, 1H), 4.45 (dd, J = 10.0, 
4.3 Hz, 1H), 3.87 (s, 3H), 3.80 (s, 3H), 3.49 (ddd, J = 5.8, 3.9, 1.9 Hz, 2H), 3.19 (dd, J = 
14.2, 10.0 Hz, 1H), 2.88 (dd, J = 14.2, 4.3 Hz, 1H), 2.24 (s, 3H), 2.03-1.99 (m, 2H); 2.02 
(s, 3H), 1.65-1.54 (m, 2H), 1.46-1.44 (m, 2H), 1.11 (s, 3H), 0.93 (s, 3H); 13C NMR (125 
MHz, CDCl3) 150.3, 146.0, 139.3, 136.7, 133.3, 132.4, 132.0, 128.3, 114.9, 113.0, 71.2, 
60.9, 55.8, 40.5, 40.0, 34.8, 34.2, 31.2, 28.5, 28.3, 21.4, 19.3, 15.2; HRMS (ESI): 
calculated for C23H34O3 [M+Na
+] 381.2406, found 381.2388. 
 
            2-(3-allyl-4,5-dimethoxy-2-methylphenyl)-1-(2,6,6-trimethylcyclohex-1-en-1-
yl)ethanone (4.25). To a solution of alcohol 4.24 (910 mg, 2.54 mmol) in DMSO (5 
mL) was added IBX (1.07 g, 3.81 mmol) at room temperature. The resulting mixture 
was stirred at room temperature for 3h. The reaction was quenched with H2O (5 mL) at 0 
°C. The mixture was filtered and the aqueous phase was extracted with EtOAc. The 
combined organic layers were washed with brine, and dried over Na2SO4. After 
concentration in vacuo, the residue was purified by column chromatography (silica gel, 
eluted with ethyl acetate/petroleum ether = 1/1) to provide the product 4.25 (780 mg, 
86%) as a yellow liquid. IR (film, cm-1) 2937, 1691, 1596, 1487, 1285, 1226, 1113, 
1048, 995; 1H NMR (500 MHz, CDCl3) δ 6.56 (s, 1H), 5.93 (ddt, J = 17.1, 10.2, 5.7 Hz, 
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 1H), 4.99 (dq, J = 10.1, 1.7 Hz, 1H), 4.91 (dq, J = 17.1, 1.9 Hz, 1H), 3.87 (s, 2H), 3.82 
(s, 3H), 3.78 (s, 3H), 3.48 (dt, J = 5.7, 1.8 Hz, 2H), 2.11 (s, 3H), 1.99 (t, J = 6.5 Hz, 2H), 
1.72-1.67 (m, 2H), 1.63 (s, 3H), 1.48-1.46 (m, 2H), 1.11 (s, 6H); 13C NMR (125 MHz, 
CDCl3) 207.8, 150.3, 146.4, 143.1, 136.6, 132.4, 129.5, 129.1, 128.4, 114.9, 112.9, 60.8, 
55.8, 50.8, 39.0, 33.4, 31.3, 31.2, 28.8, 21.2, 18.9, 15.4; HRMS (ESI): calculated for 
C23H32O3 [M+H
+] 357.2430, found 357.2423. 
 
            2-(2,3-dimethoxy-6-methyl-5-(2-oxo-2-(2,6,6-trimethylcyclohex-1-en-1-
yl)ethyl)phenyl)acetaldehyde (4.26). To a solution of alkene 4.25 (530 mg, 1.49 mmol) 
in acetone/H2O (4/1, 15 mL) was added NMO (262 mg, 2.23 mmol) and 5% OsO4 
solution in t-BuOH (758 mg, 7.45% mmol, 2.5 wt%). After being stirred at room 
temperature for overnight, the reaction mixture was concentrated in vacuo. The residue 
was dissolved in EtOAc, washed with H2O, brine, and dried over Na2SO4. After 
concentration in vacuo, the crude diol was dissolved in CH3CN/H2O (1/1, 16 mL). To 
which, NaIO4 (478 mg, 2.24 mmol) was added at 0 °C. The reaction mixture was 
allowed to reach room temperature and was stirred for 1h before it was filtered through a 
short pad of silica gel (eluted with EtOAc) to allow the removal of insoluble salts. The 
filtrate was then washed with H2O, brine, dried over Na2SO4. After concentration in 
vacuo, the residue was purified by column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/5) to provide the product 4.26 (446 mg, 84% for 2 steps) as a 
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 white solid. IR (film, cm-1) 2937, 1720, 1697, 1484, 1279, 1229, 1108, 1066; 1H NMR 
(500 MHz, CDCl3) δ 9.68 (s, 1H), 6.62 (s, 1H), 3.89 (s, 2H), 3.84 (s, 3H), 3.81 (d, J = 
2.0 Hz, 2H), 3.78 (s, 3H), 2.07 (s, 3H), 2.00 (t, J = 6.5 Hz, 2H), 1.72-1.66 (m, 2H), 1.64 
(s, 3H), 1.49-1.46 (m, 2H), 1.12 (s, 6H); 13C NMR (125 MHz, CDCl3) 207.6, 199.7, 
150.2, 146.6, 143.0, 129.7, 129.2, 128.8, 125.7, 114.2, 60.5, 55.8, 50.8, 42.7, 38.9, 33.5, 
31.3, 28.8, 21.2, 18.8, 16.1; HRMS (ESI): calculated for C22H30O4 [M+Li
+] 365.2304, 
found 365.2312. 
 
            2-(3-(2-hydroxyethyl)-4,5-dimethoxy-2-methylphenyl)-1-(2,6,6-trimethyl 
cyclohex-1-en-1-yl)ethanone (4.27). To a solution of aldehyde 4.26 (423 mg, 1.18 
mmol) in PhH (10 mL) was added NaBH(OAc)3 (376 mg, 1.77 mmol) and acetic acid 
(0.70 mL). After being stirred at room temperature under nitrogen for 6h, the reaction 
was quenched with saturated aqueous NaHCO3 at °C. The aqueous phase was extracted 
with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4. 
After concentration in vacuo, the residue was purified by column chromatography (silica 
gel, eluted with ethyl acetate/petroleum ether = 1/1) to provide the product 4.27 (370 mg, 
87%) as a white solid. IR (film, cm-1) 3446, 2934, 1694, 1596, 1492, 1300, 1229, 1116, 
1048; 1H NMR (500 MHz, CDCl3) δ 6.55 (s, 1H), 3.88 (s, 2H), 3.83 (s, 3H), 3.82 (s, 
3H), 3.77 (t, J = 6.7 Hz, 2H), 3.00 (t, J = 6.8 Hz, 2H), 2.16 (s, 3H), 2.00 (t, J = 6.4 Hz, 
2H), 1.72-1.67 (m, 2H), 1.64 (s, 3H), 1.49-1.46 (m, 2H), 1.12 (s, 6H); 13C NMR (125 
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 MHz, CDCl3) 207.8, 150.1, 146.5, 143.0, 131.1, 129.6, 128.8, 128.8, 113.1, 62.7, 60.5, 
55.7, 50.9, 38.9, 33.5, 31.3, 30.7, 28.8, 21.2, 18.8, 15.7; HRMS (ESI): calculated for 
C22H32O4 [M+Li
+] 367.2461, found 367.2469. 
 
            2-(3-isopropyl-4,5-dimethoxyphenyl)-1-(2,6,6-trimethylcyclohex-1-en-1-
yl)ethanol (A.11). A mixture of naphthalene (4.92 g, 38.35 mmol) and lithium (266 mg, 
38.35 mmol) in THF (40 mL) was stirred at room temperature under nitrogen for 1.5h. 
To which, a solution of -cyclocitral (1.28 g, 8.44 mmol) and benzyl chloride 4.28 (1.75 
g, 7.67 mmol) in THF (10 mL) was added dropwise via syringe at 0 °C. The mixture was 
then stirred at room temperature for 2h, diluted with ether and then quenched with 
saturated aqueous NH4Cl. The organic phase was separated. The aqueous phase was 
extracted with EtOAc. The combined organic layers were washed with brine, dried over 
Na2SO4. After concentration, the residue was purified by flash column chromatography 
(silica gel, eluted with ethyl acetate/petroleum ether = 1/5) to provide allyl alcohol A.11 
(2.26 g, 85%) as a light yellow liquid. 1H NMR (500 MHz, CDCl3) δ 6.70 (d, J = 1.9 Hz, 
1H), 6.66 (d, J = 1.9 Hz, 1H), 4.42 (dd, J = 10.1, 3.6 Hz, 1H), 3.87 (s, 3H), 3.80 (s, 3H), 
3.34 (dt, J = 13.9, 6.9 Hz, 1H), 3.06 (dd, J = 13.9, 10.1 Hz, 1H), 2.82 (dd, J = 13.9, 3.5 
Hz, 1H), 2.05-1.94 (m, 2H), 1.96 (s, 3H), 1.62-1.53 (m, 2H), 1.46-1.42 (m, 2H), 1.23 (s, 
3H), 1.22 (s, 3H), 1.10 (s, 3H), 0.97 (s, 3H); 13C NMR (125 MHz, CDCl3) 152.5, 144.9, 
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 142.4, 139.0, 135.5, 131.8, 118.9, 110.7, 72.4, 60.9, 55.7, 43.4, 39.9, 34.8, 34.1, 28.6, 
28.1, 26.8, 23.6, 23.5, 21.4, 19.3.  
 
            2-(3-isopropyl-4,5-dimethoxyphenyl)-1-(2,6,6-trimethylcyclohex-1-en-1-
yl)ethanone (1.69). To a solution of A.11 (370 mg, 1.07 mmol) in DMSO (4 mL) was 
added IBX (449 mg, 1.60 mmol) at room temperature. The resulting mixture was stirred 
at room temperature for 3h. The reaction was quenched with H2O (5 mL) at 0 °C. The 
mixture was filtered and the aqueous phase was extracted with EtOAc. The combined 
organic layers were washed with brine, and dried over Na2SO4. After concentration in 
vacuo, the residue was purified by column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/5) to provide the product 1.69 (285 mg, 77%) as a yellow 
liquid. 1H NMR (500 MHz, CDCl3) δ 6.66 (d, J = 2.0 Hz, 1H), 6.64 (d, J = 2.0 Hz, 1H), 
3.85 (s, 3H), 3.80 (s, 3H), 3.79 (s, 2H), 3.33 (dt, J = 13.9, 6.9 Hz, 1H), 1.99-1.96 (m, 
2H), 1.69-1.67 (m, 2H), 1.56 (s, 3H), 1.47-1.44 (m, 2H), 1.20 (s, 3H), 1.19 (s, 3H), 1.08 
(s, 6H); 13C NMR (125 MHz, CDCl3) 152.3, 145.1, 143.1, 142.0, 129.7, 129.6, 119.7, 
111.3, 60.9, 55.7, 52.2, 38.9, 33.4, 31.2, 28.8, 26.7, 23.5, 21.2, 18.8.  
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             (4bS,8aS)-4-hydroxy-2-isopropyl-1,4b,8,8-tetramethyl-4b,5,6,7,8,8a-hexahy 
drophenanthrene-3,9-dione (4.42). To a solution of ketone 1.69 (103 mg, 0.30 mmol) 
in DCM (3 mL) was added freshly prepared BBr3 solution dropwise (1.80 mL, 1.80 
mmol, 1M in DCM) at -78 °C under nitrogen. The reaction was stirred for 30 min then 
warmed up to 0 °C and stirred for 3h. The reaction was carefully quenched with 
saturated aqueous NaHCO3. The aqueous phase was extracted with EtOAc. The 
combined organic layers were washed with brine, dried over Na2SO4. After 
concentration in vacuo, the residue was dissolved in CHCl3 (10 mL). To which, Ag2O 
was added (104 mg, 0.45 mmol). The mixture was stirred at 50 °C for 30 min and 
filtered through cotton to allow the removal of insoluble solids. The filtrate was 
concentrated and purified by column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/4) to provide the product 4.42 (36.8 mg, 39% for 2 steps) as 
an orange solid.. 1H NMR (500 MHz, CDCl3) δ 7.56 (s, 1H), 6.88 (s, 1H), 6.21 (s, 1H), 
3.10-3.04 (m, 1H), 2.95-2.92 (m, 1H), 2.60 (s, 1H), 1.78-1.14 (m, 5H), 1.27 (s, 6H), 1.18 
(d, J = 6.9 Hz, 3H), 1.16 (d, J = 6.9 Hz, 3H), 1.12 (s, 3H).  
 
            (4bS,8aR)-4-hydroxy-2-isopropyl-3-methoxy-4b,8,8-trimethyl-4b,5,6,7,8,8a-
hexahydro phenanthren-9(10H)-one (4.37). A mixture of hexamethyldisilane (0.25 
mL, 1.2 mmol) and iodine (305 mg, 1.2 mmol) was heated at 65 °C for 20 min under 
nitrogen. After cooling down to room temperature, a solution of ketone 1.69 (69 mg, 0.2 
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 mmol) in toluene (1 mL) was added. The reaction mixture was stirred at 70 °C for 4h. 
After concentration in vacuo, the residue was purified by flash column chromatography 
(silica gel, ethyl acetate/petroleum ether, 1/5) to provide 4.37 (35.9 mg, 54 %) as a 
yellow solid. IR (film, cm-1) 3414, 2955, 2931, 1694, 1448, 1418, 1300, 1229, 1057, 
1033, 998; 1H NMR (500 MHz, CDCl3) δ 6.67 (s, 1H), 5.77 (s, 1H), 3.80 (s, 3H), 3.65 
(dd, J = 22.9, 1.1 Hz, 1H), 3.47 (d, J = 22.9 Hz, 1H), 3.27 (dt, J = 13.9, 6.9 Hz, 1H), 
3.03-2.99 (m, 1H), 1.98 (s, 1H), 1.61-1.15 (m, 5H), 1.26 (d, J = 6.9 Hz, 3H), 1.24 (d, J = 
6.9 Hz, 3H), 1.24 (s, 3H), 0.94 (s, 3H), 0.30 (s, 3H); 13C NMR (125 MHz, CDCl3) 213.1, 
145.8, 144.9, 133.7, 130.4, 126.4, 122.3, 68.5, 61.9, 44.0, 42.2, 40.1, 37.4, 34.4, 32.4, 
31.9, 27.2, 22.8, 22.5, 22.4, 20.2; HRMS (ESI): calculated for C21H30O3 [M+H
+] 
331.2268, found 331.2264. 
 
            (4bS,8aS)-4-hydroxy-2-(2-hydroxyethyl)-1,4b,8,8-tetramethyl-4b,5,6,7,8,8a-
hexahydrophenanthrene-3,9-dione (1.67). To a solution of alcohol 4.27 (301 mg, 0.84 
mmol) in DCM (8 mL) was added freshly prepared BBr3 solution dropwise (5.04 mL, 
5.04 mmol, 1M in DCM) at -78 °C under nitrogen. The reaction was stirred for 30 min 
then warmed up to 0 °C and stirred for 2h. The reaction was carefully quenched with 
saturated aqueous NaHCO3. The aqueous phase was extracted with EtOAc. The 
combined organic layers were washed with brine, dried over Na2SO4. After 
concentration in vacuo, the residue was dissolved in CHCl3 (10 mL). To which, Ag2O 
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 was added (223 mg, 0.90 mmol). The mixture was stirred at 50 °C for 30 min and 
filtered through cotton to allow the removal of insoluble solids. The filtrate was 
concentrated and purified by column chromatography (silica gel, eluted with ethyl 
acetate/petroleum ether = 1/1) to provide the natural product 1.67 (103 mg, 37% for 2 
steps) as an orange solid. IR (film, cm-1) 3325, 2925, 1670, 1610, 1377, 1223, 1185, 
1146, 1045; 1H NMR (500 MHz, acetone-d6) δ 8.32 (s, 1H), 6.50 (s, 1H), 3.75 (t, J = 5.7 
Hz, 1H), 3.63-3.59 (m, 2H), 3.05-3.02 (m, 1H), 2.85-2.81 (m, 2H), 2.65 (s, 1H), 2.34 (s, 
3H), 1.76-1.70 (m, 2H), 1.59-1.54 (m, 1H), 1.40-1.36 (m, 1H), 1.29-1.26 (m, 1H), 1.27 
(s, 3H), 1.24 (s, 3H), 1.10 (s, 3H); 1H NMR (500 MHz, acetone-d6+D2O) δ 6.52 (s, 1H), 
3.59 (t, J = 7.1 Hz, 2H), 3.03 (d, J = 11.8 Hz, 1H), 2.83 (t, J = 7.2 Hz, 2H), 2.66 (s, 1H), 
2.33 (s, 3H), 1.73-1.66 (m, 2H), 1.56-1.53 (m, 1H), 1.37 (d, J = 11.7 Hz, 1H), 1.26 (s, 
3H), 1.23 (s, 3H), 1.10 (s, 3H). 13C NMR (125 MHz, acetone-d6) δ 201.1, 182.3, 146.4, 
145.1, 142.0, 134.8, 131.3, 127.0, 62.3, 61.2, 43.0, 42.9, 37.7, 33.4, 33.3, 31.0, 22.2, 
21.6, 19.3, 15.9; HRMS (ESI): calculated for C20H26O4 [M-H
+] 329.1753, found 
329.1738. 
 
            (4bS,8aS)-4-hydroxy-2-(2-(methoxymethoxy)ethyl)-1,4b,8,8-tetramethyl-
4b,5,6,7,8,8a-hexahydrophenanthrene-3,9-dione (4.38). To a solution of alcohol 1.67 
(9.9 mg, 0.03 mmol) in DCM (2 mL) was added dimethoxymethane (0.027 mL, 0.3 
mmol) and P2O5 (43 mg, 0.15 mmol). The mixture was stirred at room temperature for 
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 2h before it was diluted with DCM. The organic phase was washed with saturated 
aqueous NaHCO3 and dried over Na2SO4. After concentration in vacuo, the residue was 
purified by column chromatography (silica gel, eluted with ethyl acetate/petroleum ether 
= 1/5) to provide the product 4.38 (7.4 mg, 66%) as a yellow liquid.  IR (film, cm-1) 
3322, 2934, 1670, 1611, 1380, 1152, 1116, 1025; 1H NMR (500 MHz, CDCl3) δ 7.53 (s, 
1H), 6.51 (s, 1H), 4.60 (s, 2H), 3.62 (t, J = 6.9 Hz, 2H), 3.33 (s, 3H), 2.98-2.95 (m, 1H), 
2.93-2.88 (m, 2H), 2.59 (s, 1H), 2.29 (s, 3H), 1.74-1.70 (m, 2H), 1.62-1.59 (m, 2H), 
1.44-1.40 (m, 1H), 1.28 (s, 3H), 1.26 (s, 3H), 1.13 (s, 3H); 13C NMR (125 MHz, CDCl3) 
201.2, 181.5, 146.1, 143.7, 141.1, 133.5, 131.1, 126.6, 96.3, 65.9, 62.2, 55.2, 42.6, 42.4, 
37.1, 33.2, 32.7, 27.2, 21.9, 21.7, 18.6, 15.8; HRMS (ESI): calculated for C22H30O5 
[M+Li+] 381.2248, found 381.2262. 
 
            1-(chloromethyl)-4,5-dimethoxy-2-methylbenzene (4.39). To a solution of 
carboxylic acid 4.6 (3.92 g, 20 mmol) in THF (40 mL) was added borane dimethyl 
sulfide (16 mL, 32 mmol, 2M in THF) at 0 °C. The resulting solution was allowed to 
warm to room temperature overnight. The reaction was carefully quenched with H2O 
and the resulting solution was diluted with EtOAc. Organic Phase was separated, washed 
with H2O, dried over Na2SO4. After concentration, the residue was purified by flash 
column chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/1) to 
provide benzyl alcohol (3.28 g, 90 %) as a white solid.  
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             To a solution of the above benzyl alcohol (1.82 g, 10 mmol) in CH2Cl2 (20 mL) 
was added SOCl2 (0.87 mL, 12 mmol) dropwise at 0 °C under nitrogen. The reaction 
was stirred at room temperature for 30 min before it was carefully quenched by the 
addition of saturated aqueous NaHCO3. The organic phase was separated. Aqueous 
phase was extracted with DCM. The combined organic layers were dried over Na2SO4. 
After concentration, the residue was purified by flash column chromatography (silica 
gel, eluted with ethyl acetate/petroleum ether = 1/5) to provide product 4.39 (1.90 g, 95 
%) as a yellow oil. IR (film, cm-1) 2963, 2934, 1611, 1519, 1466, 1338, 12821226, 1105, 
998; 1H NMR (500 MHz, CDCl3) δ 6.84 (s, 1H), 6.71 (s, 1H), 4.60 (s, 2H), 3.89 (s, 6H), 
2.38 (s, 3H); 13C NMR (125 MHz, CDCl3) 149.1, 147.0, 129.8, 127.3, 113.7, 113.0, 
56.0, 55.9, 45.2, 18.4; HRMS (ESI): calculated for C10H13O2Cl [M+H
+] 201.0682, found 
201.0692. 
 
            2-(4,5-dimethoxy-2-methylphenyl)-1-(2,6,6-trimethylcyclohex-1-en-1-
yl)ethanone (4.40). A mixture of naphthalene (5.77 g, 45 mmol) and lithium (313 mg, 
45 mmol) in THF (50 mL) was stirred at room temperature under nitrogen for 1.5h. To 
which, a solution of -cyclocitral (1.51 g, 9.9 mmol) and benzyl chloride 4.39 (1.80 g, 9 
mmol) in THF (10 mL) was added via syringe at 0 °C. The mixture was then stirred at 
room temperature for 2h, diluted with ether and then quenched with saturated aqueous 
NH4Cl. The organic phase was separated. The aqueous phase was extracted with EtOAc. 
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 The combined organic layers were washed with brine, dried over Na2SO4. After 
concentration, the residue was purified by flash column chromatography (silica gel, 
eluted with ethyl acetate/petroleum ether = 1/5) to provide allyl alcohol A.12 (2.17g, 
76%) as a light yellow solid. IR (film, cm-1) 3538, 2934, 1608, 1513, 1466, 1270, 1226, 
1102, 998; 1H NMR (500 MHz, CDCl3) δ 6.74 (s, 1H), 6.69 (s, 1H), 4.44 (dd, J = 10.2, 
4.1 Hz, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.14 (dd, J = 14.2, 10.2 Hz, 1H), 2.79 (dd, J = 
14.2, 4.1 Hz, 1H), 2.33 (s, 3H), 2.03-1.94 (m, 3H), 2.00 (s,3H), 1.62- 1.53 (m, 2H), 1.45-
1.42 (m, 2H), 1.10 (s, 3H), 0.94 (s, 3H); 13C NMR (125 MHz, CDCl3) 147.3, 147.0, 
139.3, 131.9, 129.6, 128.8, 113.8, 113.7, 71.4, 56.1, 55.9, 40.0, 39.5, 34.8, 34.2, 28.5, 
28.3, 21.4, 19.6, 19.3; HRMS (ESI): calculated for C20H30O3 [M+Li
+] 325.2355, found 
325.2339. 
            To a solution of the above allyl alcohol A.12 (960 mg, 3.03 mmol) in DMSO (6 
mL) was added IBX (1.27 g, 4.55 mmol) at room temperature. The resulting mixture 
was stirred at room temperature for 2h. The reaction was quenched with H2O (6 mL) at 0 
°C. The mixture was filtered and the aqueous phase was extracted with EtOAc. The 
combined organic layers were washed with brine, and dried over Na2SO4. After 
concentration in vacuo, the residue was purified by column chromatography (silica gel, 
eluted with ethyl acetate/petroleum ether = 1/3) to provide the product 4.40 (701 mg, 
73%) as a light solid. IR (film, cm-1) 2931, 1700, 1516, 1460, 1270, 1229, 1108, 1039, 
998; 1H NMR (500 MHz, CDCl3) δ 6.71 (s, 1H), 6.61 (s, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 
3.82 (s, 2H), 2.23 (s, 3H), 1.99 (t, J = 6.4 Hz, 2H), 1.71-1.66 (m, 2H), 1.62 (s, 3H), 1.48-
1.46 (m, 2H), 1.11 (s, 6H); 13C NMR (125 MHz, CDCl3) 147.8, 146.8, 143.0, 129.5, 
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 129.4, 124.5, 113.7, 113.6, 56.0, 55.8, 49.7, 38.9, 33.4, 31.2, 28.8, 21.1, 19.6, 18.8; 
HRMS (ESI): calculated for C20H28O3 [M+H
+] 317.2117, found 317.2126. 
 
            (4bS,8aS)-4-hydroxy-1,4b,8,8-tetramethyl-4b,5,6,7,8,8a-hexahydrophenan 
threne-3,9-dione (4.41). To a solution of ketone 4.40 (95 mg, 0.30 mmol) in DCM (3 
mL) was added freshly prepared BBr3 solution dropwise (1.80 mL, 1.80 mmol, 1M in 
DCM) at -78 °C under nitrogen. The reaction was stirred for 30 min then warmed up to 0 
°C and stirred for 3h. The reaction was carefully quenched with saturated aqueous 
NaHCO3. The aqueous phase was extracted with EtOAc. The combined organic layers 
were washed with brine, dried over Na2SO4. After concentration in vacuo, the residue 
was dissolved in CHCl3 (10 mL). To which, Ag2O was added (104 mg, 0.45 mmol). The 
mixture was stirred at 50 °C for 30 min and filtered through cotton to allow the removal 
of insoluble solids. The filtrate was concentrated and purified by column 
chromatography (silica gel, eluted with ethyl acetate/petroleum ether = 1/4) to provide 
the product 4.41 (35.9 mg, 42% for 2 steps) as an orange solid. IR (film, cm-1); 3432, 
2925, 1673, 1626, 1413, 1380, 1356, 1223, 1146, 773; 1H NMR (500 MHz, CDCl3); δ 
7.42 (s, 1H), 6.43 (s, 1H), 6.42 (d, J = 1.2 Hz 1H), 2.97-2.94 (m, 1H), 2.59 (s, 1H), 2.26 
(d, J = 1.3 Hz, 3H), 1.77-1.66 (m, 2H), 1.62-1.57 (m, 1H), 1.43-1.39 (m, 1H), 1.27 (s, 
3H), 1.26 (s, 3H), 1.24-1.16 (m, 1H), 1.12 (s, 3H); 13C NMR (125 MHz, CDCl3) 201.1, 
181.6, 150.3, 144.5, 140.9, 131.3, 126.9, 126.4, 62.4, 42.9, 42.4, 37.1, 33.2, 32.8, 21.9, 
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 21.7, 19.8, 18.6; HRMS (ESI): calculated for C18H22O3 [M-H
+] 285.1496, found 
285.1501. 
 
A.5 Crystal and Molecular Structure Determination for 3.18 
X-ray Diffraction Laboratory 
Department of Chemistry 
Texas A&M University 
 
 
 
Figure A.1. X-ray structure of 3.18 
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 Table A.2. Crystal data and structure refinement for 3.18 
Empirical formula  C11H15ClO3 
Formula weight  230.68 
Temperature  110(2) K 
Wavelength  1.54178 Å 
Crystal system  Tetragonal 
Space group  I4(1) 
Unit cell dimensions a = 18.2294(4) Å = 90°. 
 b = 18.2294(4) Å = 90°. 
 c = 7.0465(3) Å γ = 90°. 
Volume 2341.63(12) Å3 
Z 8 
Density (calculated) 1.309 Mg/m3 
Absorption coefficient 2.785 mm-1 
F(000) 976 
Crystal size 0.10 x 0.05 x 0.02 mm3 
Theta range for data collection 6.74 to 59.95°. 
Index ranges -20<=h<=20, -20<=k<=20, -7<=l<=7 
Reflections collected 21338 
Independent reflections 1655 [R(int) = 0.0441] 
Completeness to theta = 59.95° 96.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9464 and 0.7681 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1655 / 1 / 138 
Goodness-of-fit on F2 1.077 
Final R indices [I>2sigma(I)] R1 = 0.0390, wR2 = 0.0962 
R indices (all data) R1 = 0.0414, wR2 = 0.0974 
Absolute structure parameter 0.03(2) 
Largest diff. peak and hole 0.840 and -0.186 e.Å-3 
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 Table A.3. Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(Å2 x 103). U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
_______________________________________________________________________  
 x y z U(eq) 
______________________________________________________________________  
Cl(1) 9838(1) 11059(1) 11191(1) 30(1) 
O(1) 8185(1) 10405(1) 5265(3) 24(1) 
O(2) 8657(2) 11546(1) 5138(4) 36(1) 
O(3) 7894(1) 8191(1) 8158(3) 27(1) 
C(1) 8927(3) 8003(2) 5123(7) 44(1) 
C(2) 8796(2) 8734(2) 6084(6) 27(1) 
C(3) 8957(2) 9358(2) 5233(6) 29(1) 
C(4) 8858(2) 10102(2) 6116(5) 22(1) 
C(5) 8766(2) 10048(2) 8280(5) 19(1) 
C(6) 8605(2) 10787(2) 9165(4) 22(1) 
C(7) 9237(2) 11309(2) 9252(5) 28(1) 
C(8) 7958(2) 10978(2) 9850(5) 29(1) 
C(9) 8175(2) 11122(2) 4839(5) 27(1) 
C(10) 8488(2) 8708(2) 8070(5) 24(1) 
C(11) 8223(2) 9445(2) 8760(5) 22(1) 
_______________________________________________________________________
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 Table A.4. Bond lengths [Å] and angles [°] for 3.18 
_______________________________________________________________________  
Cl(1)-C(7)  1.809(3) 
O(1)-C(9)  1.342(4) 
O(1)-C(4)  1.473(4) 
O(2)-C(9)  1.188(4) 
O(3)-C(10)  1.438(4) 
O(3)-H(3)  0.8400 
C(1)-C(2)  1.513(5) 
C(1)-H(1A)  0.9800 
C(1)-H(1B)  0.9800 
C(1)-H(1C)  0.9800 
C(2)-C(3)  1.319(5) 
C(2)-C(10)  1.509(5) 
C(3)-C(4)  1.504(5) 
C(3)-H(3A)  0.9500 
C(4)-C(5)  1.537(5) 
C(4)-H(4)  1.0000 
C(5)-C(6)  1.513(5) 
C(5)-C(11)  1.519(4) 
C(5)-H(5)  1.0000 
C(6)-C(8)  1.321(5) 
C(6)-C(7)  1.496(5) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-H(8A)  0.9500 
C(8)-H(8B)  0.9500 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.508(4) 
C(10)-H(10)  1.0000 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
_______________________________________________________________________  
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 Table A.4. (Continued) Bond lengths [Å] and angles [°] for 3.18 
_______________________________________________________________________  
C(9)-O(1)-C(4) 117.8(3) 
C(10)-O(3)-H(3) 109.5 
C(2)-C(1)-H(1A) 109.5 
C(2)-C(1)-H(1B) 109.5 
H(1A)-C(1)-H(1B) 109.5 
C(2)-C(1)-H(1C) 109.5 
H(1A)-C(1)-H(1C) 109.5 
H(1B)-C(1)-H(1C) 109.5 
C(3)-C(2)-C(10) 122.1(3) 
C(3)-C(2)-C(1) 121.4(4) 
C(10)-C(2)-C(1) 116.5(3) 
C(2)-C(3)-C(4) 124.3(4) 
C(2)-C(3)-H(3A) 117.8 
C(4)-C(3)-H(3A) 117.8 
O(1)-C(4)-C(3) 105.6(3) 
O(1)-C(4)-C(5) 109.7(2) 
C(3)-C(4)-C(5) 111.4(3) 
O(1)-C(4)-H(4) 110.0 
C(3)-C(4)-H(4) 110.0 
C(5)-C(4)-H(4) 110.0 
C(6)-C(5)-C(11) 115.2(3) 
C(6)-C(5)-C(4) 111.9(3) 
C(11)-C(5)-C(4) 109.8(3) 
C(6)-C(5)-H(5) 106.5 
C(11)-C(5)-H(5) 106.5 
C(4)-C(5)-H(5) 106.5 
C(8)-C(6)-C(7) 120.3(3) 
C(8)-C(6)-C(5) 124.0(3) 
C(7)-C(6)-C(5) 115.7(3) 
C(6)-C(7)-Cl(1) 109.7(2) 
C(6)-C(7)-H(7A) 109.7 
_______________________________________________________________________  
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 Table A.4. (Continued) Bond lengths [Å] and angles [°] for 3.18 
_______________________________________________________________________  
Cl(1)-C(7)-H(7A) 109.7 
C(6)-C(7)-H(7B) 109.7 
Cl(1)-C(7)-H(7B) 109.7 
H(7A)-C(7)-H(7B) 108.2 
C(6)-C(8)-H(8A) 120.0 
C(6)-C(8)-H(8B) 120.0 
H(8A)-C(8)-H(8B) 120.0 
O(2)-C(9)-O(1) 125.7(3) 
O(2)-C(9)-H(9) 117.1 
O(1)-C(9)-H(9) 117.1 
O(3)-C(10)-C(11) 109.2(3) 
O(3)-C(10)-C(2) 110.0(3) 
C(11)-C(10)-C(2) 113.0(3) 
O(3)-C(10)-H(10) 108.2 
C(11)-C(10)-H(10) 108.2 
C(2)-C(10)-H(10) 108.2 
C(10)-C(11)-C(5) 111.4(3) 
C(10)-C(11)-H(11A) 109.4 
C(5)-C(11)-H(11A) 109.4 
C(10)-C(11)-H(11B) 109.4 
C(5)-C(11)-H(11B) 109.4 
H(11A)-C(11)-H(11B) 108.0 
_______________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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 Table A.5. Anisotropic displacement parameters (Å2 x 103) for 3.18. The anisotropic 
displacement factor exponent takes the form: -2π2[h2 a*2U11 +... +2 hk a* b* U12] 
_______________________________________________________________________  
 U
11
 U
22
  U
33
 U
23
 U
13
 U
12
 
_______________________________________________________________________  
Cl(1) 24(1)  31(1) 33(1)  -4(1) -5(1)  -1(1) 
O(1) 25(1)  26(1) 22(1)  1(1) -1(1)  -2(1) 
O(2) 50(2)  26(1) 31(1)  3(1) 1(1)  -4(1) 
O(3) 22(1)  22(1) 38(2)  5(1) -9(1)  -8(1) 
C(1) 60(3)  24(2) 49(2)  -11(2) 12(2)  0(2) 
C(2) 25(2)  24(2) 33(2)  -8(2) 1(2)  1(1) 
C(3) 30(2)  24(2) 33(2)  -3(2) 9(2)  0(2) 
C(4) 19(2)  25(2) 23(2)  0(2) 5(1)  1(1) 
C(5) 15(2)  22(2) 21(2)  0(1) 4(1)  1(1) 
C(6) 27(2)  26(2) 15(2)  4(1) -9(1)  0(2) 
C(7) 32(2)  25(2) 25(2)  -3(1) -3(2)  -5(2) 
C(8) 26(2)  35(2) 26(2)  -5(2) -1(2)  5(2) 
C(9) 40(2)  22(2) 20(2)  0(2) 4(2)  4(2) 
C(10) 17(2)  24(2) 30(2)  4(1) -4(1)  -5(2) 
C(11) 19(2)  25(2) 21(2)  0(2) 0(1)  -3(1) 
_______________________________________________________________________  
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 Table A.6. Hydrogen coordinates (x104) and isotropic displacement parameters (Å2  x 
103) for 3.18 
_______________________________________________________________________  
                                           x                      y                      z                    U(eq) 
_______________________________________________________________________  
H(3) 7994 7861 8951 41 
H(1A) 9106 8086 3829 66 
H(1B) 8467 7726 5077 66 
H(1C) 9294 7724 5840 66 
H(3A) 9148 9336 3980 35 
H(4) 9286 10423 5802 27 
H(5) 9251 9887 8796 23 
H(7A) 9053 11815 9442 33 
H(7B) 9512 11295 8041 33 
H(8A) 7893 11450 10401 35 
H(8B) 7559 10645 9791 35 
H(9) 7746 11308 4247 33 
H(10) 8884 8536 8945 28 
H(11A) 8151 9426 10152 26 
H(11B) 7744 9558 8168 26 
_______________________________________________________________________  
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APPENDIX B 
SPECTRA OF IRIOMOTEOLIDE-1A, ALOTAKETAL A and 1.67 
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